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Head and neck is the sixth most common cancer type worldwide, with the highest incidence 
observed in South and Southeast Asia. Comprised of a heterogeneous group of malignancies, 
head and neck cancers (HNC) span several anatomical subsites, including the: oral cavity, 
oropharynx, hypopharynx, nasopharynx, larynx, salivary glands, paranasal sinuses and nasal 
cavity. While ~90% of these neoplasms are morphologically characterized as squamous cell 
carcinoma, etiological differences across cancer subsite, along with geographic attributes that 
influence the variable global incidence and mortality trends, make HNC a therapeutically 
challenging and behaviorally variable disease.  
 
The goal of this dissertation is to improve the current state of knowledge surrounding HNC 
through the use of descriptive and molecular epidemiological methods. To do so, the first aim 
utilized several sources of cancer registry data to assess trends in head and neck, and separately 
nasopharyngeal, carcinoma to better understand how temporal changes in environmental and 
behavioral risk factors, as well as advances in clinical practices, influence cancer onset and 
survival. Culminating in four manuscripts, the first two focused on nasopharyngeal carcinoma 
(NPC); findings revealed Asian/Pacific Islanders living in the U.S., a non-endemic region, to 
have comparable rates of NPC incidence as those in endemic Thailand. Interestingly, the 
Epstein-Barr virus (EBV) related differentiated non-keratinizing subtype was shown to be 
increasing across nearly all gender and race groups in the U.S., while survival rates appeared to 
vary.  
 
The remaining studies highlighted the role of decreasing tobacco, alcohol and betel quid use, 
three major risk factors in HNC development, on decreasing laryngeal and oral cavity cancer 
rates across the U.S. and Southeast Asia. Nevertheless, as the world’s largest tobacco 
x 
manufacturer and consumer of ~30% of the world’s cigarettes, Chinese males in Shanghai 
experienced a 9.1% annual increase in laryngeal cancer between 1998 and 2002.  
 
The reductions in tobacco use have elucidated the role of human papilloma virus (HPV) as an 
important causal factor in oropharyngeal carcinoma (OPC). To date, this etiological shift has 
almost exclusively been studied and proposed to effect Western, more developed countries. 
Using descriptive epidemiology in aim one to inform molecular analyses in aim two, the results 
of these studies challenged previous assumptions. Having undergone rapid socioeconomic 
change, cancer has superseded infectious disease as the leading cause of mortality in Thailand. In 
accordance with economic growth, changes in cultural norms have allowed for an etiological 
transition that has led to an increase in oral HPV infections, and consequently OPC incidence. 
Although far from the 80% prevalence observed in the U.S., OPC HPV rates in Thailand have 
increased from 16% in 2012 to 26% in 2017—expecting to exceed 50% by 2030.  
 
Despite medical advances in HNC treatment, 5-year relative survival has remained 
disappointingly stable at 50-60% over the past few decades. Recent studies have shown the 
presence of tumor-infiltrating lymphocytes to be an important prognostic tool in guiding HNC 
treatment. For the last aim, dietary factors, which have previously been shown to be important in 
HNC risk, progression and prognosis, were assessed and shown to significantly influence tumor 
immune response and subsequently survival.  
 
Overall, the research presented in this dissertation not only provides a better understanding of 
HNC on a global scale, but also offers a basis for future studies to aid in elucidating etiology and 











Cancer accounts for one in seven deaths worldwide. When assessing disparity, cancer is the 
second leading cause of death in high-income countries (after cardiovascular diseases) and the 
third leading cause of death in low- and middle-income countries (after cardiovascular diseases 
and infectious and parasitic diseases) 1. Harboring a complex pathology, incidence and survival 
rates associated with carcinogenesis are closely linked to social, cultural and socio-economic 
determinants of health. Although squamous cell carcinoma of the head and neck (HNSCC) is the 
sixth most common cancer in the world 2, geographic differences, such as the population age 
structure, prevalence of established risk factors and access to screening and care, all play a key 
role in making HNSCC both a therapeutically challenging and behaviorally heterogeneous 
disease. 
 
HNSCC encompasses lesions found in several principal subsites, which include: oral cavity, 
nasopharynx, oropharynx, and larynx 3. As with many other cancers, genomic instability is an 
essential feature of HNSCC 4; it is fundamental in the transformation of host cells toward 
malignancy, promotion of invasion and metastasis, and impacts the response of a tumor to 
treatment. Genomic instability is the most common cause of chromosomal mutation, which is 
thought to be the most readily observed feature of cancer, and is influenced by the accumulation 
of DNA damage, lack of proper DNA repair and replication stress. DNA damage response 
functions to inhibit cell cycle progression through checkpoint signaling for either DNA repair or 
apoptosis (programmed cell death). In head and neck cancer, the propensity for DNA damage is 
increased by exposure to a multitude of carcinogens, which likely play a role in explaining the 
disproportionately high male predominance of this disease. 
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HNSCC is unique in that each principle subsite is characterized by distinct etiological risk 
factors and molecular characteristics that inform treatment strategy and prognosis. Nevertheless, 
despite improvements in HNSCC treatment, 5-year relative survival among afflicted patients 
remains stagnant at 50-60%. To better understand head and neck cancer on a global scale, this 
dissertation utilizes descriptive epidemiology methods to inform molecular analyses that can 
then be translated into the clinical setting in hopes of improving prevention strategies, quality of 
life, morbidity, and mortality among HNSCC patients.  
 
Lifestyle Factors 
The association between HNSCC, tobacco and alcohol use have long been established 5,6.  While 
these etiological factors may account for the majority of HNSCC cases in the United States, 
several other behavioral risk factors have been identified elsewhere in the world. One relevant 
exposure is the use of betel quid, which often consists of areca-nut, slaked lime, betel-leaf and 
sometimes tobacco. Betel chewing is a common habit in many parts of Asia, and several studies 
have been published on the risk of betel quid, and its interaction with smoking on head and neck 
cancer development 7.  
 
In developing countries, an estimated 60% of cancers of the oral cavity, pharynx and esophagus 
are thought to be associated with micronutrient deficiencies related to a restricted diet low in 
fruits, vegetables and animal products 8-10. Several studies have previously investigated the role 
of individual food groups 11,12 and nutrients 13-16 on HNSCC prognosis. Previous reports have 
found potential protective effects associated with plasma carotenoids, specifically lutein, α-
carotene, β-carotene 13, and lycopene 14 on HNSCC survival. Additionally, a previous study 
conducted by our group found that pretreatment dietary patterns within a U.S. cohort can be 
defined into two distinct groupings, and that the group characterized by a diet rich in vegetables, 
fruit, fish, poultry, and whole grains showed significantly improved survival compared to that 
characterized by a diet rich in red and processed meats, refined grains and potatoes 17. 
 
Inflammation 
Dysregulation of healing processes, chronic infections and immune-mediated diseases have the 
ability to cause chronic inflammation, which can consequently activate cellular pathways that 
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constitute risk factors for both cellular transformation and cancer progression18.  In a chronically 
inflamed state, cytokines, chemokines, prostaglandins, reactive oxygen and nitrogen radicals 
accumulate within the affected microenvironment, which if persistent, have the ability to 
promote prolonged cell survival and to induce cell proliferation 19,20. The activation of oncogenes 
and inactivation of tumor suppressor genes in this manner can result in genetic instability and 
consequently increase the risk of cancer.   
 
The intrinsic cellular circuits associated with cellular proliferation and survival of genetically 
altered cells can also lead to the production and secretion of inflammatory mediators. This 
cellular adaptation allows for angiogenesis promotion and aids the cancer in evading the body’s 
protective immune responses 19,21,22.  Several precancerous conditions, namely oral submucosal 
fibrosis and to a lesser degree, oral lichen planus, are characterized by immune-inflammatory 
processes that have previously been implicated in carcinogenesis 23. Although relatively 
common, a definitive association between these conditions and the development of OSCC has 
not been established.  
 
Several studies have previously reported increased inflammation associated with both alcohol 
consumption and western dietary patterns 18. Hyperadiposity has also previously been linked to 
chronic subclinical inflammation through a number of mechanisms including: switching the 
phenotype of adipose-tissue macrophages from the M2 anti-inflammatory phenotype to M1 
proinflammatory phenotype, increased production of proinflammatory cytokines (eg. TNF, 
interleukins IL-6 and IL-1β), and elevation in glucose, free fatty acids, leptin, insulin and insulin-
like growth factor (IGF1) 24,25. High consumption of red meat has also been implicated in 
carcinogenesis though proposed mechanisms such as increased insulin resistance, oxidative 
stress and inflammation 26-28. Whole grains, on the other hand, have been shown to be protective  
against tumorigenic processes by improving insulin sensitivity, lowering insulin and glucose 
levels, and by inhibiting inflammation and oxidative stress 28,29. Although consensus on dietary 
studies largely remain inconclusive, there is reason to believe that diet/dietary effects impact 
cancer risk independently and through inflammatory pathways.   
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Infectious Agents 
Human papillomavirus (HPV) 
Human papillomavirus (HPV) has been associated with oral squamous cell carcinoma (OSCC) 
for over thirty years 30. Nevertheless, recent cultural shifts leading to decreased tobacco use and 
increased HPV prevalence have allowed for an epidemiological change that has highlighted the 
role of HPV in HNSCC pathology. This subset of the disease is seen more commonly in younger 
patients, is associated with an improved prognosis and consequently has a different treatment 
profile from non-HPV oropharyngeal HNSCC 31-34. In the western world, most of these 
infections are attributed to “high risk” HPV subtypes 16 and 18 35, and have been shown to be 
present in up to 60-80% of non-oral HNSCC and ~30% of OSCC 36-39. On the molecular level, 
HPV associated HNSCC tumors often present with elevated p16 levels, and an absence of p53 
and RB1 mutations 40,41. These characteristics are unique to HPV positive HNSCC, as HPV 
negative tumors characteristically have inactivated p53 and p16 tumor suppressors and amplified 
RB1, consequently promoting cell cycle progression 42. Nevertheless, very little is known about 
HPV as a potential etiological factor elsewhere in the world.  
 
Epstein-Barr Virus (EBV) 
Epstein-Barr virus (EBV) belongs to the Herpesviridae family, which consists of eight viruses 
grouped into three subcategories: Alpha, Beta, and Gamma. In addition to acute disease, one of 
the hallmarks for these viruses is their ability to maintain latency; the subgroupings allow for 
differentiation of these viruses based on factors such as reproductive cycle, the particular cells 
which harbor the latency, and the consequent effect of potential re-activation later in life. EBV is 
one of the two gamma herpes viruses (HHV-8 being the second), characterized as such based on 
their ability to replicate in lymphoblastoid cells. Unlike HHV-8, EBV maintains latency in the 
lymphoid tissue, allowing areas of the oral cavity, such as tonsils and adenoids, to be primary 
regions of entry and egress of the virus 43. EBV initially infects epithelial cells in the oropharynx, 
where it replicates and consequently is able to infect B-cells by binding to the CD21 receptor in 
the B-cell surface, resulting in the internalization of the virus 44. Once infected, the cell can either 
proceed into the lytic phase (leading to new virions) or a latent phase (allowing the cell to 
transform to have nearly unlimited growth potential). Reactivated EBV infected cells have been 
shown to have the ability to transform into various types of malignancies, including: Burkitt 
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lymphoma, nasopharyngeal carcinoma, Hodgkin’s lymphoma and gastric carcinoma 43. 
Approximately 95% of the world's population harbors an asymptomatic, life-long infection with 
EBV, nevertheless, only a small proportion presents with an EBV-related cancer 45. Focusing on 
head and neck cancer, nasopharyngeal carcinoma has been sub-characterized into three 
histological groupings by the World Health Organization (WHO): keratinizing squamous cell 
carcinoma (type I) and non-keratinizing squamous cell carcinoma (further divided into 
differentiated and undifferentiated) and basaloid squamous cell carcinoma (WHO type 3) 46,47. 
While basaloid squamous cell carcinoma is incredibly rare, both classes of non-keratinizing SCC 
are associated with EBV infection, cumulatively accounting for an estimated 80% of worldwide 
nasopharyngeal cancers 47,48. According to GLOBOCAN 2012, 71% of all new nasopharyngeal 
cancer cases were reported in east and southeast Asia 49.  EBV is commonly classified into two 
groups: type 1 (or A) and type 2 (or B), and diverge through their genomic differences within a 
subset of latent genes that encode the EBV nuclear antigens 50,51. Although little is currently 
known about the prevalence of EBV in head and neck cancer in Thailand, one study 
investigating the role of EBV in nasopharyngeal cancer found high incidence of type-1 EBV in 
cases and controls (96.0% and 97.7%, respectably).  
 
Tumor Infiltrating Lymphocytes  
Recent cancer studies suggest tumorigenesis to be an immunologic disease as well as a genetic 
one. Immune cell infiltration (TILs) plays a significant role in HNSCC due to the close proximity 
of these lesions to the Waldeyer’s ring; this allows for dense infiltration of immune cells into the 
tumor, which has been shown to be prognostically significant in guiding treatment decisions 52. 
Additionally, HPV associated oropharyngeal squamous cell carcinomas have been reported to 
have deep lymphocytic infiltrates and are thought to evolve with immune cells specific for viral 
antigens 53. Although HPV positive HNSCCs commonly display nodal metastasis, the overall 
and progression-free survival rates are usually better than HPV negative HNSCC. One 
hypothesis for this phenomenon is that the body’s immune response against HPV may aid in the 
destruction of the tumor 54,55.  
 
Chemotherapy and radiotherapy are two of the primary treatment options for HNSCC patients. In 
addition to these classic techniques, anti-tumor immune activation has been repeatedly noted as 
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an important mechanism in maximizing treatment efficacy 56. In regards to chemoradiotherapy, 
increased levels of CD3 and CD8 T-cell infiltration have been associated with improved 
response to treatment 57. That being said, recent literature highlighted the importance of the 
infiltration pattern of these immune cells, noting the importance of their presence within or in 
close proximity to the tumor cells, rather than in the tumor stroma or the periphery, on prognostic 
value 58. 
 
Despite advances in both our knowledge of HNSCC biology and treatment, head and neck 
cancer remains a highly disfiguring disease with a high mortality rate. With an increase in the 
world’s aging population and increasing incidence of chronic diseases in developing countries, 
more research is needed to address global risk factors leading to this disease. 
 
Specific Aims  
This dissertation aims to advance our understanding of the heterogeneity that exists in the 
distribution, etiology, characterization and survival of head and neck cancer on a global scale. 
Figure I.1 illustrates the conceptual framework for these aims. Using both descriptive and 
molecular epidemiology methods, the following aims address critical gaps in the literature 
relevant to cancer monitoring, prevention and treatment.  
 
Specific Aim 1: Characterize and compare age-standardized incidence and mortality rates of 
head and neck cancer by sub-site and gender across, and within, South Asia, Southeast Asia and 
the United States.  
 
Hypothesis 1: Due to cultural, geographic and policy-driven variability in the proposed 
geographic locations, variations in risk and thereby prevalence are expected to be observed. 
Head and neck cancer is a male dominant disease, which is not expected to drastically change 
between settings. Site-specific analyses may reflect dissimilarity, largely due to frequency in 
smoking patterns, betel quid use, as well as HPV and EBV prevalence. 
 
Specific Aim 2: Use molecular epidemiology methods to assess HPV prevalence in 
oropharyngeal carcinoma in Thailand, assess utility of p16 staining as a surrogate measure of 
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HPV in this setting, and compare patient characteristics and tumor presentation to those in 
Western countries.  
 
Hypothesis 2: Based on evidence derived from descriptive epidemiology studies that suggest 
increasing oropharyngeal carcinoma incidence in Thailand, it is reasonable to believe that the 
etiological shift to HPV+ cancer has similarly begun to occur in Southeast Asia.   
Specific Aim 3: Investigate the potential role of pretreatment diet on tumor infiltrating 
lymphocytes by assessing both individual nutrients and dietary patterns within the UM-SPORE 
cohort.  
 
Hypothesis 3: Previous literature has shown that foods typically associated with a western diet 
may impact immune response by increasing inflammatory reactions, impacting 
immunosurveillance and influencing factors related to cellular proliferation (eg. insulin, leptin, 
etc.). Consequently, it is reasonable to believe that both individual dietary nutrients as well as 
dietary patterns may impact TILs, with increasing TIL counts being associated with higher 
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Subtype Specific Nasopharyngeal Carcinoma Incidence and Survival Trends: 




Background: While nasopharyngeal carcinoma (NPC) is rare in non-endemic regions such as 
the North America, endemic countries, such as Thailand, continue to struggle with high 
incidence and mortality burden. NPC has a complex etiology that varies by histological subtype. 
As Thailand undergoes rapid socioeconomic development, it is important to assess temporal 
trends in subtype specific NPC.   
 
Methods: NPC cases from 1990-2014 were identified using the International Classification of 
Diseases for Oncology (ICD-O) code C11 from the Chiang Mai, Khon Kaen, Lampang, and 
Songkhla cancer registries and compared to Asian/Pacific Islanders (A/PI) from the US SEER 
program. Age-standardized incidence rates and changes in annual percent change (APC) for 
overall and subtype specific NPC were assessed using R and Joinpoint regression software. 
Kaplan Meier curves were generated in SAS to evaluate differences in survival by sex, year of 
diagnosis and histological subtype. Five-year relative survival estimates were calculated between 
2000-2014. 
 
Results: Non-keratinizing NPC predominated across all registries except Songkhla, where the 
keretinizing subtype made up ~60% of all reported cases. Incidence of keratinizing NPC 
significantly decreased among Chiang Mai males between 1996 and 2014 (APC: -13.0 [95%CI: -
16.2, -9.6]), Songkhla females (APC: -4.0 [95%CI: -7.4, -0.5]) and males between 2006 and 
2014 (APC: -15.5 [95%CI: -25.0, -4.7]), as well as A/PI females (APC: -5.1 [95%CI: -6,7, -3.4]) 
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and males (APC: -4.8 [95%CI: -5.9, -3.7]). Non-keratinizing NPC increased among Songkhla 
males (APC: 4.3 [95%CI: 1.8, 6.9]). The keratinizing subtype exhibited the worst survival, while 
the non-keratinizing undifferentiated subtype had the best survival. Although US A/PI had the 
highest 5-year relative survival estimates, among the Thai registries Chiang Mai had the best and 
Lampang the worst survival.  
Conclusion: Although US A/PIs exhibited similar rates of NPC as seen in the endemic Thai 
population, improved tobacco control has led to a decrease in keratinizing NPC incidence 
irrespective of geography. Additionally, while challenges associated with access to care may still 
exist among rural Thais, chemoradiation was shown to confer a survival benefit in non-
























Arising in the epithelial lining of the nasopharynx, nasopharyngeal carcinoma (NPC) is uniquely 
characterized by its striking racial and geographic variation. In most of the world, including the 
United Stated,  NPC is considered to be a rare malignancy, with age-adjusted incidence among 
both genders reported to be less than one per 100,000 population 1.  Nevertheless, in endemic 
regions such as southern China, Southeast Asia, the Middle East and North Africa, NPC 
continues to contribute to a large proportion of the overall cancer burden 2. The World Health 
Organization (WHO) classified NPC into three distinct histological subtypes: keratinizing 
squamous cell carcinoma (WHO type 1), non-keratinizing carcinoma (WHO type 2), which can 
further be divided into differentiated and undifferentiated, and basaloid squamous cell carcinoma 
(WHO type 3) 3,4. While basaloid squamous cell carcinoma is very rare and sparsely mentioned 
in the literature, in high-incidence countries, non-keratinizing squamous cell carcinoma is 
considered to be the predominant histological subtype, accounting for an estimated 95% of cases 
2,5,6. Interestingly, keratinizing squamous cell carcinoma comprises the vast majority of NPCs in 
non-endemic regions, believed to be associated with alcohol and tobacco consumption patterns 7. 
 
Several epidemiological studies have established the WHO histological classifications as 
independent prognostic factors for NPC survival 8,9; non-keratinizing carcinoma has been shown 
to have significant survival advantages when compared to keratinizing squamous cell carcinoma, 
with 5-year survival rates of 51% and 6%, respectively 10. Epstein-Barr virus (EBV) has long 
been implicated as a causal factor in NPC, as well as several other malignancies 11 and is 
primarily associated with non-keratinizing carcinoma 12,13. Despite being ubiquitous, infecting 
and persisting latently in over 90% of the world’s population 14, and with numerous studies 
finding associations between anti-EBV antibodies, tumor burden and prognosis 15-29, there has 
been no strong evidence to suggest a correlation between the distribution of EBV strains and 
international patterns of NPC 2.  
 
Located in Southeast Asia, Thailand is an endemic nation for NPC. Rapid socioeconomic 
development in this region during the past few decades has led to a decrease in communicable 
diseases and an increase in cancer related mortality 30. Using data from four of Thailand’s 16 
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province- and regional- based registries 31, we compared age standardized NPC incidence and 
mortality rates across Thailand to those in the Asian/Pacific Islander (A/PI) population within the 





Data Selection and Criteria 
 
Cancer incidence data between 1990 and 2014 were obtained directly from the Chiang Mai, 
Khon Kaen, Lampang and Songkhla cancer registries in Thailand 32-35 as well as the 
Surveillance, Epidemiology, and End Results Program 9 (SEER) 36. For each Thai registry, 
population estimates by year, age and sex were based on decennial census data from 1990, 2000, 
and 2010, which were conducted by the Thai National Statistical Office 37,38. Annual intercensal 
population estimates for the various provinces were calculated using a log-linear function by 5-
year sex-specific age groups. Population counts beyond 2010 were modeled by the Office of the 
National Economic and Social Development Board 39,40.   
 
Nasopharyngeal cancer cases were identified in the various registries using the International 
Classification of Diseases for Oncology (ICD-O) code ‘C11’ and assessed as sex stratified, 
temporal trends in incidence rates aggregated over 5-year age groups (0-85+). All malignant 
nasopharyngeal cancer cases identified between the years of 1990 and 2014 were used for these 
analyses. In addition to cancer site, case information included age, sex, date of diagnosis, stage, 
histology, morphology, vital status and date last seen.  Histological groupings were created 
according to criteria specified by the WHO International Classification of Diseases for Oncology 
(ICD-O-3) 3,41 and included: keratinizing squamous cell carcinoma (ICD-O histology codes 8070 
and 8071), differentiated non-keratinizing carcinoma (ICD-O histology codes 8072 and 8073), 
undifferentiated non-keratinizing carcinoma (ICD-O histology codes 8020, 8021, and 8082) and 
‘carcinoma not otherwise specified’ (ICD-O histology code 8010).




Incidence trend analyses were conducted using Joinpoint Regression Program version 4.5.0.1. 42 
to assess trends under a log-linear model and to compute the annual percent change (APC) in 
age-standardized incidence rates.  The aforementioned program utilizes a Monte Carlo 
permutation method in order to assess number of joinpoints, slope in the trends, as well as the 
corresponding significance 43. Sex stratified trends were assessed by registry and morphological 
subtype. In circumstances where no cases were reported within a given year, a half-case was 
added to the age strata with the largest population to enable computation on the log-linear scale 
32,43,44. In order to improve comparability between the various Thai registries and SEER, Segi 
(1960) standardization was applied 45,46.  R-statistical software version 3.3.3 47 was used to shape 
the data and generate graphs based on Joinpoint outputs. Due to small sample sizes of sex 
stratified differentiated and undifferentiated non-keratinizing carcinomas within the Thailand 
registries, incidence trends for these morphological subtypes were grouped into a single non-




Kaplan Meier curves assessing differences in survival by sex, year of diagnosis (in five-year 
groupings) and histological subtype were generated for each registry and strata were compared 
using log-rank tests. Since Thailand does not have data on expected survival by age, sex, 
calendar year and province, a life table was ascertained from the WHO Global Health 
Observatory data repository for the years of 2000-2014 to calculate 5-year relative survival 
among the Thai registries. Five-year relative survival was computed among Asian/Pacific 
islanders, for the corresponding years, by sex and subtype, using the Kaplan-Meier method in 




Between 1990 and 2014, 1,894 cases of NPC were diagnosed among A/PIs in the United States, 
934 in Chiang Mai, 704 in Khon Kaen, 549 in Songkhla and 390 in Lampang. Cases were found 
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to be predominantly male across all the registries, with mean age at diagnosis ranging from 47-
53 years. Among A/PI in the US, the non-keratinizing subtype predominated, making up 51% of 
cases for both males and females. In Chiang Mai, Khon Kaen and Lampang, non-keratinizing 
nasopharyngeal carcinoma constituted 66-79% of cases, with no significant differences in 
distribution between genders within each given registry. Interestingly, in Songkhla the majority 
of cases were found to be of the keratinizing subtype, comprising about 60% of all reported 
NPCs (Table 2.1). 
 
At the beginning of the study period, in 1990, US A/PIs had the highest overall NPC incidence, 
with an expected age standardized rate (EASR) of 4.48 and 1.60 per 100,000 among males and 
females, respectively. As time progressed, incidence among A/PI men decreased with an APC of 
-1.9 (95%CI: -2.6, -1.2) and -1.8 (95%CI: -2.8, -0.8) among women. Declines in NPC incidence 
were similarly observed among Chiang Mai males, at an APC of -2.2 (95%CI: -3.4, -0.9). Khon 
Kaen and Lampang presented with suggested increases in nasopharyngeal cancer incidence 
among both sexes, largely driven by increases in the non-keratinizing subtype. Accounting for 
these changes in trends, in 2014, US A/PI males remained the highest incident group of NPC 
(EASR: 2.81 per 100,000), while Lampang emerged as having the highest rates among women 
(EASR: 1.28 per 100,000) (Figure 2.1).   
 
Assessing trends by the presence of keratinization revealed consistent decreases in the 
keratinizing NPC sub-type; significant decreases were observed among Chiang Mai men 
between 1996 and 2014 (APC: -13.0 [95%CI: -16.2, -9.6]), Songkhla females (APC: -4.0 
[95%CI: -7.4, -0.5]) and males between 2006 and 2014 (APC: -15.5 [95%CI: -25.0, -4.7]), as 
well as A/PI females (APC: -5.1 [95%CI: -6,7, -3.4]) and males (APC: -4.8 [95%CI: -5.9, -3.7]). 
Conversely, non-keratinizing NPC appeared to be increasing, particularly among men, across all 
the registries except Chiang Mai and the US. This observation was found to have the greatest 
significant impact in Songkhla males, with an APC of 4.3 (95%CI: 1.8, 6.9) (Figure 2.1). 
 
Sex stratified Kaplan-Meier (KM) plots demonstrated significantly improved survival among 
females in Songkhla, Khon Kaen and Chiang Mai (logrank p: 0.01, 0.002 and 0.001, 
respectively) but no differences across the other registries.
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The keratinizing squamous cell carcinoma subtype was found to elicit the worst survival, with 
significant differences noted in Chiang Mai (logrank p: <0.0001), Songkhla (logrank p: <0.0001) 
and US A/PIs (logrank p: 0.0004). While the nonkeratinizing differentiated subtype appeared to 
provide the greatest survival advantage in Songkhla, undifferentiated NPC was associated with 
improved survival among A/PIs. Khon Kaen was the only registry to demonstrate improved 
survival with later years of diagnosis (logrank p: 0.002) (Figure 2.2). Five-year relative survival 
estimates, between the years of 2000 and 2014, closely mirrored the KM results. Although US 
A/PI had the highest 5-year relative survival estimates, Chiang Mai had the best 5-year relative 




While numerous studies on nasopharyngeal carcinoma have been conducted within Chinese 
populations 48-52, this is the first paper, to our knowledge, to assess temporal trends in NPC 
incidence and mortality across Thailand in comparison to Asian/Pacific Islanders in the United 
States. As an endemic country for NPC undergoing rapid economic development, it is important 
to evaluate the role of both preventative risk factors on incidence, as well as changes in 
healthcare and treatment protocols on survival among NPC patients in Thailand. In this study, we 
found overall NPC incidence to be decreasing among US A/PIs of both sexes, as well as Chiang 
Mai males; nevertheless, the remainder of our study sites displayed stagnant NPC incidence. We 
additionally found distinct survival differences by sex, registry, and subtype, reflective of the 
variability of population dynamics, cultural norms and access to care. 
 
Use of combustible tobacco has repeatedly been shown to influence the risk of cancer 
development across a number of head and neck cancer sites, including the nasopharynx. A recent 
study in Singaporeans found that current smokers exhibited a four-fold increase in NPC 
development when compared to never smokers, while ever-smokers exhibited a 2-fold increase 
53. Similar findings have been reported in Thailand 54,55, China 56,57, Taiwan 58, the Philippines 59 
and the United States 7,60-62. A meta-analysis of the current literature demonstrated that the risks 
of combustible tobacco use on NPC were particularly relevant to keratinizing squamous cell 
carcinoma 53. Largely due to cultural norms, male smoking rates are much higher than those 
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among females across Thailand; nevertheless, Thailand does display geographic variability in 
smoking, with the south having the highest smoking prevalence 63. Initiated in 1991, Thailand 
was among the first countries in Asia to implement strict tobacco control policies, including bans 
on advertisements and smoking in certain public places, health warnings and taxation 64-67. 
According to the Tobacco Control Research and Knowledge Center, smoking prevalence has 
decreased across Thailand, but smoking behaviors remain highest in the south (decreasing from 
60.9% in 1994, to 49.9% in 2007) 68,69. The greater proportion of male smokers likely contributes 
to the higher incidence of keratinizing squamous cell carcinoma among males observed across 
all study sites. Songkhla (located in southern Thailand) was the only registry to exhibit higher 
keratinizing rather than non-keratinizing NPC incidence, likely due to the higher smoking rates 
within the region.  
 
Keratinizing squamous cell carcinoma typically predominates in non-endemic regions such as 
the United States 70. Nevertheless, previous studies have shown that Asian Americans continue 
to exhibit higher rates of NPC, particularly the non-keratinizing subtype, when compared to 
other race groups 70,71. In this study, we found US A/PIs to have the highest age standardized rate 
of NPC, when compared to the Thai registries. Decreases in incidence over the time period 
resulted in Lampang females superseding US A/PI females, US A/PI males remained the highest 
incident group. Although, this study validated previous observations of a predominance of non-
keratinizing NPC among this population, the decreased incidence observed within overall NPC is 
largely attributable to decreases in keratinizing squamous cell carcinoma, while the non-
keratinizing subtype remained stagnant.   
 
While non-keratinizing NPC is believed to present with a more aggressive behavior and a higher 
risk of distant metastasis, keratinizing squamous cell carcinoma has been reported to be less 
responsive to treatment 72. Historically, radiotherapy has been the cornerstone of treatment across 
NPC subtypes. In the minority of patients diagnosed in early stages, NPC has relatively high 
sensitivity to radiation, but this treatment has been shown to fail among patients with locally 
advanced disease 72. More recently, concurrent chemo-radiation treatment has been shown to 
improve survival among non-keratinizing locally advanced patients, particularly those with 
undifferentiated tumors 72,73. Chiang Mai was the first registry location in Thailand to implement
    
21 
the use of chemoradiation in NPC treatment, beginning enrollment in a clinical trial in 1989 and 
adapting the treatment into practice in 1996 74. Shortly upon completion of the phase 3 
randomized Intergroup 0099 Study in 1995 75, the US adopted chemoradiation as the primary 
treatment for advanced stage NPC; Khon Kaen, Lampang and Songkhla similarly implemented 
the new treatment guidelines soon after the US 76,77.  Coinciding with the literature, our study 
found significantly worse survival among those diagnosed with keratinizing squamous cell 
carcinoma in Chiang Mai, Songkhla, and US A/PI. Undifferentiated non-keratinizing NPC 
appeared to be associated with improved survival in Chiang Mai, Lampang and the US, likely 
due in part to tumor treatment response, and in part to the earlier age of onset for this cancer 
subtype (data not shown) 78. Five-year relative survival results indicated that US A/PIs have the 
best survival, regardless of cancer subtype. Among the Thai registries, Chiang Mai proved to 
provide the best survival rates, likely due to the early adaptation of chemoradiation. 
 
Although the early adaptation of improved treatment modalities may improve patient survival, 
equal access to care remains a problem in parts of Thailand. Northern Thailand is unique in that 
it encapsulates the ‘hill tribe’ population. These individuals reside in the mountain slopes and are 
divided into six primary groups: Akha, Lahu, Hmong, Lisu, Yao and Karen. In addition to 
having different cultural practices, the hill tribes have unique languages, as well as beliefs that 
influence their health care practices 79,80. Originating largely from Southern China (a high 
incidence region for NPC), the Akha are the largest tribe, comprised of an estimated 70,000 
individuals 80. Historically migrant populations, many hill tribe residents did not have legal 
identification and were not considered Thai citizens until recently. A 2014 report by the Mae Fah 
Luang District Office estimated that 89% of hill tribe residents had access to health care under 
the Thai Universal Coverage System, which was introduced in 2000 81,82. In 2011, the National 
Health Examination Survey Office reported that smoking rates among Ahka young adults was 
higher than that of Thai young adults (28% and 19.9%, respectively) 83. While exhibiting various 
high risk behaviors, previous studies have demonstrated that factors such as language 
barrier/illiteracy rates, lack of transportation, financial restrictions and reliance on traditional 
medical practices are all factors that contribute to health disparities within hill tribe populations 
80,82,84,85. These various obstacles consequently impact utilization of both treatment and 
preventative care. Unlike trends observed in Khon Kaen and Songkhla, the Chiang Mai and 
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Lampang registries appear to have worsening survival with successive years of diagnosis, 
particularly corresponding to the initiation of universal healthcare. Due to limitations in access to 
care, these trends may be attributable to an increase of hill tribe patients, who would likely be 
diagnosed at later stages and be less willing and able to comply with modern treatment protocols.  
 
Differences in data collection methods and population composition pose challenges to 
comparability between registries. Although Thailand’s cancer registries have been verified to 
have high quality data 44,86, data collection methods vary from passive, to active, to a 
combination of the two 87-90. Additionally, while population-based cancer registries allow results 
to be generalized to nearby provinces, it is difficult to quantify the precise number of unreported 
cancer cases, particularly within rural areas.  Finally, changes to histology practices, such as the 
introduction of immunohistochemistry staining, may influence subsite specific classification, 
leading to misclassification bias. This effect is likely observed in the Chiang Mai and Songkhla 
registries, where the apparent trends between keratinizing and non-keratinizing NPC incidence 
invert around 1996 and 2006, respectively.  
 
In conclusion, albeit not being an endemic country for NPC, US A/PIs appear to have 
comparable incidence rates to those observed in the endemic Thai population—even exceeding 
the cancer burden observed among Thai males. This study also demonstrated the role of tobacco 
control on keratinizing NPC incidence, as well as the survival benefit associated with the 
introduction of chemoradiation in non-keratinizing NPC treatment. Finally, it puts into 
perspective the challenges associated with access to care in rural populations, irrespective of the 
introduction of universal health care. In order to address this and other potential health disparities 
in these communities, local health professionals should be encouraged to develop culturally 
appropriate health promotion and educational programs in order to aid in curbing high-risk 
behaviors and improving access and acceptance of care.  











1. Parkin DM WS, Ferlay J, Teppo L, Thomas D. Cancer Incidence in Five Continents, vol 
8. IARC Scientific Publications: International Agency for Research on Cancer, 
Lyon;2002. 
2. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. 
Cancer Epidemiol Biomarkers Prev. 2006;15(10):1765-1777. 
3. Barnes L, Eveson J, Reichart P, Sidransky D. World Health Organization classification of 
tumours. Pathology and genetics of head and neck tumours. International Agency of 
Research on Cancer. 2005. 
4. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell. 
2004;5(5):423-428. 
5. Yu MC HB. Cancer Epidemiology and Prevention. 2nd ed. New York: Oxford 
University Press; 1996. 
6. Zong YS, Zhang RF, He SY, Qiu H. Histopathologic types and incidence of malignant 
nasopharyngeal tumors in Zhongshan County. Chin Med J (Engl). 1983;96(7):511-516. 
7. Vaughan TL, Shapiro JA, Burt RD, et al. Nasopharyngeal cancer in a low-risk 
population: defining risk factors by histological type. Cancer Epidemiol Biomarkers 
Prev. 1996;5(8):587-593. 
8. Burt RD, Vaughan TL, McKnight B. Descriptive epidemiology and survival analysis of 
nasopharyngeal carcinoma in the United States. Int J Cancer. 1992;52(4):549-556. 
9. Levine PH, Connelly RR, Easton JM. Demographic patterns for nasopharyngeal 
carcinoma in the United States. Int J Cancer. 1980;26(6):741-748. 
10. Reddy SP, Raslan WF, Gooneratne S, Kathuria S, Marks JE. Prognostic significance of 
keratinization in nasopharyngeal carcinoma. Am J Otolaryngol. 1995;16(2):103-108. 
11. Guidry JT, Birdwell CE, Scott RS. Epstein–Barr virus in the pathogenesis of oral cancers. 
Oral Diseases. 2017. 
12. Shi W, Pataki I, MacMillan C, et al. Molecular pathology parameters in human 
nasopharyngeal carcinoma. Cancer. 2002;94(7):1997-2006. 
13. Niedobitek G, Deacon EM, Young LS, Herbst H, Hamilton-Dutoit SJ, Pallesen G. 
Epstein-Barr virus gene expression in Hodgkin's disease. Blood. 1991;78(6):1628-1630. 
14. Rickinson AB KE. Epstein-Barr virus. In: David M. Knipe PMHM, Diane E. Griffin MD 
PhD, Robert A. Lamb PhD ScD, Malcolm A. Martin MD, Bernard Roizman, Stephen E. 
Straus, ed. Field’s virology. 4th ed. Lippincott, Williams & Wilkins2001:2575-2627. 
15. Gunven P, Klein G, Henle W, et al. Immunological studies on a case of recurrent 
Burkitt's lymphoma during immune stimulant treatment. Int J Cancer. 1973;12(1):115-
123. 
24 
16. de Schryver A, Klein G, Henle W, Henle G. EB virus-associated antibodies in Caucasian 
patients with carcinoma of the nasopharynx and in long-term survivors after treatment. 
Int J Cancer. 1974;13(3):319-325. 
17. Barlow GH, Kakkar VV, Bentley PG, Chan PS, Jones NA, Mistry FD. Biochemical 
comparison of intermittent streptokinase and intermittent streptokinase plasminogen 
therapy. Thromb Res. 1979;15(1-2):135-142. 
18. Mathew GD, Qualtiere LF, Neel HB, 3rd, Pearson GR. IgA antibody, antibody-
dependent cellular cytotoxicity and prognosis in patients with nasopharyngeal carcinoma. 
Int J Cancer. 1981;27(2):175-180. 
19. Tsuzuki K, Tanahashi T. [Complex tone processing in the brain stem--responses of 
inferior colliculus neurons to vowel-like stimulus sounds in the rabbit]. Nihon Jibiinkoka 
Gakkai Kaiho. 1982;85(7):791-804. 
20. Naegele RF, Champion J, Murphy S, Henle G, Henle W. Nasopharyngeal carcinoma in 
American Children: Epstein-Barr virus-specific antibody titers and prognosis. Int J 
Cancer. 1982;29(2):209-212. 
21. Neel HB, 3rd, Pearson GR, Weiland LH, et al. Application of Epstein-Barr virus serology 
to the diagnosis and staging of North American patients with nasopharyngeal carcinoma. 
Otolaryngol Head Neck Surg. 1983;91(3):255-262. 
22. Tamada A, Makimoto K, Yamabe H, et al. Titers of Epstein-Barr virus-related antibodies 
in nasopharyngeal carcinoma in Japan. Cancer. 1984;53(3):430-440. 
23. de-Vathaire F, Sancho-Garnier H, de-The H, et al. Prognostic value of EBV markers in 
the clinical management of nasopharyngeal carcinoma (NPC): a multicenter follow-up 
study. Int J Cancer. 1988;42(2):176-181. 
24. Mutirangura A, Pornthanakasem W, Theamboonlers A, et al. Epstein-Barr viral DNA in 
serum of patients with nasopharyngeal carcinoma. Clin Cancer Res. 1998;4(3):665-669. 
25. Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus 
DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 
1999;59(6):1188-1191. 
26. Lin JC, Chen KY, Wang WY, et al. Detection of Epstein-Barr virus DNA in the 
peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant 
metastasis and survival. J Clin Oncol. 2001;19(10):2607-2615. 
27. Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in 
patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350(24):2461-
2470. 
28. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum 
DNA of head and neck cancer patients. Nat Med. 1996;2(9):1035-1037. 
29. Chan AT, Lo YM, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease 
after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst. 
2002;94(21):1614-1619. 
30. Vatanasapt V, Martin N, Sriplung H, et al. Cancer incidence in Thailand, 1988-1991. 
Cancer Epidemiol Biomarkers Prev. 1995;4(5):475-483. 
31. Tangjaturonrasme N, Vatanasapt P, Bychkov A. Epidemiology of head and neck cancer 
in Thailand. Asia Pac J Clin Oncol. 2017;14(1):16-22. 
32. Demanelis K, Sriplung H, Meza R, et al. Differences in childhood leukemia incidence 
and survival between Southern Thailand and the United States: a population-based 
analysis. Pediatr Blood Cancer. 2015;62(10):1790-1798
    25 
 
 
33. Alvarez CS, Virani S, Meza R, Rozek LS, Sriplung H, Mondul AM. Current and Future 
Burden of Prostate Cancer in Songkhla, Thailand: Analysis of Incidence and Mortality 
Trends From 1990 to 2030. https://doiorg/101200/JGO1700128. 2018. 
34. Virani S, Sriplung H, Rozek LS, Meza R. Escalating burden of breast cancer in southern 
Thailand: analysis of 1990-2010 incidence and prediction of future trends. Cancer 
Epidemiol. 2014;38(3):235-243. 
35. Mitro SD, Rozek LS, Vatanasapt P, et al. Iodine deficiency and thyroid cancer trends in 
three regions of Thailand, 1990-2009. Cancer Epidemiol. 2016;43:92-99. 
36. Abazov VM, Abbott B, Abolins M, et al. Search for neutral supersymmetric Higgs 
Bosons in multijet events at sqrt[s]=1.96 TeV. Phys Rev Lett. 2005;95(15):151801. 
37. 2000 Population and Housing Census. National Statistics Office;2002. 
38. 2010 Population and Housing Census. National Statistics Office;2012. 
39. Sriplung H, Bilheem S, Kuntipundee T, Geater SL. Differences in cancer incidence 
among predominantly Muslim and Buddhist subpopulations in Songkhla. Asian Pac J 
Cancer Prev. 2014;15(22):9979-9983. 
40. Sriplung H, Singkham P, Iamsirithaworn S, Jiraphongsa C, Bilheem S. Success of a 
cervical cancer screening program: trends in incidence in songkhla, southern Thailand, 
1989-2010, and prediction of future incidences to 2030. Asian Pac J Cancer Prev. 
2014;15(22):10003-10008. 
41. Ou SH, Zell JA, Ziogas A, Anton-Culver H. Epidemiology of nasopharyngeal carcinoma 
in the United States: improved survival of Chinese patients within the keratinizing 
squamous cell carcinoma histology. Ann Oncol. 2007;18(1):29-35. 
42. Joinpoint Regression Program - Surveillance Research Program. 2018; 
https://surveillance.cancer.gov/joinpoint/. 
43. Kim HJ, Syracuse University DoM, 215 Carnegie Building, Syracuse University, 
Syracuse, NY 132441150, U.S.A., Syracuse University DoM, 215 Carnegie Building, 
Syracuse, NY 132441150, U.S.A., et al. Permutation tests for joinpoint regression with 
applications to cancer rates. Statistics in Medicine. 2000;19(3):335-351. 
44. Argirion I, Zarins KR, Defever K, et al. Temporal Changes in Head and Neck Cancer 
Incidence in Thailand Suggest Changing Oropharyngeal Epidemiology in the Region. J 
Glob Oncol. 2019;5:1-11. 
45. Bray F, Guilloux A, Sankila R, Parkin DM. Practical implications of imposing a new 
world standard population. Cancer causes & control : CCC. 2002;13(2):175-182. 
46. Segi M, Kyōkai NT, Igakubu TD. Cancer mortality for selected sites in 24 countries 
(1950-57). 1960; https://www.ncbi.nlm.nih.gov/pubmed/. 
47. R: A language and environment for statistical computing [computer program]. Vienna, 
Austria: R Foundation for Statistical Computing 2008. 
48. King H, Haenszel W. Cancer mortality among foreign—and native-born Chinese in the 
United States. Journal of Clinical Epidemiology. 1973;26(10):623-646. 
49. Hu LF, Zabarovsky ER, Chen F, et al. Isolation and sequencing of the Epstein-Barr virus 
BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol. 1991;72 ( 
Pt 10):2399-2409. 
50. Zou XN, Lu SH, Liu B. Volatile Nnitrosamines and their precursors in chinese salted 
fisha possible etological factor for NPC in China. International journal of cancer. 
1994;59(2):155-158
    26 
 
 
51. Yu MC, Ho JH, Ross RK, Henderson BE. Nasopharyngeal carcinoma in Chinese---salted 
fish or inhaled smoke? Prev Med. 1981;10(1):15-24. 
52. Chan AS, To KF, Lo KW, et al. High frequency of chromosome 3p deletion in 
histologically normal nasopharyngeal epithelia from southern Chinese. Cancer Res. 
2000;60(19):5365-5370. 
53. Yong SK, Ha TC, Yeo MC, Gaborieau V, McKay JD, Wee J. Associations of lifestyle 
and diet with the risk of nasopharyngeal carcinoma in Singapore: a case-control study. 
Chin J Cancer. 2017;36(1):3. 
54. Ekburanawat W, Ekpanyaskul C, Brennan P, et al. Evaluation of non-viral risk factors for 
nasopharyngeal carcinoma in Thailand: results from a case-control study. Asian Pac J 
Cancer Prev. 2010;11(4):929-932. 
55. Fachiroh J, Sangrajrang S, Johansson M, et al. Tobacco consumption and genetic 
susceptibility to nasopharyngeal carcinoma (NPC) in Thailand. Cancer causes & control 
: CCC. 2012;23(12):1995-2002. 
56. Ji X, Zhang W, Xie C, Wang B, Zhang G, Zhou F. Nasopharyngeal carcinoma risk by 
histologic type in central China: impact of smoking, alcohol and family history. Int J 
Cancer. 2011;129(3):724-732. 
57. Yuan JM, Wang XL, Xiang YB, Gao YT, Ross RK, Yu MC. Non-dietary risk factors for 
nasopharyngeal carcinoma in Shanghai, China. Int J Cancer. 2000;85(3):364-369. 
58. Cheng YJ, Hildesheim A, Hsu MM, et al. Cigarette smoking, alcohol consumption and 
risk of nasopharyngeal carcinoma in Taiwan. Cancer Causes Control. 1999;10(3):201-
207. 
59. West S, Hildesheim A, Dosemeci M. Non-viral risk factors for nasopharyngeal 
carcinoma in the Philippines: results from a case-control study. Int J Cancer. 
1993;55(5):722-727. 
60. Mabuchi K, Bross DS, Kessler, II. Cigarette smoking and nasopharyngeal carcinoma. 
Cancer. 1985;55(12):2874-2876. 
61. Nam JM, McLaughlin JK, Blot WJ. Cigarette smoking, alcohol, and nasopharyngeal 
carcinoma: a case-control study among U.S. whites. J Natl Cancer Inst. 1992;84(8):619-
622. 
62. Chow WH, McLaughlin JK, Hrubec Z, Nam JM, Blot WJ. Tobacco use and 
nasopharyngeal carcinoma in a cohort of US veterans. Int J Cancer. 1993;55(4):538-540. 
63. Benjakul S, Kengganpanich, M., Termsirikulchai, L., Kengganpanich, T., Theskayan, N. 
Puckcharern, H., Touchchai, C., Lohtongmongkol, A. . Global Adult Tobacco Survey: 
Thailand Report 2011. Nice Earth Design Co., LTD.; 2012. 
64. Chantornvong S, McCargo D. Political economy of tobacco control in Thailand. Tob 
Control. 2001;10(1):48-54. 
65. Chantornvong S, Collin J, Dodgson R, et al. Political economy of tobacco control in low-
income and middle-income countries: lessons from Thailand and Zimbabwe. Global 
Analysis Project Team. Bull World Health Organ. 2000;78(7):913-919. 
66. Vateesatokit P, Hughes B, Ritthphakdee B. Thailand: winning battles, but the war's far 
from over. Tob Control. 2000;9(2):122-127. 
67. Haman S. Thailand: victories and defeats in the long war. Tob Control. 2003;12(1):8.
    27 
 
 
68. Tobacco Control Research and Knowledge Management Center: Thailand Tobacco 
Control Policies. Bangkok, Thailand: Tobacco Control Research and Knowledge 
Management Center;2008. 
69. Chang JT, Jeon J, Sriplung H, et al. Temporal Trends and Geographic Patterns of Lung 
Cancer Incidence by Histology in Thailand, 1990 to 2014. J Glob Oncol. 2018;4:1-29. 
70. Wang Y, Zhang Y, Ma S. Racial differences in nasopharyngeal carcinoma in the United 
States. Cancer Epidemiol. 2013;37(6):793-802. 
71. Argirion I, Zarins KR, Ruterbusch JJ, et al. Increasing incidence of Epstein-Barr virus-
related nasopharyngeal carcinoma in the United States. Cancer. 2019. 
72. Paiar F, Di Cataldo V, Zei G, et al. Role of chemotherapy in nasopharyngeal carcinoma. 
Oncol Rev. 2012;6(1):e1. 
73. Perri F, Bosso D, Buonerba C, Lorenzo GD, Scarpati GD. Locally advanced 
nasopharyngeal carcinoma: Current and emerging treatment strategies. World J Clin 
Oncol. 2011;2(12):377-383. 
74. Chua DT, Sham JS, Choy D, et al. Preliminary report of the Asian-Oceanian Clinical 
Oncology Association randomized trial comparing cisplatin and epirubicin followed by 
radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally 
advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association 
Nasopharynx Cancer Study Group. Cancer. 1998;83(11):2270-2283. 
75. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in 
patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 
0099. J Clin Oncol. 1998;16(4):1310-1317. 
76. Pornthep Kasemsiri CT, Krittika Suwanrungruang. Long-term Survival Outcome of 
Treatment for Nasopharyngeal Carcinoma in Srinagarind Hospital, Thailand: 10-year 
Retrospective Analysis. Srinagarind Med J. 2015;30(2). 
77. Cancer Incidence in Northern Thailand: 2003-2007. 2009. 
78. Leu Y-S, Chang Y-F, Lee J-C, Lo A-C, Chen Y-J, Chen H-W. Prognosis of 
nasopharyngeal carcinoma in the elderly is worse than in younger individuals–experience 
of a medical institute. International Journal of Gerontology. 2014;8(2):81-84. 
79. Besaggio D, Fuselli S, Srikummool M, et al. Genetic variation in Northern Thailand Hill 
Tribes: origins and relationships with social structure and linguistic differences. BMC 
Evol Biol. 2007;7 Suppl 2:S12. 
80. Apidechkul T, Wongnuch P, Sittisarn S, Ruanjai T. Health situation of Akha hill tribe in 
Chiang Rai Province, Thailand. Journal of Public Health and Development. 
2016;14(1):77-79. 
81. Chiang  Rai MFLDPHO. Annual report: health status in 2014. 2014. 
82. Apidechkul T, Laingoen O, Suwannaporn S. Inequity in accessing health care service in 
Thailand in 2015: a case study of the hill tribe people in Mae Fah Luang district, Chiang 
Rai, Thailand. J Health Res vol. 2016;30(1). 
83. Office NHES. The 4th report of population Thai health by physical examination. 2011. 
84. Rittirong J, Prasartkul P, Rindfuss RR. From whom do older persons prefer support? The 
case of rural Thailand. Journal of aging studies. 2014;31:171-181. 
85. Pitchayakan P. Inter-relationship of subsistence economy and population problem: a 
study of the Akha case in Thailand. SEAPRAP research report; no 89. 1982. 
28 
86. Suwanrungruang K, Sriplung H, Attasara P, et al. Quality of case ascertainment in cancer 
registries: a proposal for a virtual three-source capture-recapture technique. Asian Pac J 
Cancer Prev. 2011;12(1):173-178. 
87. IACR - Chiang Mai Cancer Registry. 2018; 
http://www.iacr.com.fr/index.php?option=com_comprofiler&task=userprofile&user=990
&Itemid=498. 
88. IACR - Lampang Cancer Registry. 2018; 
http://www.iacr.com.fr/index.php?option=com_comprofiler&task=userprofile&user=992
&Itemid=498. 
89. IACR - Songkhla Cancer Registry. 2018; 
http://www.iacr.com.fr/index.php?option=com_comprofiler&task=userprofile&user=994
&Itemid=498. 





    29 
 
Table 2.1: Distribution of Cases by Gender and Registry (1990-2014) 
 
 






   USA-Asian/Pacific 
Islander 
Chiang Mai Khon Kaen Songkhla Lampang 
 Male Female Male Female Male Female Male Female Male Female 
























557 (29.41) 650 (69.59) 284 (30.41) 491 (69.74) 213 (30.26) 399 (72.68) 150 (27.32) 261 (66.92) 129 (33.08) 
Cell Type, N (%)           
Keratinizing 320 (23.93) 122 (21.90) 178 (27.38) 59 (20.77) 139 (28.31) 57 (26.76) 240 (60.15) 86 (57.33) 72 (27.59) 37 (28.68) 
Non-Keratinizing 686 (51.31) 284 (50.99) 466 (71.69) 223 (78.52) 344 (70.06) 150 (70.42) 156 (39.10) 60 (40.00) 178 (68.20) 85 (65.89) 
Differentiated 284 (41.40) 130 (45.77) 231 (49.57) 81 (36.32) 199 (57.85) 89 (59.33) 37 (23.72) 14 (23.33) 101 (56.74) 47 (55.29) 
Undifferentiated  402 (58.60) 154 (54.23) 235 (50.43) 142 (63.68) 145 (42.15) 61 (40.67) 119 (76.28) 46 (76.67) 77 (43.26) 38 (44.71) 
NOS 331 (24.76) 151 (27.11) 6 (0.92) 2 (0.70) 8 (1.63) 6 (2.82) 3 (0.75) 4 (2.67) 11 (4.21) 7 (5.43) 
NOS=not otherwise specified  
   USA- Asian/Pacific Islander Chiang Mai Khon Kaen Songkhla Lampang 
 Male Female Male Female Male Female Male Female Male Female 
Number of Cases, N 
(%) 
824 338 395 188 341 151 270 97 181 90 























































9.70 (2.03, 17.36) 15.48 (1.61, 
29.34) 








19.42 (8.03, 30.81) 20.82 (7.38, 34.27) 17.40 (0.00, 37.59) 3.36 (0.00, 12.01) 9.79 (0.47, 19.12) 9.05 (0.00, 25.94) 














9.57 (0.00, 24.75) 22.44 (0.00, 
47.11) 
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Figure 2.1: Joinpoint analyses of nasopharyngeal carcinoma by morphology and registry (APC [95% CI]) 
 
(*) denotes statistical significance at alpha = 0.05.
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Background:  Incidence of nasopharyngeal carcinoma (NPC) has been historically low in the 
US. While etiological factors differ by histological subtype, Epstein-Barr virus (EBV) is 
accepted as the primary risk factor for non-keratinizing NPC. In light of the changing 
epidemiology of viral-associated cancers, it is important to evaluate temporal incidence of NPC 
in the US.  
Methods: Incidence and survival data from 1973-2015 were obtained from the Surveillance, 
Epidemiology and End Results (SEER) Program. Stratified analyses were conducted to assess 
temporal trends in NPC by histological subtype, sex and race. The data were analyzed using SAS 
and Joinpoint Regression Software to determine age-adjusted incidence rates, trends in annual 
percent change (APC), and calculate 5-year relative survival estimates and Kaplan-Meier curves.  
Results:  Although overall NPC incidence is decreasing in the US, the non-keratinizing 
differentiated subtype is starkly increasing with an APC of approximately 4% among white 
males (95%CI: 2.5, 5.2), white females (95%CI: 1.9, 6.2), and black males (95%CI: 2.0, 5.7), 
2.7% among black females (95%CI: 0.8, 4.6) and 1.8% among women of other race (95%CI: 
0.4, 3.3). Racial disparities were noted, with 32% of non-keratinizing NPC cases among blacks 
occurred before the age of 40. Additionally, black males displayed consistently worse survival 
across all histological subtypes, while those individuals in the “other” race category, particularly 
females, experienced the highest 5-year relative survival estimates. 
Conclusions: Our results indicate that the EBV-related differentiated NPC subtype is increasing 
across all genders and races in the US, with distinct incidence and survival disparities among 
blacks.  
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Introduction  
 
Nasopharyngeal carcinoma (NPC) incidence varies greatly throughout the world. While 
historically rare in the United States, NPC is endemic to southeast China, Southeast Asia, the 
Middle East and North Africa 1. Arising from the surface epithelium of the posterior 
nasopharynx 2, NPC is currently classified by the World Health Organization (WHO) into three 
major histological subtypes: keratinizing squamous cell carcinoma (WHO type 1), non-
keratinizing carcinoma (WHO type 2), which can further be divided into differentiated and 
undifferentiated, and basaloid squamous cell carcinoma (WHO type 3) 3. These pathological 
classifications have been repeatedly correlated with clinicopathologic features, treatment 
response and prognosis 4,5. Basaloid squamous cell carcinoma is infrequent and thus is rarely 
reported in the literature 6. Non-keratinizing NPC predominates in endemic regions, while the 
keratinizing subtype is most frequently observed in the non-endemic regions such as the United 
States (US) 7.  The unique geographic and ethnic distribution of NPC incidence throughout the 
world suggests a multifactorial etiology that involves viral, genetic and environmental 
components.  
 
NPC incidence has been reported to rise monotonically with age in non-endemic countries, 
whereas in high-risk populations, such as southern China, incidence peaks between 45 and 54 
years among both genders, implying that early exposure to carcinogens and Epstien-Barr virus 
(EBV) may result in younger onset NPC 8. EBV, a herpesvirus most commonly known for 
causing mononucleosis, is generally accepted as the primary etiologic factor in non-keratinizing 
NPC. Increased latent EBV infection has been reported in dysplastic nasopharyngeal epithelium 
and NPC, suggesting that the infection occurs in the early stages of carcinogenesis 9-12. Due to 
the ubiquitous nature of infection, and disproportionate global case distribution of NPC, several 
studies have assessed interactions between EBV and other lifestyle risk factors in high-risk 
populations. Dietary factors, namely early life exposure to Cantonese salted dried fish and other 
preserved foods containing volatile N-nitrosamines, have been implicated in NPC carcinogenesis 
through both the activation of latent EBV 13 and as independent carcinogens 14.  
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In non-endemic regions such as the United States, cigarette smoking and heavy alcohol 
consumption have been associated with keratinizing squamous cell carcinoma 15. Compared to 
never smokers, heavy smokers have been reported to have a two- to four- fold increased risk of 
NPC 15-22. Several studies have suggested that the effect conferred by smoking and alcohol 
primarily pertains to those diagnosed over age 50, suggesting a differing etiology among younger 
patients 15. The increased prevalence of high-risk human papillomavirus (HPV) in oropharyngeal 
cancer etiology, paired with the similarities exhibited between the lymphoid and epithelium 
tissue of the oropharynx and nasopharynx, has led to investigation into the role of HPV in 
nasopharyngeal carcinogenesis. While results remain inconsistent, largely due to small sample 
sizes, there is evidence to suggest the role of HPV, and even HPV/EBV coinfection, in NPC 4,23-
26.   
 
It is important to evaluate incidence of NPC in the US over time in light of the changing 
epidemiology of HPV-associated oral cancers. Thus, in these analyses, we assess NPC incidence 
and mortality trends in the United States from 1973-2015 using the Surveillance, Epidemiology 
and End Results Program (SEER). In doing so, we aim to identify potential variation across race 




Data Selection and Criteria  
 
Cancer incidence and survival data were obtained from the Surveillance, Epidemiology and End 
Results (SEER) Program.  For this analysis, SEER 9 data were used, which includes data from 
the following registries; Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San 
Francisco-Oakland, Seattle-Puget Sound and Utah registries. Data from 1973-2015 were 
available for all sites, with the exception of Seattle-Puget Sound and Atlanta, which joined in 
1974 and 1975, respectively. Corresponding population estimates were obtained from 
SEER*Stat 8.3.5 27 which are based upon the US Census Bureau’s Population Estimates 
Program 28. In addition to diagnosis, case information included: age, sex, race, date of diagnosis, 
SEER historical staging, histology, cause of death classification, and survival time in months. 
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Due to the small sample size of American Indians/Alaska Natives, this race group was combined 
with Asian/Pacific Islander to create the ‘Other’ race grouping.  
 
Tumor site and histology were identified according to the International Classification of Diseases 
for Oncology (ICD-O-3) 6,29. Histologic subtypes for NPC (Site codes: C11.0-C11.9) included: 
keratinizing squamous cell carcinoma (ICD-O histology codes 8070 and 8071), differentiated 
non-keratinizing carcinoma (ICD-O histology codes 8072 and 8073), undifferentiated non-
keratinizing carcinoma (ICD-O histology codes 8020, 8021, and 8082) and ‘carcinoma not 
otherwise specified’ (ICD-O histology code 8010) 5. In accordance with WHO guidelines, 
differentiated and undifferentiated non-keratinizing carcinomas were analyzed both separately 
and jointly to comprise the single non-keratinizing group. Overall NPC was defined as the 
culmination of all the aforementioned histological groupings. Basaloid squamous cell 
carcinomas (ICD-O histology code 8083) were excluded from these analyses due to small 
sample size (N=30).  Additional exclusion criteria included unknown race, non-malignant 
carcinoma, and prior diagnosis of malignancy. Patient characteristics were assessed by 
histological subgrouping and further evaluation of age at diagnosis (in five year groupings) was 
conducted by visually displaying case frequencies by race for overall, keratinizing and non-
keratinizing NPC.  
 
Sex stratified exploratory analyses assessing incidence trends in extranodal NK/T-cell 
lymphoma, nasal type (ICD-O histology code 9719) were conducted for all effective years, 
2001-2015, to further evaluate the potential role of EBV in US malignancies.     
 
Incidence Trends  
 
Age-adjusted incidence rates (standardized to the US population) and annual percent change 
(APC) were assessed using a log-linear model stratified by race, sex, and histological 
classification in Joinpoint Regression Program version 4.5.0.1 30. Joinpoint utilizes a Monte 
Carlo permutation method in order to assess number of joinpoints, slope in the trends, as well as 
their corresponding significance 31. In circumstances where no cases were reported within a 
given year, a half-case was added to the age strata with the largest population to enable 
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computation on the log-linear scale 31,32. SAS 9.4 software 27 was used to shape the data and 
generate descriptive statistics.  
 
Survival Analysis  
 
Individual-level data from the SEER*Stat case listing session was used to create Kaplan Meier 
curves in SAS 9.4 software. Graphs were gender specific, stratified by histologic type, and strata 
were compared using log-rank tests. Patients whose survival data were obtained from death 
certificates or autopsy only, as well as those with unknown survival duration, were excluded. In 
addition, those who cases with unknown age or those with a previous invasive cancer diagnosis 
were excluded from survival analyses.  Five year relative survival, calculated as the ratio of the 
observed survival for NPC patients to the expected survival rate based on age, race, and calendar 
year, were computed using the Kaplan-Meier method in SEER*Stat. Expected survival life tables 
were constructed using the US Decennial Life Tables from the National Center for Health 




Between 1973 and 2015, 4,447 cases of NPC were reported among males and 1,838 among 
females in the US. Regardless of histological subtype, males accounted for ~70% of the overall 
cancer burden. In general, the peak incidence occurred at age 55 for both sexes, with the 
undifferentiated non-keratinizing carcinoma subgroup representing the youngest mean age at 
diagnosis (49.34 and 49.15 for males and females, respectively). Exploratory analyses revealed a 
bimodal distribution among blacks, with 25% of all cases being diagnosed under the age of 40, 
as compared to 12% and 21% of their white and other counterparts, respectively. While this 
trend was not apparent for keratinizing NPC, 32% of non-keratinizing NPC cases among blacks, 
21% among whites and 22% among the other race group occurred under the age of 40 (Figure 
3.3). The keratinizing squamous cell carcinoma subtype made up the majority of NPC cases, 
largely due to its predominance among white patients, who accounted for 49% of the overall 
sample size. Non-keratinizing NPC was diagnosed more frequently among blacks and 
predominated among the other race group. Among those with non-keratinizing NPC, the 
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undifferentiated cell type was more frequently reported across all races. SEER summary stage 
was available for cases diagnosed prior to 2004, and most cases were diagnosed with regional 
disease (Table 3.1).  
 
While NPC incidence rates for the overall population appeared to have remained relatively 
stagnant among males (APC: -0.2 [95%CI: -0.4, 0.1]) and females (APC: -0.4 [95%CI: -0.8, 
0.0]), these trends vary greatly across both race and histology. At the beginning of the study 
period, the expected age standardized rate (EASR) for white and black males were 0.67 and 0.66 
per 100,000, respectively. White and black females both had notably lower rates, with EASRs of 
0.34 and 0.16 per 100,000, respectively.  The other race category, largely comprised of 
Asian/Pacific Islanders, exhibited the highest NPC rates, with an EASR of 4.79 and 1.76 per 
100,000 among males and females, respectively. Temporal assessment of NPC incidence 
revealed significant decreases in white males (APC: -1.2 [95%CI: -1.5, -0.8]) and females (APC: 
-1.6 [95%CI: -2.1, -1.0]), black females (APC: -1.4 [95% CI: -2.5, -0.4]) as well as other males 
(APC: -1.0 [95%CI: -1.4, -0.6]) and females (APC: -1.3 [95%CI: -1.9, -0.7]) (Table 3.2). 
 
These observed decreases in overall NPC are largely attributable to declines in the predominant 
keratinizing squamous cell carcinoma subtype.  Joinpoint regression results for the overall 
population exhibited non-significant increases in keratinizing carcinoma among men from 1973-
1985 (APC: 1.1 [95%CI: -1.2, 3.5]), followed by a significant decrease from 1985-2015 (APC: -
2.6 [95%CI: -3.2, -2.1]); similar declines were observed among women (APC: -2.4 [95%CI: -3.0, 
-1.7]). While this pattern of reduced keratinizing NPC is seen across all races, it was not found to 
be significant among black males, and demonstrated the greatest impact among males (APC: -3.4 
[95%CI: -4.1, -2.7]) and females (APC: -4.2 [95%CI: -5.1, -3.2]) of the other race category 
(Table 3.2).  
 
Non-keratinizing NPC revealed two very different patterns in incidence trends, depending on 
histological subtype. Undifferentiated carcinomas significantly decreased with an APC of 
approximately -2% among white males (95%CI: -2.8, -1.3) and females and (95%CI: -3.0, -0.6), 
-2.7% among black females (95%CI: -4.2, -1.1), -1.5% among other males (95%CI: -2.2, -0.6) 
and -2.4% among women of other race (95%CI: -3.5, -1.4). The differentiated subtype, on the 
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other hand, increased starkly in incidence with an APC of approximately 4% among white males 
(95%CI: 2.5, 5.2), white females (95%CI: 1.9, 6.2), and black males (95%CI: 2.0, 5.7), 2.7% 
among black females (95%CI: 0.8, 4.6) and 1.8% among women of other race (95%CI: 0.4, 3.3). 
This dichotomy in incidence between differentiated and undifferentiated led to an attenuation in 
the overall trends of non-keratinizing NPC (Table 3.2).  
 
Exploratory analyses on incidence trends in extranodal NK/T-cell lymphoma nasal type revealed 
very similar trends to those apparent in differentiated non-keratinizing NPC.  Between 2001 and 
2015, incidence increased among both sexes, with an APC of 3.2% (95%CI: 0.7, 5.8) among 
males and 3.9% (95%CI: 0.2, 7.8) among females. Race stratified analysis demonstrated even 
steeper increases among white males (APC: 3.8 [95%CI: 0.6, 7.1]) and females (APC: 4.1 
[95%CI: 0.7, 7.6]). No significant increases were notes for the other race groups, likely due to 
small sample sized within these groups.   
 
5-year relative survival estimated by race, sex and histological subtype can be found in Table 
3.3. For all NPC types, 5 year relative survival was 53.0% among males, and 55.8% among 
females. Figure 3.1 displays sex stratified Kaplan Meier survival plots by histological 
subgrouping. Both male and female patients with keratinizing squamous cell carcinoma had the 
worst survival when compared to the other histological subtypes (log rank p<0.001). 5-year 
relative survival rates for keratinizing squamous cell carcinoma were 41.9% and 41.5% for males 
and females of all races, respectively.  While black males had consistently poorer survival across 
all histological subtypes, those individuals in the “other” race category, particularly females, 




This is the first study, to our knowledge, to assess temporal changes in NPC incidence in the 
United States. Although overall NPC incidence appears to be decreasing in the US, the EBV-
related differentiated non-keratinizing NPC subtype is increasing at a concerning rate among all 
race groups and genders in the US. NPC has long been considered a relatively rare disease in the 
US, with a reported incidence rate less than 1 per 100,000 2,33,34. Nevertheless, in endemic 
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regions, NPC remains a major public health problem, with annual incidence rates exceeding 20 
per 100,000 individuals 33. Several studies have previously reported decreased incidence of NPC 
in successive generations of Chinese migrants to the US 35; however, the EASR among those 
belonging to the other race category, of which 98% identify as Asian/Pacific Islanders, remain 
over 5 times higher in females and 7 times higher among males, when compared to their white 
counterparts. Additionally, the rate of change in overall NPC incidence, represented as APC, 
between the white and other race individuals remained comparable throughout the study period, 
leading to continued disparity among this race group across time.  
 
EBV, a prominent etiological factor in NPC, is a ubiquitous virus that infects and persists 
latently in over 90% of the global population 36. Although primary infection is often subclinical, 
EBV replication can occur in oropharyngeal epithelial cells 37 as well as B lymphocytes in 
normal and malignant nasopharyngeal tissue 38. EBV-encoded RNA has repeatedly been detected 
in both premalignant and malignant tissues of primarily non-keratinizing NPC39-41; nevertheless, 
few studies, particularly in non-endemic countries, have characterized the potential differences in 
etiology between differentiated and undifferentiated NPC. Antibody titers, particularly for IgA, 
have also been shown to not only precede cancer development 42, but to be associated with 
prognosis and recurrence 43.  A considerable amount of research has been conducted in order to 
determine whether particular strains of EBV may, at least in part, explain the international 
patterns of NPC 44-47. Several different sequence variations have been detected in the oncogenic 
viral latent membrane protein 1 (LMP1) of EBV in NPC tumors 44,48-50, however, there remains 
no strong evidence to suggest an increased risk associated with different EBV variants 33,49-52. In 
this study, we found differentiated non-keratinizing NPC incidence to be increasing among all 
sex and race groups, leading to speculation of an increased role of EBV in US NPC. Exploratory 
analyses into SEER incidence trends of extranodal NK/T-cell lymphoma, a form of non-
Hodgkin's lymphoma consistently associated with EBV 53-67, demonstrated significant increases 
in this cancer type among both genders over this time period, further supporting the possibility 
for an increasing role in EBV etiology in US malignancies (Figure 3.2).   
 
In certain endemic populations, such as the Cantonese, early age incidence peaks in NPC are 
generally associated with childhood consumption of, or even traditional weaning by 68, salted 
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fish and other preserved foods high in volatile N-nitrosamines 13. Early-life infection by EBV 
69,70, as well as genetic predisposition, have both been proposed as possible risk factors for early 
onset NPC, but little consensus has been reached regarding the etiology of such cases in the US. 
Although the average age at diagnosis in our study was 55 among both sexes, we noted a 
bimodal distribution in cases among blacks, with 25% of patients being diagnosed under the age 
of 40 as compared to 12% of their white counterparts. While this distribution has been observed 
previously 35, we noted this disparity to be particularly apparent in the non-keratinizing subtype, 
where 32% of cases among blacks occurred before the age of 40 (Figure 3.3). Though we are 
unable to definitively conclude that the increase in these young onset cases is due to EBV alone, 
EBV seroprevalence has been reported to be significantly higher among African-American youth 
when compared to their white peers 71,72. Further studies are needed in order to properly assess 
the role childhood infection by EBV, as well as possible gene-environment interactions in the US 
population.  
 
The majority of case control studies report a  2- to 4-fold increased risk in NPC among smokers 
15,16,18-22.  Vaughan et al. estimated that two thirds of keratinizing NPC in the US are attributable 
to smoking, while both subtypes of non-keratinizing carcinoma failed to demonstrate significant 
associations 15. Decreases in smoking prevalence in the US 73 may explain the decreases in 
keratinizing squamous cell carcinoma seen in our analyses. Diet, which has been the primary 
nonviral exposure associated with NPC in endemic regions, has been postulated to impact NPC 
primarily thought the consumption of preformed nitrosamines or nitrosamine precursors 74. 
While cultural differences in dietary patterns preclude early and repeated exposure to salted fish 
75, harissa, quaddid and touklia 76 from US dietary etiology, preserved meats, which contain high 
levels of added nitrites, have been studied and found not to be significantly associated with NPC 
carcinogenesis 74. Although this particular study did not assess genetic variation, individuals 
processing the c2/c2 metabolic genotype for CYP2E1, a catalytic enzyme for the metabolic 
activation of low-molecular weight nitrosamines, have been shown to experience a 2.6-fold 
increased risk of NPC when compared to those possessing one or two copies of the wild-type 
allele 77. Moreover, alcohol, in addition to its innate role as a carcinogen 15,18, has been shown in 
animal models to increase the carcinogenicity of ingested nitrosamines 78,79, further stressing the 
importance of dietary interaction studies in the understanding of nasopharyngeal carcinogenesis. 
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Our study confirmed previous reports of a survival advantage of the undifferentiated non-
keratinizing morphology over the differentiated non-keratinizing and keratinizing squamous cell 
NPC 5,35. Additionally, we found that the ‘other’ racial grouping had consistently improved 
survival when compared to white and black patients, particularly among those presenting with 
keratinizing squamous cell carcinoma; these findings are consistent with other reports of a 
survival advantage among Chinese/Asian patients 5,35,80. One proposed rationale for this 
observation may be the high proportion of polymorphisms in the epidermal growth factor 
receptor (EGFR) found in the Chinese/Asian population, leading to lower EGFR expression, and 
consequently improved prognosis 5,81-84.  
  
There are several limitations present in this study. Although the use of SEER-9 allows for 
temporal analysis of cancer trends since 1973, it represents only half of the participating 
registries to date. Additionally, population estimates used for trends analyses were only available 
for the White, Black and Other race categories until 1990, resulting in our inability to assess age-
adjusted NPC incidence trends in specific other races (American Indian/Alaska Native and 
Asian/Pacific Islander) or by Hispanic ethnicity for the entire study period. Treatment variables, 
particularly those pertinent to NPC such as chemotherapy and radiation, are not suggested for 
use by SEER due known data gaps for these variables. The absence of data regarding 
comorbidities, smoking, drinking behavior, and EBV prevalence, limits our ability to make 
definitive statements regarding the underlying etiology influencing the observed trends. 
Although more precise treatment and comorbidity variables are available by linking the SEER 
database to the Medicare claims database, the majority of NPC patients in this study are too 
young to qualify for Medicare (<65 years old). Trends in adenocarcinoma of the nasopharynx, 
largely associated with occupational exposures such as wood dust 85-87, were not able to be 
assessed due to small sample sizes. Finally, the WHO classification system for NPC had changed 
several times throughout the study period, consequently leading to concerns regarding the 
interpretability of subtype specific results. That being said, the changes within the WHO 
guidelines were made in the grouping of the subtypes, not the pathology; this study utilizes 
morphology codes to define NPC subtypes, and therefore the changes in WHO classifications 
have no effect on the study nor the conclusions. 
 
 43  
 
Although NPC remains relatively rare in the overall US population, the EBV-related 
differentiated subtype is increasing across all genders and races. Many studies assessing non-
keratinizing NPC, particularly in the US, aggregate differentiated and undifferentiated carcinoma 
due to lack of sample size; the results of this study highlight the need for additional research to 
elucidate the potential etiological differences between these histological subgroups, consequently 
addressing the rationale for the disparity in the observed incidence trends. Due to the fact that 
prospective cohort studies with comprehensive exposure assessment would require decades to 
recruit a sufficient sample size to assess gene-environment interactions, multicenter studies or 
case-control studies in high incidence regions may prove to be a more feasible method to 
improve understanding of NPC etiology. Additionally, studies evaluating the biological 
mechanism by which EBV is involved in NPC are needed in order to move EBV preventative 
and targeted therapeutic methods forward, such as immunotherapy or even an EBV vaccine. 
Recent interest into the possible role of HPV in NPC, likely representing subepithelial extension 
from the oropharynx due to the lack of anatomical constraints in Waldeyer’s ring 1, may also aid 
in understanding incidence trends and NPC pathogenesis.  Finally, comprehensive 
characterization of risk factors among young adults is needed in order to reveal the cause for the 
adolescent incidence peak observed in African American populations in this study.
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Table 3.1: Nasopharyngeal Carcinoma Distribution, 1973-2015, by Sex and Histology 
 







 Male Female Male Female Male Female Male Female Male Female 
Number of Cases, N (%) 4447 (70.76) 1838 (29.24) 1979 (70.30) 836 (29.70) 710 (73.35) 258 (26.65) 996 (70.49) 417 (29.51) 762 (69.97) 327 (30.03) 
Mean age (SD) 54.55 (15.00) 55.36 (16.47) 57.35 (13.65) 59.24 (14.76) 53.91 (13.24) 54.18 (16.30) 49.34 (16.28) 49.15 (16.45) 54.69 (16.22) 54.31 (18.02) 
Race           
White 2175 (48.91) 893 (48.59) 1247 (63.01) 568 (67.94) 268 (37.75) 68 (26.36) 361 (36.24) 143 (34.29) 299 (39.24) 114 (34.86) 
Black  426 (9.58) 163 (8.87) 209 (10.56) 69 (8.25) 60 (8.45) 28 (10.85) 85 (8.53) 41 (9.83) 72 (9.45) 25 (7.65) 
Asian/Pacific Islander 1813 (40.77) 761 (41.40) 510 (25.77) 194 (23.21) 377 (53.10) 156 (60.47) 543 (54.52) 227 (54.44) 383 (50.26) 184 (56.27) 
American Indian/Alaska 
Native 
33 (0.74) 21 (1.14) 13 (0.66) 5 (0.60) 5 (0.70) 6 (2.33) 7 (0.70) 6 (1.44) 8 (1.05) 4 (1.22) 
Stage           
Localized 388 (8.72) 175 (9.52) 202 (10.21) 103 (12.32) 47 (6.62) 12 (4.65) 91 (9.14) 43 (10.31)  48 (6.30) 17 (5.20) 
Regional 1786 (40.16) 759 (41.29) 848 (42.85) 366 (43.78) 235 (33.10) 90 (34.88) 441 (44.28) 180 (43.17) 262 (34.38) 123 (37.61) 
Distant         493 (11.09) 190 (10.34) 281 (14.20) 102 (12.20) 54 (7.61) 10 (3.88) 100 (10.04) 52 (12.47) 58 (7.61) 26 (7.95) 
        Unstaged 247 (5.55) 132 (7.18) 122 (6.16) 75 (8.97) 11 (1.55) 4 (1.55) 47 (4.72) 19 (4.56) 67 (8.79) 34 (10.40) 
Cases diagnosed 2004+ 1533 (34.47) 582 (31.66) 526 (26.58) 
 













 All White Black Other 
 Male Female Male Female Male Female Male Female 
Cell Type, % (CI)         
Overall Nasopharyngeal 53.0 (51.3, 54.7) 55.8 (53.2, 58.4) 47.7 (45.2, 50.2) 45.7 (41.8, 49.6) 44.4 (38.7, 49.9) 56.5 (47.1, 64.8) 60.8 (58.2, 63.2) 66.1 (62.2, 69.7) 
        Keratinizing 41.9 (39.4, 44.4) 41.5 (37.6, 45.4) 37.7 (34.6, 40.9) 37.1 (32.3, 41.8) 35.5 (27.7, 43.4) 35.9 (22.9, 49.0) 53.2 (48.3, 57.7) 54.3 (46.3, 61.6) 
Non- Keratinizing 64.7 (62.0, 67.2) 67.7 (63.5, 71.6) 64.4 (59.8, 68.6) 61.0 (52.7, 68.3) 54.4 (44.4, 63.3) 70.6 (55.8, 81.2) 66.4 (62.8, 69.7) 70.5 (65.1, 75.2) 
Differentiated 63.1 (58.7, 67.1) 63.4 (56.0, 69.9) 62.3 (55.0, 68.7) 51.6 (36.2, 65.0) 49.5 (32.8, 64.2) 66.5 (41.2, 82.9) 65.3 (59.4, 70.5) 67.3 (58.1, 74.9) 
Undifferentiated 65.8 (62.4, 69.0) 70.1 (64.8, 74.8) 65.8 (59.7, 71.1) 65.0 (55.1, 73.3) 57.1 (44.5, 67.9) 72.6 (53.2, 85.0) 67.1 (62.5, 71.3) 72.5 (65.6, 78.3) 
        NOS 54.6 (50.4, 58.6) 66.2 (59.7, 71.9) 51.9 (45.0, 58.4) 58.6 (46.5, 68.9) 47.7 (34.3, 59.9) 69.1 (42.9, 85.1) 57.5 (51.8, 62.9) 69.9 (61.6, 76.7) 
 All White Black Other 
 Male Female Male Female Male Female Male Female 
Overall Nasopharyngeal -0.2 (-0.4, 0.1) -0.4 (-0.8, 0.0) -1.2* (-1.5, -0.8) -1.6* (-2.1, -1.0) -0.1 (-1.0, 0.7) -1.4* (-2.5, -0.4) -1.0* (-1.4, -0.6) -1.3* (-1.9, -0.7) 
Keratinizing 1.1 (-1.2, 3.5)ˠ 
-2.6* (-3.2, -2.1)¥ 
-2.4* (-3.0, -1.7) -2.1* (-2.6, -1.6) -2.4* (-3.2, -1.6) -1.2 (-2.4, 0.0) -2.3* (-4.1, -0.4) -3.4* (-4.1, -2.7) -4.2* (-5.1, -3.2) 
Non-Keratinizing 1.0* (0.5, 1.5) 1.2* (0.5, 1.8) 0.5 (-0.2, 1.1) -0.0 (-1.1, 1.1) 0.6 (-0.8, 2.0) -0.6 (-2.1, 0.9) -0.8* (-1.5, -0.2) -0.6 (-1.5, 0.2) 
Differentiated 3.0* (2.1, 3.9) 4.4* (3.0, 5.9) 3.8* (2.5, 5.2) 4.0* (1.9, 6.2) 3.9* (2.0, 5.7) 2.7* (0.8, 4.6) -0.1 (-1.3, 1.0) 1.8* (0.4, 3.3) 
Undifferentiated  -0.5 (-1.1, 0.1) -0.8* (-1.5, -0.0) -2.1* (-2.8, -1.3) -1.8* (-3.0, -0.6) -1.6 (-3.3, 0.2) -2.7* (-4.2, -1.1) -1.5* (-2.2, -0.6) -2.4* (-3.5, -1.4) 
* denote statistical significance at α=0.05 
ˠ 1973-1985 
¥ 1985-2015 
Table 3.2: Joinpoint Analyses of Nasopharyngeal Trends by Sex and Morphology [APC (CI)]  
 
Table 3.3: Five-year Relative Survival Estimates by Sex and Race [% (CI)]   
 
 





















Figure 3.1: Kaplan Meier Survival Curves for Overall Survival by Sex and Histology 
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Decreasing Rates of Head and Neck Cancer in Southeast, but not East, Asia 




Background:  Head and neck cancer (HNC) is the sixth most common cancer in the world, with 
the largest burden occurring in developing countries. Although the primary risk factors have 
been well characterized, little is known about the temporal trends in HNC across Asian countries.  
 
Methods: Cancer cases from three Thai provinces (Songkhla, Chiang Mai, Lampang), 
Singapore, Manila, Shanghai, and the US were selected by ICD-10 code from the IARC CI5plus 
database for the following sites: oral cavity (00, 03-06), tongue (01-02), pharynx (09-10, 12-14), 
and larynx (32). The data were analyzed using R software (3.3.3) and Joinpoint Regression 
Software (4.5.0.1) to determine age-standardized incidence rates (ASR) and trends of annual 
percent change (APC).  
 
Results: Males had higher incidence rates of HNC than females across all registries. Among 
females, the highest baseline rates were observed in Manila (ASR: 9.09 per 100,000) and the 
lowest in Shanghai (ASR: 1.85 per 100,000). Among males, the highest baseline incidence rates 
were seen in the US (ASR: 21.44 per 100,000) and the lowest in Shanghai (ASR: 5.79 per 
100,000). Incidence is decreasing everywhere except among Shanghai males from 1998 and 
2002 (APC: 7.87; [95%CI: 1.1, 15.1]). Subsite analyses reveal increases in male laryngeal cancer 
(APC: 9.10 [95%CI: 2.2, 16.4]) contributing to Shanghai’s upward trend.  
 
Conclusions:  Largely in concurrence with strong tobacco control policies, HNSCC rates appear 
to be decreasing across the US and Southeast Asia; however, dangerously high smoking rates in 
Shanghai are likely attributable for Shanghai’s concerningly increasing laryngeal cancer rates.  
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Introduction 
Head and neck cancer (HNC) is the sixth most common malignancy worldwide and is comprised 
of several principal subsites, including the oral cavity, pharynx, larynx and nasal cavity 1,2. 
Globally, HNC accounted for more than 650,000 cases and 330,000 deaths in 2018 3. More than 
90% of head and neck neoplasms are squamous cell carcinomas (HNSCC) 4, and nearly 40% of 
HNSCCs arise from the epithelium of the mucosal lining of the oral cavity 3.  While HNSCC 
accounts for 5-10% of all new cancer cases in North America and Europe 5, geographic 
differences, such as the population age structure, prevalence of established risk factors and 
access to screening and care, all play a key role in making HNSCC a behaviorally heterogeneous 
and therapeutically challenging disease. Although incidence rates differ by subsite, the greatest 
burden of head and neck cancer is observed in low and middle-income countries 6,7. Globally, the 
highest incidence of oral cavity cancer (OCC) is in Melanesia with an age standardized rate 
(ASR) of 22.9 for males and 16.0 for females, followed by South-Central Asia with an ASR of 
9.9 for males and 4.7 for females 8. Nevertheless, regardless of geography, incidence rates of 
head and neck cancer are significantly higher for men than women worldwide, with subsite-
specific male to female ratios up to 10:1 9-12. 
         
The wide geographical variation in HNSCC incidence can primarily be attributed to 
demographic differences in established risk behaviors, such as the use of alcohol and tobacco 
consumption (both smoked and smokeless). The habit of chewing betel quid, consisting of betel 
leaf, areca nut, slaked lime, and occasionally tobacco, has predominantly been thought to 
account for the high incidence of OCC in Asian countries 11,13,14. As the prevalence of these 
known risk factors change, they consequently influence trends in HNC. This phenomenon has 
recently been observed in the United States (U.S.) and other high-income countries, where 
decreasing incidence of oral and laryngeal squamous cell carcinomas, corresponding to declines 
in the use of tobacco products 15, have led to the detection of an epidemiologic shift that has 
elucidated the role of high-risk human papillomavirus (HPV) strains in head and neck cancer 
pathology 16,17.   
 
While numerous studies have been conducted to assess the changing etiology of HNSCC in the 
western world, little is known about HNC behavior in high incidence areas, such as East and 
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Southeast Asia. To provide an overview of the temporal changes to HNSCC in these regions, we 
utilized IARC’s Cancer Incidence in Five Continents database to assess subsite specific trends 
across three Thai registries (Chiang Mai, Lampang and Songkhla), Shanghai (China), Singapore, 
Manila (Philippines) and compare them to the U.S.     
 
Methods  
Head and neck cancer incidence rates aggregated over 5-year age groups (0-85+) by year, sex, 
subsite and cancer registry were obtained from IARC’s Cancer Incidence in Five Continents 
Time Trends Database (CI5-Plus). The CI5 series of databases are comprised of high-quality 
data obtained in order to assess annual global cancer incidence 18. In this study, we restricted our 
analyses to six cancer registries in East and Southeast Asia including: Manila (1983-2002), 
Singapore (1980-2007), Shanghai (1988-2002), Lampang (1993-2007), Songkhla (1993-2007), 
Chiang Mai (1983-2002) and compared them to those in the United States (1975-2007).   
 
Cases included confirmed malignant neoplasms within the head and neck as defined by the 
International Classification of Diseases codes for oncology (ICD-O). Sites of interest included 
the oral cavity, tongue, pharynx and larynx. Oral cavity sites included the lip (C00.0-C00.6, 
C00.8-C00.9), gum (C03.0-C03.1, C03.9), floor of the mouth (C04.0-C04.1, C04.8-C04.9), 
palate (C05.0-C05.2, C05.8-C05.9), and other parts of the mouth (C06.0-C06.2, C06.8-C06.9). 
Tongue included the base of the tongue as well as other and unspecified parts of the tongue (C01, 
C02.0-C02.4, C02.8-C02.9). Pharynx sites included the tonsil (C09.0-C9.1, C09.8-C09.9), 
oropharynx (C10.0-C10.4, C10.8-C10.9), pyriform sinus (C12), hypopharynx (C13.0-C13.2, 
C13.8-C13.9), and other and ill-defined sites in the lip, oral cavity and pharynx (C14.0, C14.2, 
C14.8).  All laryngeal sites were used (C32.0-C32.3, C32.8-C32.9) and overall HNSCC 
incidence was calculated as the sum across all subsites. Nasal cavity (C30.0), nasopharyngeal 
(C11.0-C11.3, C11.8-C11.9) and salivary gland (C07, C08.0-C08.1, C08.9) cancers were 
excluded due to differing etiology 19,20.  
 
Joinpoint Regression Program version 4.5.0.1 was used to assess trends under a log-linear model 
and to compute the annual percent change (APC) in age-standardized incidence rates 21.  The 
aforementioned program utilizes a Monte Carlo permutation method in order to assess number of 
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joinpoints, slope in the trends and their significance 22. When no cases were present within a 
given year, a half-case was added to the age strata with the largest population  to enable 
computation on the log-linear scale 21. Population denominators were similarly obtained from 
CI5-Plus by 5-year age grouping for each year and Segi (1960) standardization was applied 23.  
R-statistical software 3.3.3 was used to shape the data and Joinpoint outputs were used to 
generate plots.  
 
Results 
HNSCC cases were predominantly male across all registries, with the greatest disproportion 
observed in Songkhla and Singapore, where males accounted for ~80% of all reported cases 
within their respective registries. While age at diagnosis was not available for those >80 years 
old within the Songkhla, Chiang Mai and Manila registries, the majority of HNSCC cases 
occurred between the ages of 61 and 80 across all study sites. Among men, laryngeal cancer 
accounted for the highest proportion of cases across all the registries except Songkhla, where 
pharyngeal cancer made up just over 30% of reported cases.  Among women, oral cavity cancer 
was the primary contributor to head and neck cancer burden across all study sites except 
Singapore, where there was a slight observed predominance of tongue cancer (Table 4.1). 
 
At baseline, the U.S. was found to have the highest overall HNSCC incidence among men, with 
an expected age standardized rate (EASR) of 21.44 per 100,000. Although much lower than that 
among males, Manila stood out as having the highest HNSCC burden among females, with an 
EASR of 9.09 per 100,000. Overall, these trends appear to be decreasing across both genders and 
all registries except Shanghai males, where there is an observed, statistically significant increase 
in HNSCC cancer burden between 1998 and 2002 (APC: 7.87 [95%CI: 1.1, 15.1]). While the 
majority of these overall decreases are modest, with Shanghai and Lampang females as well as 
both sexes in Songkhla failing to reach statistical significance, a drastic decrease in HNSCC was 
noted among Filipino females, where the EASR dropped from 6.68 per 100,000 in 1997 to 3.14 
per 100,000 in 2002 (APC: -13.8 [95%CI: -19.9, -7.1]) (Figure 4.1).  
 
With an EASR of 7.30 per 100,000, the U.S. boasted the highest laryngeal cancer rates among 
men at baseline; nevertheless, with consistent decreases at a magnitude of 1.2% (95%CI: -2.1, -
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0.4) between 1980 and 1990, and 3.1% (95%CI: -3.7, -2.4) between 1990 and 2002, this rate 
dropped to 4.45 per 100,000 by 2002. Decreases in laryngeal cancer incidence were also 
observed among males in Lampang (APC: -6.3 [95%CI: -9.5, -3.0]), Chiang Mai from 1998-
2002 (APC: -19.7 [95%CI: -34.2, -2.0]), Singapore (APC: -2.5 [95%CI: -3.1, -1.9]), and Manila 
from 1995-2002 (APC: -5.1 [95%CI: -9.1, -0.9]). While male trends appear to have remained 
stagnant in Songkhla, Shanghai was the only registry in which laryngeal cancer incidence 
increased, with an APC of 9.1% (95%CI: 2.2, 16.4). When compared to those amid males, 
female laryngeal cancer incidence rates appeared to be much lower, with Chiang Mai having the 
highest EASR of 2.92 per 100,000 at baseline. Temporal trends demonstrated significant 
decreases in laryngeal cancer in Chiang Mai (APC: -8.0 [95%CI: -11.7, -4.2]), Singapore (APC: 
-5.6 [95%CI: -7.2, -4.1]), Manila (APC: -2.6 [95%CI: -4.4, -0.7]), Shanghai (APC: -4.3, [95%CI: 
-7.9, -0.7]), and the U.S. from 1989-2002 (APC: -2.7 [95%CI: -4.1, -1.3]) (Figure 4.2). 
 
While oral cavity rates at baseline were highest among U.S. males, with an EASR of 6.82 per 
100,000, among females, the highest rates were found to be in Manila, with an EASR of 4.40 per 
100,000. Significant decreases in incidence were noted among males in Chiang Mai (APC: -2.8 
[95%CI: -4.5, -1.0]), Singapore (APC: -2.7 [95%CI: -3.8, -1.7]), Manila (APC: -3.8 [95%CI: -
5.3, -2.4]), Shanghai (APC: -2.7 [95%CI: -4.6, -0.7]), and the U.S. (APC: -3.5 [95%CI: -3.8, -
3.2]). Similarly, among females, significant reductions in oral cavity cancer burden were found 
in Singapore (APC: -2.9 [95%CI: -4.2, -1.7]), Manila (APC: -5.4 [95%CI: -6.9, -3.8]) and the 
U.S. (APC: -2.0 [95%CI: -2.3, -1.7]) (Figure 4.2).  
 
When compared to other registries, Songkhla males and Filipino females were found to have the 
highest EASR for both pharyngeal (4.88 and 1.64 per 100,000, respectively) and tongue cancer 
(3.74 and 2.55 per 100,000, respectively). While cancer incidence among both of these subsites 
have remained stagnant in Songkhla, decreases in pharyngeal cancer were noted among 
Lampang males and females (APC: -5.7 [95%CI: -9.2, -2.1]; APC: -6.8 [95%CI: -13.0, -0.1], 
respectably), Chiang Mai males and females (APC: -3.4 [95%CI: -5.6, -1.3]; APC: -4.8 [95%CI: 
-8.2, -1.3], respectably), Singapore males and females (APC: -1.1 [95%CI: -1.9, -0.3]; APC: -2.5 
[95%CI: -4.7, -0.4], respectably), U.S. males and females (APC: -0.9 [95%CI: -1.3, -0.5]; APC: -
2.7 [95%CI: -3.2, -2.1], respectably) and, most notably, Filipino females for 1996-2002 (APC: -
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16.0 [95%CI: -27.9, -2.1]). Conversely, incidence trends for tongue cancer appear to be much 
more variable, with wide fluctuations in rates leading to largely null results. Nevertheless, 
significant decreases were noted among Chiang Mai females (APC: -5.2 [95%CI: -8.7, -1.5]) and 
Filipino females (APC: -4.0 [95%CI: -6.4, -1.6]) (Figure 4.2).  
 
Discussion 
In this study, we found HNSCC to be decreasing across Thailand, Singapore, Manila and the US, 
but increasing among Shanghai males. While policies around relevant risk behaviors vary across 
these study sites, general decreases in smoking and betel quid use in Southeast Asia are likely 
attributable to the favorable cancer trends within this region. Nevertheless, largely stagnant 
temporal incidence rates in tongue cancer across these registries point to research opportunities 
in cancer etiology within this subsite. 
 
Tobacco use, whether it be in chewing or combustible form, has long been accepted as the 
leading risk factor for head and neck cancer 1,24. HNSCC rates among smokers have been 
estimated to be approximately ten times that of never smokers, with risk estimates increasing in a 
dose-dependent manner based upon duration and extent of smoking 15. While this association is 
strongest for laryngeal cancer, use of combustible tobacco has also been shown to increase the 
risk of hypopharyngeal, oropharyngeal and oral cavity cancer development 25. Smoking cessation 
has been shown to reduce cancer risk, but ever-smokers continue to have a greater likelihood of 
developing HNSCC when compared to never-smokers 26. Additionally, alcohol consumption, 
while being an independent risk factor for HNSCC, also has a synergistic multiplicative effect 
when combined with tobacco use 1,9,24,27.  Both tobacco and alcohol consumption have 
historically been much more common among men than women, leading to the male 
predominance seen within HNSCC 28,29. While the World Health Organization (WHO) reports 
progressive decreases in smoking rates in the U.S., Singapore, Thailand, the Philippines and 
Singapore 30-32, alcohol consumption has increased dramatically in the past 50 years across all 
study sites except the U.S. 28,29,33,34. 
 
Tobacco history in the US can largely be characterized by its widespread adoption in the first 
half of the 20th century and its control thereafter. Particularly in recent years, rising public 
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awareness and support for tobacco control efforts have markedly influenced smoking rates, with 
adult ‘current smoker’ prevalence down from 42.5% in 1965 to 20.9% in 2005 35-37. These 
reductions are reflected in HNSCC rates, particularly within laryngeal cancer, where incidence 
rates decreased among both males and females. Although the international trade of tobacco is a 
substantial income source for Singapore, the government has demonstrated effective control over 
the domestic use of tobacco. Initially introduced in 1970 to control smoking in public places, 
Singapore has since expanded its legislation to include national control policies that encompass 
educational reform, taxation, intersectoral collaboration and community participation 38. While 
smoking prevalence rates among females have historically been low, fluctuating around 3%, 
rates among males dropped from 37% in 1984 to 27% in 1998 38; these decreases were 
consequently reflected within the decreasing laryngeal cancer rates among both sexes. Likewise, 
Thailand is known for having some of the strongest tobacco control policies in Asia 39,40, with 
numerous regulations including health warnings, taxation, bans on advertisement and smoking in 
many public spaces 41,42. Due in large part to these efforts, the smoking rate in Thailand has 
decreased from 30% in 1976 to 19.9% in 2013 15; subsequently, these behavioral modifications 
have led to significant decreases in laryngeal cancer among Lampang and Chiang Mai males, as 
well as Chiang Mai females. In contrast, Manila has essentially no regulations on advertisement 
or sale of tobacco, minors are able to buy and sell products, and the taxation rate is considerably 
lower than is recommended by the WHO 43.  The National Coalition on Tobacco control was 
established in 1988, but this has done little to reform tobacco legislation; nevertheless, smoking 
rates have been reported to be decreasing 44. Although Manila’s laryngeal cancer rates remain 
among the highest when compared to our other study sites, incidence is decreasing among both 
Filipino males and females. Finally, China is the world’s largest tobacco manufacturer and 
accounts for about 30% of the world’s cigarette consumption. While Shanghai has set forth 
regulations on smoking in certain public areas, as well as initiated a project aimed at improving 
cessation clinics 45, reports from 2005 and 2010 indicated that 74% and 84% of smokers in 
China, respectively, had no desire to and have never thought about quitting smoking 45,46. 
Although both smoking and laryngeal cancer rates appear to be decreasing among women, 
Shanghai was the only registry to demonstrate significant increases in male laryngeal cancer 
incidence rates, with an APC of 9.1% (95%CI: 2.2, 16.4) between 1998 and 2002.  
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In the US, outside of the aforementioned risk behaviors, the use of smokeless tobacco in the form 
of chewing tobacco, wet snuff, or dried out snuff are the primary etiological factors associated 
with OCC 47. The decreased popularity of these products 48 has led to corresponding decreases in 
oral cavity cancer among both males and females in the US. Throughout Asia, betel quid, 
defined as sliced or processed areca nut wrapped in the leaves of the piper betel plant and mixed 
with slaked lime (calcium hydroxide), is often chewed in social or religious settings 49.  Tobacco 
is only included in some uses of betel nut, but studies have shown that both with and without 
tobacco, chewing betel nut leads to an increased risk of OCC 49-51.  In Thailand, overall betel nut 
usage has been declining, and is now predominantly seen in the older and more rural populations 
52-54. Although significant decreases in OCC were only observed among Chiang Mai males, 
incidence data suggests decreases across all Thai study populations with the exception of males 
in rural Lampang. Manila is also seeing a decrease in OCC, likely corresponding to decreases in 
betel nut usage with successive  generations and thought to be associated with migration out of 
rural communities, attainment of higher education and economic status 13.  The decreasing OCC 
rates in Singapore can likely be attributed to the anti-spitting laws, which have indirectly 
discouraged the use of betel-quid chewing in the general population 55. Although little is known 
about betel quid use in mainland China, the existing literature points to the habit being localized 
to the southern provinces of Hunan, Hainan and Yunnan 56-59. Consequently, the decreases in 
OCC observed among Shanghai males are likely more reflective of changes in traditional 
combustible tobacco and alcohol risk factors; however, several studies have previously 
questioned the data quality of China’s registries, particularly in regards to the escalating tobacco 
epidemic in this region and low reported incidence of OCC 60,61.  
          
High risk human papillomavirus (HPV) strains have been shown to be an independent risk factor 
for head and neck cancer and are found primarily in the oral cavity and oropharynx 9,10,62. The 
burden of HPV related oral cancers appears to be increasing in developed countries, likely due to 
changes in sexual behaviors, but corresponding data is largely lacking for developing countries 
10,60,63. HPV positive tumors are typically diagnosed at higher stages but are more responsive to 
treatment, providing important implications for screening and quality of care 64,65. While 
pharyngeal cancer rates appear to be decreasing among both genders in Lampang, Chiang Mai, 
Singapore, the US as well as Filipino females, tongue cancer incidence rates appear to be much 
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more stagnant, with significant decreases localized to Filipino and Chiang Mai females. 
Although etiological inference is limited, further research is needed to assess the potential role of 
HPV in HNSCC within Asian populations.  
 
This is the first study, to our knowledge, to assess temporal trends in overall and site specific 
HNSCC across southeast and eastern Asia in comparison to the US. The use of high-quality 
IARC CI5 cancer incidence data is a strength in our study, however, there are also several 
limitations. Data ascertainment is limited by geographical coverage and quality, subsequently 
leading to restrictions on generalizability to country-wide incidence rates. Stratification by 
nationality, or sub-population (i.e. patients coming from urban vs. rural settings) were also either 
limited by sample size or availability of data, restricting interpretability. Finally, inception years, 
conversion to population-based systems, and variability in data sources and follow-up methods 
between registries limit comparability 66.   
 
In general, HNSCC incidence appears to be decreasing across parts of Asia and the US, with the 
exception of Shanghai males. While introduction of tobacco control policies in places such as 
Thailand and Singapore have led to decreases in risk behaviors and subsequent cancer incidence, 
concerns regarding China’s continuing wide-scale use of tobacco products likely plays a role in 
escalating laryngeal cancer rates within this population and should be closely monitored. 
Additionally, further studies should be conducted to evaluate the potential role of HPV in oral 
and oropharyngeal cancer, particularly in economically transitioning countries, where adaptation 
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Table 4.1: HNSCC case distribution by registry and sex 
  
  
Lampang Songkhla Chiang Mai  Singapore Manila Shanghai United States 
Males Females Males Females Males Females Males Females Males Females Males Females Males Females 
Diagnosis Period 1993-2007 1993-2007 1983-2002 1980-2007 1983-2002 1988-2002 1980-2002 






























Age at diagnosis, N 
(%) 
             
≤50 81 (17.88) 45 (15.68) 177 (12.95) 29 (9.35) 163 (11.68) 99 (15.05) 457 (12.17) 197 
(22.09) 
544 (19.59) 301 (16.82) 406 (11.81)  209 (15.36) 7105 (13.16) 2571 (12.42) 
51-60 65 (14.35) 39 (13.59) 234 (17.12) 81 (26.13) 248 (17.77) 142 
(21.58) 
880 (23.44) 169 
(18.95) 











880 (31.69) 540 (30.17) 1143 
(33.24) 





78 (27.18) 533 (38.99) 159 
(51.29) 
483 (34.60) 196 
(29.79) 
948 (25.25) 209 
(23.43) 
587 (21.14) 572 (31.96) 1057 
(30.74) 
392 (28.80) 12218 
(22.63) 
5051 (24.40) 
≥81 57 (12.58) 39 (13.59)   
   
199 (5.30) 72 (8.07) 
  
285 (8.29) 160 (11.76) 4376 (8.11) 2860 (13.82) 
Year of diagnosis, N 
(%) 
             
1980-1983         63 (4.51) 36 (5.47) 457 (12.17) 121 
(13.57) 
113 (4.07) 92 (5.14)     9587 (17.76) 3445 (16.64) 
1984-1987         254 (18.19) 120 
(18.24) 
454 (12.09) 99 (11.10) 461 (16.60) 369 (20.61)     9556 (17.70) 3593 (17.36) 
1988-1991         288 (38.83) 165 
(25.08) 
466 (12.41) 129 
(14.46) 
552 (19.88) 363 (20.28) 993 (28.87) 407 (29.90) 9365 (17.35) 3646 (17.62) 
1992-1995 104 
(22.96) 
44 (15.33) 238 (17.41) 53 (17.15) 291 (20.85) 131 
(19.91) 
531 (14.14) 115 
(12.89) 
615 (22.15) 393 (21.96) 935 (27.19) 334 (24.54) 9416 (17.44) 3671 (17.74) 
1996-1999 103 
(22.74) 
85 (29.62) 327 (23.92) 74 (23.95) 316 (22.64) 129 
(19.60) 
598 (15.93) 132 
(14.80) 
607 (21.86) 380 (21.23) 793 (23.06) 318 (23.37) 9142 (16.94) 3642 (17.60) 
2000-2003 123 
(27.15) 
97 (33.80) 385 (28.16) 96 (31.07) 184 (13.18) 77 (11.70) 584 (15.56) 143 
(16.03) 
429 (15.45) 193 (10.78) 718 (20.88) 302 (22.19) 6914 (12.81) 2701 (13.05) 
2004-2007 123 
(27.15) 
61 (21.25) 417 (30.50) 86 (27.83)     664 (17.69) 153 
(17.15) 
          
Sub-Site, N (%)              




340 (24.87) 173 
(55.99) 
294 (21.06) 234 
(35.56) 
615 (16.38) 277 
(31.05) 
587 (21.14) 680 (37.99) 640 (18.61) 568 (41.73) 15065 
(27.91) 
7401 (35.76) 
Tongue 87 (19.21) 54 (18.82) 319 (23.34) 63 (20.39) 210 (15.04) 118 
(17.93) 
587 (15.64) 283 
(31.73) 
484 (17.43) 450 (25.14) 418 (12.15) 385 (28.29) 8521 (15.79) 4501 (21.75) 
Larynx 153 
(33.77) 








265 (14.80) 2066 
(60.08) 





37 (12.89) 417 (30.50) 48 (15.53) 403 (28.87) 142 
(21.58) 
842 (22.43) 151 
(16.93) 
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Lampang Songkhla Chiang Mai Singapore Manila Shanghai USA 
Overall Head and 
Neck 
       
Males  -3.3* (-6.5, -0.0) -0.5 (-1.6, 0.7) -2.5* (-3.8, -1.2) -1.9* (-2.3, -1.5) 1.2 (-0.3, 2.8) 
-5.9* (-8.9, -2.8) 
-3.5* (-5.1, -
1.9) 
 7.9* (1.1, 15.1) 
-1.3* (-1.9, -0.8) 
-2.5* (-2.9, -2.1) 
Females -2.5 (-6.2, 1.5) -1.7 (-4.4, 1.2) -4.5* (-6.6, -2.4) -2.7* (-3.4, -1.9) -2.3* (-3.6, -1.0) 
-13.8* (-19.9, -7.1) 
-1.3 (-3.1, 0.6) -0.2 (-1.5, 1.2) 
-2.1* (-2.5, -1.6) 
* Denotes statistical significance at 	α=0.05 
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Figure 4.2: Joinpoint analyses of temporal trends in subsite specific HNSCC by sex and registry APC (95%CI) 
 
 
Lampang Songkhla Chiang Mai Singapore Manila Shanghai USA 
Males Females Males Females Males Females Males Females Males Females Males Females Males Females 
Oral 
Cavity 
1.1 (-5.1, 7.7) -3.5 (-8.6, 1.9) -1.4 (-4.2, 
1.5) 
-3.6 (-7.8, 0.7) -2.8* (-4.5, -
1.0) 






-5.4* (-6.9, -3.8) -2.7* (-4.6, -
0.7) 
-1.5 (-4.3, 1.3) -3.5* (-3.8,-
3.2 ) 
-2.0*  (-2.3, -
1.7) 
Tongue 0.2 (-6.2, 7.1) 2.4 (-5.9, 11.3) -0.2 (-3.5, 
3.1) 




-0.8 (-2.4, 0.9) -0.8 (-3.5, 
2.0) 
-4.0* (-6.4, -1.6) -0.2 (-2.8, 
2.5) 







-0.2 (-0.6, 0.3) 


















0.6 (-3.6, 4.9) 
-16.0* (-27.9, -
2.1) 




Larynx -6.3* (-9.5, -
3.0) 













2.6* (0.4, 4.8) 
-5.1* (-9.1, -
0.9) 










1.2 (-1.2, 3.7) 
-2.7* (-4.1, -
1.3) 
* Denotes statistical significance at 	α=0.05	









Temporal Changes in Head and Neck Cancer Incidence in Thailand Suggest 




Background:  Head and neck cancer (HNC) is the sixth most common cancer in the world, with 
the largest burden occurring in developing countries. Although the primary risk factors have 
been well characterized, little is known about temporal trends in HNC across Thailand.  
Methods: Head and neck squamous cell carcinoma (HNSCC) cases diagnosed between 1990 and 
2014 were selected by ICD-10 code from the Songkhla, Lampang, Chiang Mai and Khon Kaen 
Cancer Registries and the U.S. Surveillance, Epidemiology, and End Results Program for: oral 
cavity (00, 03-06), tongue (01-02), pharynx (09-10, 12-14), and larynx (32). The data were 
analyzed using R and Joinpoint Regression Software to determine age-standardized incidence 
rates and trends of annual percent change (APC). Incidence rates were standardized using the 
Segi (1960). Stratified linear regression models were conducted to assess temporal trends in early 
onset HNSCC across 20-year age groups.  
Results:  While overall HNSCC rates are decreasing across all registries, subsite analyses 
demonstrate consistent decreases in both larynx and oral cavity cancers, but suggested increases 
in tongue cancers among both sexes in the US (APCM: 2.36 and APCF: 0.77) as well as 
pharyngeal cancer in Khon Kaen and US males (APC: 2.1 and APC: 2.23, respectively). Age-
stratified APC analyses assessing young onset (<60 years old) trends demonstrated increased 
incidence in tongue cancer in Thailand and the U.S., as well as pharyngeal cancers in Khon Kaen 
males age 40-59 and US males age 50-59.      
Conclusions:  Although overall trends in HNSCC are decreasing across both Thailand and the 
United States, there is reason to believe that the etiological shift to oropharyngeal cancers in the 
US may be occurring in Thailand.  
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Introduction:  
 
Worldwide, head and neck cancer (HNC) accounts for more than 550,000 cases and 300,000 
deaths each year 1,2, with a dismal five-year overall survival rate of 40-50% 3. HNC is the sixth 
most common cancer in the world 4, with the highest incidence observed in South and Southeast 
Asia 5,6. Many of these cases are attributed to use of betel quid, although there have been no 
systematic studies of risk factors for this set of cancers within these regions of the world. In the 
western world, decreased combustible tobacco use and increased human papillomavirus (HPV) 
prevalence 7 have allowed for an epidemiological shift that has highlighted the role of high-risk 
HPV strains in head and neck squamous cell carcinoma (HNSCC) pathology 8. This subset of the 
disease is seen more often in younger patients, and is most commonly presents in the oral cavity, 
tongue and oropharynx 9,10. However, most of these data are from Western countries, with little 
knowledge regarding the presentation and prevalence of this important etiological factor in other 
high incidence areas such as Thailand.  
 
A first step to addressing the burden of HNC in Southeast Asia is to analyze surveillance data for 
trends in incidence of HNSCC. In the past few decades, rapid socioeconomic development has 
allowed for improved control of communicable diseases, resulting in the emergence of cancer as 
the leading cause of death 11. Thailand has an efficient universal healthcare system that, among 
many other benefits, facilitates the collection of health statistics 12. Subsequently, Thailand’s 
high quality cancer statistics are obtained and managed by 16 province- and regional- based 
registries that build on the healthcare infrastructure 13. Additionally, the sociocultural factors in 
Thailand are similar to those in surrounding countries, and thus, incidence trends may reflect 
regional changes in HNSCC.  
 
Here we take advantage of data available from the Thai Cancer Information Network to evaluate 
incidence trends in four areas of Thailand. We identify evidence for increases in HPV-associated 
oropharyngeal cancer similar to those seen in the United States (U.S.), while noting overall 
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Methods:  
 
HNSCC incidence data available from 1990-2014 were obtained from the Songkhla, Khon Kaen, 
Lampang and Chiang Mai cancer registries, and compared to those found in the U.S. 
Surveillance, Epidemiology, and End Results Program (SEER) (Figure 5.1) 14-18. Each Thai 
registry has case ascertainment of ~ 90% within their catchment area 19.  Chiang Mai, which was 
the first cancer registry to be established in Thailand, has actively obtained cancer cases from all 
provincial hospitals within the province since 1983 20. Lampang passively collects data from 
cancer centers and all public and private hospitals within the province 21. Khon Kaen, which 
represents an estimated third of the overall population of Thailand, collects data from all care 
facilities using both active and passive methods 22. The province of Songkhla has a population-
based registry that was established in 1989 and managed by the Prince of Songkla University 23.  
Finally, the U.S. SEER database which was established in 1973 and uses both passive and active 
data collection (Table 5.3).  All registries provide data for the International Agency for Research 
on Cancer's (IARC) Cancer Incidence in Five Continents repository (CI5)24.  
 
Inclusion criteria for case selection was based upon International Classification of Disease, 10th 
Edition (ICD-10) codes. Site-specific cancers were defined by the following codes: oral cavity 
(C00, C03-C06), tongue (C01-C02), pharynx (C09-C10, C12-C14) and larynx (C32). Overall 
HNSCC incidence was calculated as the sum across all subsites. In addition to diagnosis, case 
information included: age, sex, date of diagnosis, stage, histology and morphology. For the Thai 
data, population denominators by registry, year, age and sex were based upon decennial census 
data from 1990, 2000, and 2010, which were conducted by the Thai National Statistical Office 
25,26. Annual intercensal population structures for the various provinces were estimated by 5-year 
sex-specific age groups, using a log-linear function between successive censuses. Population 
counts beyond 2010 were estimated by the Office of the National Economic and Social 
Development Board 27,28. Population denominators for the SEER data were obtained from 
SEER*Stat 8.3.518 and based upon the US Census Bureau’s Population Estimates Program29.  
 
Data were analyzed using R-statistical software version 3.3.3 30. To assess sex-specific HNSCC 
trends, annual percent change (APC) was calculated using age-adjusted incidence rates in 
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Joinpoint regression model version 4.5.0.1. 31.  This software utilizes a Monte Carlo permutation 
method to assess the number of joinpoints, slope in the trends and their significance 32. When no 
cases were present within a given year, a half-case was added to the age strata with the largest 
population to enable computation on the log-linear scale 14,32. This method was repeated for all 
sub-sites, standardized to the Segi (1960) world population for comparability 33,34. Additional 
exploratory analyses using stratified linear regression models were conducted to assess temporal 




Between 1990 and 2014, 91,491 cases of HNSCC were reported in the U.S., 2,938 in Chiang 
Mai, 2,158 in Khon Kaen, 2,947 in Songkhla, and 1,202 in Lampang. The distribution of age at 
diagnosis was relatively similar across all study sites, with means ranging from 61-67 years old.  
HNSCC incidence was higher among males than females in all registries except Khon Kaen, 
where females represented 50.14% of the observed cancer cases. In the U.S., Chiang Mai and 
Lampang, laryngeal cancer accounted for the highest proportion of HNSCC among men, while 
oral cavity and pharynx cancers were predominant in Khon Kaen and Songkhla, respectively.  
Among females, oral cavity cancers contributed the greatest case burden across all registries 
(Table 5.1).  
 
Songkhla was found to have the highest overall HNSCC incidence among men, with an expected 
age standardized rate (EASR) of 14.68 per 100,000 in 2014. Although much lower among males, 
the U.S. stood out as having the highest HNSCC burden among females, with an EASR2014 of 
4.32 per 100,000. Overall, these rates are decreasing across all registries except Khon Kaen and 
Chiang Mai, where there is an observed, non-statistically significant increase in incidence among 
males (APC: 0.5 [95%CI: -0.6, 1.6] and APC: 8.1 [95%CI: -3.3, 20.9] respectively). Despite 
these general decreases, analyses assessing sub-site incidence trends demonstrated great 
variability in slope, and corresponding significance, across registries and anatomical location 
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When compared to other registries, laryngeal cancer rates were highest among US women and 
men (EASR1990-2014: 1.0 and 4.7 per 100,000, respectively).  Laryngeal cancer among women is 
significantly decreasing in Lampang (APC: -4.8 [95%CI: -7.7, -1.9]), Chiang Mai (APC: -11.2 
[95%CI: -13.7, -8.7]), and the U.S. (APC: -2.7 [95%CI: -3.2, -2.3]). Among men, these trends 
have been more variable, with the most recent significant decreases observed in Lampang from 
2007-2014 (APC: -11.8 [95%CI: -19.3, -3.5]), and the U.S. (APC: -2.8 [95%CI: -3.0, -2.5]) 
(Figure 5.2).  
 
Khon Kaen women and Songkhla men were found to have to highest oral cavity cancer rates, 
both with EASR1990-2014 of 3.8 per 100,000.  Although oral cavity cancers contribute the greatest 
proportion of HNSCC cases among females, the incidence of these cancers has declined across 
all registries, with significant decreases observed in Songkhla (APC: -5.1 [95%CI: -6.8, -3.4]), 
Khon Kaen (APC: -4.6 [95%CI: -6.0, -3.1]), Lampang (APC: -3.1 [95%CI: -5.4, -0.8]) and the 
U.S. (APC: -1.8 [95%CI: -2.1, -1.5]). Similarly, trends among men also note reductions in oral 
cavity cancer incidence, particularly in Songkhla (APC: -2.1 [95%CI: -3.4, -0.8]), Khon Kaen 
(APC: -2.6 [95%CI: -4.5, -0.7]) and Lampang (APC: -3.1 [95%CI: -5.8, -0.3]) (Figure 5.2).  
 
Pharyngeal cancer rates were highest among US females (EASR1990-2014: 1.0 per 100,000) and 
Songkhla males (EASR1990-2014:  5.1 per 100,000).  Decreased incidence rates were noted among 
Chiang Mai females (APC: -8.2 [95%CI: -9.9, -6.4]) as well as both females and males in 
Lampang (APC: -4.0 [95%CI: -7.0, -0.9]; APC: -4.5 [95%CI: -6.1, -2.8], respectably). 
Conversely, increases in pharyngeal cancer incidence were found among males in Khon Kaen 
(APC: 2.1 [95%CI: 0.4, 3.8]) and the U.S. from 2002-2014 (APC: 2.2 [95%CI: 1.5, 3.0]). 
Tongue cancer rates were highest among US females (EASR1990-2014: 1.2 per 100,000) and 
Songkhla males (EASR1990-2014: 3.9 per 100,000). These rates were found to be significantly 
increasing among females in the U.S. (APC: 0.8 [95%CI: 0.4, 1.2]) as well as males from 1998-
2014 (APC: 2.4 [95%CI: 1.9, 2.9]). A suggested increase in incidence of tongue cancer was 
observed among Lampang males, as well as both sexes in Khon Kaen and Chiang Mai, but these 
trends did not reach statistical significance (Figure 5.2).  
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Exploratory analyses into younger onset (< 60 years old) trends demonstrated significant 
increases in tongue cancer among Chiang Mai females age 50-59, Khon Kaen females age 30-39, 
Khon Kaen males age 30-59, Lampang males age 50-59, Songkhla females age 30-49, U.S. 
females 30-49 as well as US males age 40-59. Pharyngeal cancers were also seen to increase in 
Khon Kaen males age 40-59, and U.S. males age 50-59 (Table 5.2) (Figure 5.2).      
 
Discussion 
In this study, we found HNSCC decreasing across four registries in Thailand, as well as the U.S., 
with distinct variability across anatomical sub-site, sex and geographical location.  While the 
vast majority of these changes may be attributed to anti-smoking campaigns, changes in policy 
and consequent shifts in risk behaviors, there also appears to be evidence suggesting the growing 
impact of HPV-related etiology on increasing oropharyngeal cancer incidence in Thailand and 
the U.S.  
 
HNC is comprised of highly heterogeneous cancers, with global incidence reflective of trends in 
tobacco and alcohol use 35,36, and sexual norms 37,38.  As these risk behaviors change over time, 
the site-specific incidence contributing to overall HNC trends reflect these changes in a 
population- and gender-specific manner. In 1990, the largest proportion of HNSCC among men 
were observed in the larynx in the U.S. and Lampang (EASR1990 of 6.40 and 1.89 per 100,000, 
respectively), oral cavity in Khon Kaen and Songkhla (EASR1990: 2.09 and 4.97 per 100,000, 
respectively), and pharynx in Chiang Mai (EASR1990: 6.67 per 100,000). In contrast, in 2014 the 
largest drivers of HNSCC among men shifted to pharyngeal cancer in the U.S., Songkhla and 
Chiang Mai (EASR2014: 4.54, 4.70 and 2.33 per 100,000, respectively) and tongue cancer in 
Khon Kaen and Lampang (EASR2014: 1.62 and 1.83 per 100,000, respectively). Among females, 
oral cavity cancers appear to have historically predominated HNSCC incidence across all 
registries and, although to a lesser degree, continue to do so in Khon Kaen, Chiang Mai and 
Lampang; on the other hand, in the U.S. and Songkhla, these trends appear to have shifted in 
recent years, resulting from a decrease in oral cavity incidence and an increase in tongue cancer. 
Nevertheless, HNSCCs among women have significantly decreased across all Thai registries, 
while such observations are less apparent among males.  
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While an estimated 7% of oral cavity cancers in the U.S. are attributed to chewing tobacco 39, the 
practice of chewing betel quid, comprised of areca-nut, slaked lime, betel leaf and often tobacco, 
is widely prevalent throughout Thailand. A study conducted in Northeastern Thailand found that 
ever chewers of betel quid had a 9.01-fold increased risk of oral cancer compared to never 
chewers in multivariate analyses 40; numerous other studies have also implicated betel quid use 
in the etiology of oral cavity cancer 40-45. Several studies from northeastern Thailand have 
demonstrated the high prevalence of betel use among women, commonly used as a social 
activity, particularly among older generations 42,45,46.  Conversely, chewing tobacco use among 
women in the US has historically been low;  according to the National Survey on Drug Use and 
Health, an estimated 0.5% of adult women utilized smokeless tobacco in the U.S. in 201647. 
After years of education and political campaigns to decrease betel-quid use in Thailand, recent 
data shows declines in this risk behavior, especially among younger populations 13,42. The impact 
of this cultural shift is apparent in the consistent decreases in oral cavity cancers, particularly 
among women, and most notably in Khon Kaen, where the incidence reduced by two-thirds: 
from an EASR1990 of 6.37 per 100,000 to an EASR2014 of 2.08 per 100,000 (APC: -4.6 [95%CI: -
6.0, -3.1]). 
 
Tobacco use has long been considered the leading cause of HNSCC, often working 
synergistically with alcohol consumption 48,49. A study in the International Head and Neck 
Cancer Epidemiology Consortium estimated that ~90% of HNSCC patients have a history of 
tobacco use 50, conferring a 10-fold increase in laryngeal cancer risk and a 4 to 5-fold increase in 
hypopharynx, oropharynx and oral cavity cancer risk 51. Being dose-dependent in nature 50,52, 
several studies have suggested smoking cessation to reduce the risk of HNSCC 53,54. In the U.S., 
increased societal awareness and support for combustible tobacco control has led to a decrease in 
cigarette consumption 55,56, and consequently laryngeal cancer rates, with an APC of -2.8% 
(95%CI: -3.0, -2.5) among men and -2.7% (95%CI: -3.2, -2.3) among females. Beginning in 
1991, Thailand was the first nation in Asia to implement strong tobacco control policies 57,58. 
Since then, numerous regulations have been put into place, including bans on advertisement and 
smoking in certain public places, health warnings, and taxation 59,60. As a result of these 
aggressive control methods, the overall smoking rate in Thailand has dropped from 30% in 1976 
to 19.9% in 2013 61 and lung cancer rates, particularly in Northern Thailand, have also decreased 
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62. As demonstrated in Figure 5.2, EASR of laryngeal cancer among females in Thailand has 
been, and remains, relatively low, with observed decreases across all registries. In addition to the 
aforementioned control methods, cultural norms in Thailand have historically resulted in women 
abstaining from smoking and drinking 13,61.  Interestingly, comparing reported alcohol 
consumption rates in Thailand between 2003/2004 to those in 2008/2009 demonstrated 
decreased drinking rates among young men and increasing rates among young women, pointing 
to a potential change in cultural practices 63,64.  Although inconsistent across time, significant 
decreases in laryngeal cancer incidence can be observed among men in Lampang, with an APC -
11.8% (95%CI: -19.3, -3.5) from 2007-2014. Chiang Mai also shows decreased incidence of 
laryngeal cancer among men, but these trends fail to reach statistical significance, while trends in 
both Khon Kaen and Songkhla remain stagnant.   
 
Historically, tongue and pharyngeal tumors have been associated with similar risk factors as 
other HNSCC sites, such as combustible tobacco and alcohol 52,65. An etiological shift in 
oropharyngeal tumors in the U.S. has led to increased global awareness of high-risk HPV as a 
causal factor in carcinogenesis of these sites, with current prevalence estimates in the U.S. near 
80% 8,66-72. While pharyngeal cancer incidence rates varied widely across the different registries, 
tongue cancer rates appeared to increase across all registries except both genders in Songkhla 
and Lampang females. Studies assessing the differences in HPV-positive and negative HNSCC 
demonstrated an increase in HPV-positive tumors among younger cohorts with a lower smoking 
prevalence and multiple sexual partners 72. In an exploratory analysis to assess the change in 
incidence of tongue and pharynx cancer among younger individuals (<60 years old) we found 
significant increases in tongue cancer across all registries, as well as pharyngeal cancer in Khon 
Kaen males (Table 5.2). A sensitivity analysis to assess these trends in the oropharynx as 
defined by ICD-10 codes: C01, C02.4, C09.0-09.9, and C10.0-10.9 8 demonstrated significant 
increases in incidence rates among Khon Kaen males age 30-39 and 50-59, Khon Kaen females 
age 40-49, Songkhla females age 50-59 and Lampang females age 30-39 (data not shown). To 
date, there have only been two studies conducted in the Thai population to assess HPV 
prevalence in HNSCC—both in the oral cavity 73,74. The more recent of the two studies utilized 
146 archival tissue samples of oral squamous cell carcinoma, and found 56.2% to be positive for 
high risk HPV, and 43.8% to express HPV E6/E7 mRNA 73.  
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This study was the first, to our knowledge, to assess HNSCC trends across multiple registries in 
Thailand in comparison to the U.S. While data obtained from population-based registries allow 
for results to be extrapolated to the pertinent provinces, it is difficult to approximate the number 
of unreported cases of cancer, particularly among those living in rural villages. The introduction 
of universal health coverage by the Thai National Health Security Office in 2002 allowed for 
improved access to care, leading to a presumed increase in case ascertainment and, consequently, 
increased incidence trends. In this study, however, we did not observe any significant changes in 
incidence between the periods before and after the introduction of this policy, noting primarily 
decreases in overall HNSCC incidence.  
 
The comparison of trends across different registries poses challenges not only due to variability 
in data collection methods, but also in population composition. While Thailand’s registries boast 
high quality data collection 16,19, with methods varying from passive, to active, to a combination 
of the two 20-23, analyses of incidence near the inception of a given registry may lead to concerns 
regarding data reliability; this is particularly relevant in Lampang, where registry data prior to 
1993 was collected retrospectively, and may be biased towards cases alive at the time of the 
registry’s foundation. Nevertheless, this study assessed HNSCC trends across twenty-four years, 
resulting in a comprehensive temporal analysis. Finally, changes in population structure have 
become increasingly apparent across Thailand, with rural to urban migration of individuals 
within Thailand, as well as immigration into the country 75,76.  
 
In conclusion, although HNSCC appears to be decreasing across Thailand as well as the U.S., 
there is evidence to suggest that the increase in high-risk HPV associated oropharyngeal cancers 
previously reported in the U.S., may also be relevant in Thailand. HPV positive tumors have 
been shown to be more responsive to treatment, ultimately leading to suggested restaging, and 
consequently less aggressive treatment, of these lesions by the American Joint Committee on 
Cancer 77. Due to the younger onset nature of these lesions, de-escalation of treatment may lead 
to improvements in morbidity and mortality of afflicted patients. With the potential increase in 
HPV-positive tumors in Thailand, further molecular studies are necessary in order to evaluate 
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oropharyngeal etiology, subsequently leading to improved public health practice and treatment 
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 USA Chiang Mai Lampang Khon Kaen Songhkla 
 Male Female Male Female Male Female Male Female Male Female 
Mean Age, y 62.63 65.29 64.72 65.64 63.73 65.99 61.05 66.98 64.42 67.25 
























Subsite, N (%)           
Oral Cavity 15,353 
(23.23) 






















72 (15.32) 249 (23.14) 58 (5.36) 759 (31.53) 87 (16.11) 
Larynx 19,791 
(29.95) 




87 (18.51) 275 (25.26) 23 (2.13) 516 (21.44) 42 (7.78) 
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 USA Chiang Mai Lampang Khon Kaen Songhkla 
 Male Female Male Female Male Female Male Female Male Female 
H&N           
30-39 -0.129 
(<0.0001) 
0.012 (0.08) -0.022 (0.64) -0.097 
(<0.0001) 





-0.013 (0.37) -0.098 (0.37) -0.127 (0.01) -0.023 
(0.80) 
0.016 (0.77) 0.264 
(0.001) 
-0.013 (0.74) 0.149 
(0.18) 
0.055 (0.09) 
50-59 -0.302 (0.003) -0.209 
(<0.0001) 










          
30-39 -0.095 
(<0.0001) 
-0.003 (0.37) 0.015 (0.48) -0.057 (0.001) -0.023 
(0.27) 
0.001 (0.98) -0.013 
(0.18) 
-0.039 (0.02) 0.013 (.55) 0.012 (0.26) 
40-49 -0.158 
(<0.0001) 







-0.092 (0.04) -0.270 (0.02) -0.004 
(0.95) 








Tongue           
30-39 -0.002 (0.77) 0.017 (0.001) 0.006 (0.78) -0.020 (0.19) 0.024 (0.24) 0.024 (0.35) 0.053 (0.02) 0.051 (0.01) 0.036 
(0.12) 
0.038 (0.02) 
40-49 0.028 (0.04) 0.021 (0.01) -0.042 (0.28) -0.028 (0.25) 0.063 (0.24) 0.022 (0.58) 0.118 
(0.003) 













Pharynx           
30-39 -0.017 (0.01) 0.004 (0.21) -0.034 (0.22) -0.010 (0.09) 0.032 (0.11) 0.008 (0.76) 0.027 (0.11) -0.008 (0.49) 0.037 
(0.16) 
0.004 (0.77) 
40-49 0.032 (0.14) -0.004 (0.44) -0.018 (0.61) -0.036 (0.10) -0.043 
(0.27) 













Larynx           
30-39 -0.014 (0.001) -0.006 (0.04) -0.009 (0.19) -0.010 (0.09) -0.001 
(0.96) 
-0.001 (0.89) -0.001 
(0.95) 





-0.016 (0.01) 0.018 (0.65) -0.035 (0.01) -0.059 
(0.19) 










-0.259 (0.0003) -0.207 
(0.01) 





 87  
Table 5.3: Registry Characteristics and Data Quality Measures 
 
 
 USA (SEER-9) Chiang Mai Lampang Khon Kaen Songhkla 
Year Started  1973 1978 1993 1985 1988 
Years Data Collected Retrospectively N/A N/A 1990-1992 N/A N/A 
Active/Passive Active/Passive Active Passive Active/Passive Active 
Population Based (Y/N)- Year Started* Y-1973 Y-1983 Y-1995 Y-1985 Y-1989 
Data Sources*à A-M, O A-H, J, L-M, P A-H, J, L-M, P A-J, L-N, P A-H, J, L-M 
Population in Urban Area (%)* N/A 24 30 21 38 
% Morphologically Verified for Males, Females*      
Oral cavity/pharynx (C00-14) 98.7, 98.1 92.9, 95.0 84.9, 83.5 94.5, 94.9 94.6, 93.0 
Larynx (C32) 97.9, 98.0 90.3, 66.7 95.7, 75.0 86.4, 87.5 93.6, 100.0 
% Death Certificate Only for Males, Females*      
Oral cavity/pharynx (C00-14) 0.4, 0.9 2.5, 3.2 7.0, 6.6 0.0, 0.8 1.6, 0.8 
Larynx (C32) 0.6, 0.8 1.1, 0.0 0.0, 0.0 4.5, 0.0 0.0, 0.0 
* as reported by IARC CI5 volume X 
à Sources: 
A: Pathology labs                                         I: Imaging facilities 
B: Public hospital inpatient records             J: Hematology labs 
C: Private hospital inpatient                        K: Hospice/palliative units 
D: Death certificates                                    L: Public hospital outpatient records 
E: Radiotherapy depts                                M: Private hospital outpatient records 
F: Oncology depts                                       N: General practitioner records 
G: Public hospital discharge records          O: Health insurance records 
H: Private hospital discharge records         P: Autopsy services 
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Figure 5.2. Subsite Joinpoint analyses of HNSCC trends by sex and registry. A, expected age 
standardized rate (EASR1990-2014) and 95% confidence intervals. B, Annual percent change 
(APC) and 95% confidence intervals. 
 
 
      
Oral Cavity Tongue Pharynx Larynx 
1990-2007 -4.7* (-5.0, -4.3) 1990-1998 0.2 (-1.5, 2.0) 1990-2002 -1.5* (-2.3, -0.6) 1990-2014 -2.8* (-3.0, -2.5) 
2007-2014 -0.3 (-1.6, 1.1) 1998-2014 2.4* (1.9, 2.9) 2002-2014 2.2* (1.5, 3.0) 1990-2014 -2.7* (-3.2, -2.3) 
1990-2014 -1.8* (-2.1, -1.5) 1990-2014 0.8* (0.4, 1.2) 1990-1999 -4.1* (-5.6, -2.6) 
1999-2014 0.1 (-0.6, 0.8) 
1990-2007 -7.6* (-9.9, -5.2) 1990-2010 -6.3* (-8.5, -4.0) 1990-2009 -8.3* (-10.6, -6.0) 1990-1996 -3.2 (-10.1, 4.1) 
2007-2014 8.0 (-2.2, 19.2) 2010-2014 20.9 (-5.5, 54.8) 2009-2014 12.7 (-9.8, 40.9) 1996-1999 -28.0 (-59.6, 28.3) 
1990-1996 10.3 (-1.1, 23.1) 1990-2009 -7.3* (-9.7, -4.8) 2000-2014 -8.2* (-9.9, -6.4) 1999-3014 -1.3 (-3.9, 1.4) 
1996-1999 -34.6 (-68.3, 34.7) 2009-2014 13.3 (-5.5, 35.9) 1990-2014 -11.2* (-13.7, -8.7) 
1999-2014 -3.4 (-6.9, 0.3) 
1990-2014 -3.1* (-5.8, -0.3) 1990-2014 2.1 (-0.4, 4.7) 1990-2014 -4.5* (-6.1, -2.8) 1990-1995 10.4 (-2.4, 24.9) 
1990-2014 -3.1* (-5.4, -0.8) 1990-2014 -0.3 (-4.0, 3.5) 1990-2014 -4.0* (-7.0, -0.9) 1995-1998 -24.3 (-54.9, 27.0) 
1998-2007 -0.2 (-7.0, 7.0) 
2007-2014 -11.8* (-19.3, -3.5) 
1990-2014 -4.8* (-7.7, -1.9) 
1990-2014 -2.6* (-4.5, -0.7) 1990-2014 2.0 (-0.1, 4.2) 1990-2014 2.1* (0.4, 3.8) 1990-2014 0.2 (-1.6, 2.1) 
1990-2014 -4.6* (-6.0, -3.1) 1990-2014 0.1 (-2.2, 2.5) 1990-2014 -2.9 (-6.5, 0.8) 1990-2014 -3.0 (-6.3, 0.4) 
1990-2014 -2.1* (-3.4, -0.8) 1990-2014 -0.6 (-1.9, 0.7) 1990-2014 -0.8 (-1.9, 0.4) 1990-2014 0.0 (-1.3, 1.3) 






















Increasing Prevalence of HPV in Oropharyngeal Carcinoma Suggests 





Background: Human papillomavirus (HPV) has been etiologically linked to increasing 
oropharyngeal squamous cell carcinoma (OPSCC) rates in much of the Western world. 
Nevertheless, the role of HPV in Southeast Asia, a high incidence region for head and neck 
cancer, has not been assessed.  
 
Methods: 107 formalin-fixed, paraffin-embedded (FFPE) tissue blocks and corresponding 
patient data were obtained from Srinagarind Hospital in Khon Kaen, Thailand. The samples were 
genotyped using polymerase chain reaction (PCR) and stained for p16. Patient characteristics 
between HPV+ and – patients were compared using chi-squared and t-test. Inverse probability 
weights were created based on data from the hospital-based cancer registry and used in all 
further statistical analyses. Diagnosis year, age, annual sample size and sex adjusted linear 
regression was used to assess changes in OPSCC HPV prevalence across time and to create 
projections.  Kaplan-Meier estimation and cox proportional hazard models were used to 
determine survival differences between OPSCC patients based on HPV status.  
 
Results: 14 patients exhibited monoinfection with HPV16, two with HPV18 and one was co-
infected with both HPV16 and 18. PCR results were in complete agreement with p16 staining. 
On average, HPV+ patients were younger (p-value: 0.05) and more likely to have tonsil cancer 
(p-value: 0.002).  HPV prevalence increased at a rate of 2% annually (p-value: 0.01), from 16% 
in 2012 to 26% in 2017. At the current rate, OPSCC HPV positivity is expected to exceed 50% 
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by 2030. HPV positivity was shown to be protective in both Kaplan-Meier (log-rank p=0.02) and 
sex, age and stage adjusted cox proportional hazard models (HR: 0.34 [95%CI: 0.22, 0.52]). 
 
Conclusion: Given the increased prevalence and similarities in presentation of HPV+ OPSCC to 
those observed in Western countries, we believe it is reasonable to suggest the adaptation of p16 
staining and subsequent restaging of OPSCC tumors as suggested by the American Joint 




Head and neck cancer (HNC) is comprised of a heterogeneous group of neoplasms that span 
several anatomical subsites including the: oral cavity, oropharynx, hypopharynx, nasopharynx, 
larynx, salivary glands, paranasal sinuses and nasal cavity. Taken together, HNC is considered to 
be the sixth most common cancer worldwide1 with the highest incidence reported in South and 
Southeast Asia2,3. Although variable by subsite, ~90% of HNCs are morphologically 
characterized as squamous cell carcinoma (HNSCC)4 for which the primary risk factors are well 
established and include heavy alcohol consumption, use of tobacco products (both combustible 
and chewing) and betel quid. Despite reductions in the use of tobacco products, numerous studies 
have noted rising incidence in oropharyngeal squamous cell carcinoma (OPSCC); these increases 
have been identified to be etiologically linked to persistent infection with high risk human 
papilloma virus (HPV), resulting in a clinically and epidemiologically distinct subset of 
OPSCC5,6.  
 
HPV-positive and -negative OPSCCs are distinctly different in both their presentation and 
response to treatment. Oropharyngeal squamous cell carcinomas are associated with the 
lymphoid mucosae of Waldeyer’s ring, and consequently arise from the soft palate, base of the 
tongue, tonsils, and oropharynx7,8. These sites are characteristically lined with non-keratinizing 
stratified squamous epithelium that is folded to create basal keratinocyte filled crypts that trap 
antigens and allow for nuclear integration of HPV DNA7,9. The resulting malignancies are often 
poorly differentiated and possess a non-keratinized basaloid morphology10-12.  In the Western 
world, HPV-positive OPSCC patients tend to be younger, higher socio-economic status and are 
less likely to partake in high risk behaviors typically associated with HNC13-16. Due to 
transmission modalities of HPV, sexual behaviors, particularly regarding age at sexual debut and 
number of sexual partners, are especially relevant in understanding risk and incidence of this 
cancer subtype17,18. While historically best described in cervical cancer, 14 of the more than 100 
HPV genotypes are considered to be “high risk” due to their oncogenic potential19. Of these, 
HPV16 and 18 are most frequently implicated in malignant transformation, with HPV16 
accounting for more than 90% of HNSCC cases9,20. In persistent infection, the HPV oncoprotein 
E7 competes with the E2F transcription factor for binding to the retinoblastoma protein, 
inactivating it and causing uncontrolled cellular proliferation; this disruption in the cellular cycle 
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subsequently results in the overexpression of tumor suppressor protein p1621. Due to this 
phenomenon, immunohistochemical detection of p16 is commonly used as a surrogate marker 
for biologically active HPV infection. Numerous studies have shown HPV status to be a strong 
independent prognostic factor for survival among OPSCC patients22,23, leading the American 
Joint Committee on Cancer to suggest restaging these tumors to allow for less aggressive 
treatment24.   
 
Despite its important prognostic significance, the vast majority of studies investigating the role 
of HPV in HNC have been conducted in Western countries, limiting generalizability and 
adaptation of screening and treatment methodologies on a global scale. Thailand has undergone 
rapid socioeconomic development in the last decade, allowing for improved control of 
communicable diseases and resulting in the emergence of cancer as the leading cause of 
mortality 25. Located centrally in Southeast Asia, the sociocultural factors in Thailand are similar 
to those in the surrounding countries, and while a few studies have implicated HPV as a relevant 
etiological factor in this setting 26,27, to date only anecdotal evidence has been provided. In this 
study, we present a temporal molecular and characteristic assessment of HPV prevalence in Thai 
OPSCC in hopes of informing clinical practice and improving treatment and quality of life 




Patient and Tissue Selection 
 
Oropharyngeal carcinoma patients diagnosed between 2012 and 2017 were retrospectively 
identified through the Khon Kaen Cancer Registry28. Those individuals under the age of 18 or 
who had not received biopsies or surgical resection at Srinagarind Hospital in Khon Kaen, 
Thailand were excluded and the resulting list was sent to the pathology department. One 
formalin-fixed, paraffin-embedded (FFPE) tissue sample was obtained for each eligible patient 
for whom tissue was stored in the pathology department’s biobank. Pathology records 
corresponding to each FFPE block were provided for more detailed assessment of the cancer site, 
stage and source of the sample (resection or biopsy). Additional variables including diagnosis 
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date, sex, age, stage, survival status and date last seen were obtained from the registry system. 
Once collected, both the FFPE blocks and corresponding data for the 107 patients were sent to 
the University of Michigan for further molecular and statistical assessment. OPSCC patient data 
for the corresponding years, regardless of age or tissue availability, was provided from the 
Srinagarind Hospital Cancer Registry to check for generalizability and included the following 
variables: diagnosis date, topography, stage, sex, age, postcode, survival status and date last seen.  
  
Laboratory Analyses  
 
Seven 4-micron sections were cut from each tumor block: 1 slide for H&E staining, 2 slides for 
p16 staining, and 4 slides for DNA isolation. H&E slides were reviewed by an expert pathologist 
in head and neck pathology (JM) for % cellularity, % necrosis, and tumor area. 
 
Four unstained sections from each block were placed on uncharged slides for microdissection. 
Areas of tumor circled on the H&E slide were aligned with the section on the unstained slides. 
These areas were microdissected for DNA extraction. Input for extraction varied based on the 
size of the tumor area (mm2) based on kit recommendations (up to 100 mm2 total). DNA was 
extracted per manufacturer guidelines using the DNAStorm FFPE Kit (Cell Data Sciences Inc., 
USA) including RNase treatment. Isolated DNA was stored at -20 C until further analysis. 
 
All samples were evaluated for HPV status among 14 high-risk types (16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, 66, and 68) using the 14 High-risk HPV with 16/18 Genotyping Real-Time 
Polymerase Chain Reaction (PCR) kit (HBRT-H14 kit, Hybribio Limited).  Four distinct 
fluorophores were utilized in this kit which allowed for identification of HPV-16 (HEX), HPV-
18 (ROX), 12 other high-risk types of HPV (FAM), and an internal control (Cy5) present within 
each sample.  Real-time PCR was performed following manufacturer instructions.  Briefly, PCR 
master mix, DNA Taq polymerase were combined to create a PCR mix.  To bring the total 
reaction volume to 20 µL, 2 uL of template DNA was added to each well.  One positive control 
and one negative control was included on each plate.  Samples were evaluated using 
thermocycler conditions provided by the manufacturer on the BioRad CFX96. 
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Results were assessed using the Bio-Rad CFX Manager Version 1.5.  The baseline threshold was 
set from 3-15 cycles, as directed by the kit instructions. Positive controls were valid when the 
threshold cycle (Ct)  ≤36, while negative controls were valid when undetected. Samples were re-
run if either control was deemed invalid on the plate.  Due to noise in the signal across samples, 
we did not evaluate the FAM fluorophore. This restricted our results to only HPV-16 and HPV-
18.  Positive HPV-status was determined when Ct ≤35, while negative samples did not amplify 
and had undetected Ct values.  
 
Immunohistochemical staining was performed on the DAKO Autostainer (Agilent, Carpinteria, 
CA) using Envision+ and diaminobenzadine (DAB) as the chromogen. De-paraffinized sections 
were labeled with p16 Ink4a (Abcam, Cambridge, MA, Ab-108349 Clone EPR1473, 1:2000) for 
30 minutes at ambient temperature. Heat induced epitope retrieval using 10 mM citrate buffer 
pH6.0 was used prior to staining. Appropriate negative (no primary antibody) and positive 
controls (cervix) were stained in parallel with each set of slides studied. Slides were scored for 
p16 status by JM to distinguish between p16 negative (no staining or missing staining from 
either the nuclei or cytoplasm) and p16 positive (staining of both nuclei and cytoplasm within 
³70% of the tumor tissue) samples.  
 
Worst pattern of invasion (WPOI) was assessed by a pathologist (JM) using H&E slides on scale 
of 1-5 according to previously published guidelines29-31.  In brief, the five categories were 
defined as follows: type 1=pushing border, type 2=finger-like growth, type 3=large separate 
islands of >15 cells per island, type 4=small discontiguous tumor islands with ≤15 cells, and type 
5= discontiguous tumor satellites >1mm from the main tumor or next closest satellite. In-situ 
tumors or small biopsy sections lacking margins that could not be properly scored were 
considered to be indeterminate.  
 
Statistical Analysis  
 
Descriptive statistics comparing HPV positive and negative patients were conducted using chi-
squared test (for categorical variables) and t-test (for continuous variables). Upon review of the 
pathology records, 11 samples were determined to be oral cavity and excluded from further 
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analyses. A similar analysis was completed to assess differences between our sub-cohort of 
patients and the larger Srinagarind Hospital cancer registry. To account for differences observed 
between these groups, we utilized inverse probability weighting in order to allow our subcohort 
patients to  better represent the larger registry cohort, thereby improving generalizability32. 
Propensity scores were produced using baseline demographic variables, which included: age at 
diagnosis, sex, disease site and year of diagnosis. The reciprocal of the propensity score was used 
as the weight in further statistical analyses. To evaluate trends in HPV prevalence, proportions, 
calculated as the number of HPV+ cases over the sum of all OPSCC cases diagnosed within a 
given year, were modeled using linear regression as a function of year of diagnosis, age, annual 
sample size and sex. To create a parsimonious model, covariates were selected based on a-priori 
knowledge and backward selection. Projections were modeled based on the multivariate linear 
regression model.  A Kaplan-Meier plot was generated to assess crude survival differences 
between HPV positive and negative patients and compared using a log-rank test. Finally, 
unadjusted as well as sex, age and stage adjusted cox proportional hazard (HR) models were 
employed to further evaluate survival variability based on HPV status. All statistical tests were 




Of the 107 patient samples tested, 17 were found to have to be positive for HPV, while 90 tested 
negative. HPV positivity was found only in the oropharynx, with zero cases of oral cavity cancer 
exhibiting viral DNA or p16 positivity. Among those with HPV+ OPSCC, fourteen were 
monoinfected with HPV16, two monoinfected with HPV18 and one was co-infected with both 
HPV16 and 18. PCR HPV testing results were in complete agreement with p16 staining. When 
comparing HPV positive and negative patients, HPV+ patients were, on average, slightly 
younger, with a mean age of 54.94 (p-value: 0.05), and were more likely to have tonsil cancer, 
which comprised 76.47% of all HPV+ tumors (p-value: 0.002).  Males made up the vast majority 
of the sample size regardless of HPV status, and we found no significant differences in stage, 
year of diagnosis, worst pattern of invasion or mean survival time between groups (Table 6.1). 
When comparing our sub-cohort to the larger hospital-based cancer registry of OPSCC patients, 
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significant differences were found for cancer site (p-value: <0.0001), stage (p-value: <0.0001) 
and year of diagnosis (p-value: 0.0003) (Table 6.2).  
 
Linear regression results assessing changes in HPV prevalence over time, adjusting for age, sex, 
annual sample size and year of diagnosis can be found in Figure 6.2. HPV prevalence 
significantly increased at a rate of 2% annually (p-value: 0.01), starting at 16% in 2012 and 
increasing to 26% in 2017. Assuming prevalence continues at this rate, OPSCC HPV positivity is 
expected to exceed to 50% by 2030.  
 
Survival analysis results can be found in Figure 6.3. HPV positivity was shown to elicit a strong 
survival benefit in Kaplan-Meier estimation (log-rank p=0.02). Cox proportional hazard model 
results demonstrated a marginally significant protective effect of HPV positivity in crude models 
(HR: 0.79 [95%CI: 0.62, 1.02]), but a statistically significant 66% reduced risk of overall 
mortality after adjusting for sex, age and stage (HR: 0.34 [95%CI: 0.22, 0.52]). No significant 




This is the first study to present temporal molecular and characteristic assessment of HPV in 
oropharyngeal squamous cell carcinoma samples from Southeast Asia. The results of these 
analyses provide strong evidence of an increasing prevalence of high-risk HPV in OPSCC, as 
well as a clear survival benefit conferred by the presence of this virus.  In light of these findings, 
together with the agreement between p16 staining and PCR results and the cost effectiveness of 
this screening model, we believe it is reasonable to suggest that the American Joint Committee 
on Cancer guidelines for screening and downstaging of treatment be adapted in this setting.   
 
As socioeconomic growth increased throughout Thailand, pushing the country through a rapid 
epidemiologic transition, the country saw cancer related mortality double from an age-
standardized rate (ASR) of 48.4 per 100,000 in 1998 to 95.2 per 100,000 in 201133.  Head and 
neck cancer is ranked among the top five more commonly diagnosed malignancies in Thailand, 
with age standardized incidence rates of 15.7 and 10.7 per 100,000 among males and females,
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respectively 33. Oropharyngeal carcinoma incidence in particular was recently shown to be 
increasing across Thailand, suggesting that the etiological shift to HPV+ OPSCC observed in 
much of the Western world may also be similarly occurring in Southeast Asia26. Nevertheless, 
despite the county’s high HNC burden, little is known regarding the role of HPV as a potential 
etiological factor in OPSCC. Several studies have attempted to elucidate head and neck HPV 
prevalence in the Thai populating with disparate results. Khovidhunkit at al. examined 65 oral 
squamous cell carcinoma, leukoplakia and lichen planus biopsies from Rajvithi Hospital and 
Mahidol University in Bangkok for the presence of HPV using PCR and found only one sample 
to exhibit HPV DNA34. Another study conducted in Northeastern Thailand found HPV positivity 
in 29.7% of exfoliated cells from oral squamous cell carcinoma (OSCC) cases, compared to 13% 
in controls35.  Finally, a third study examining 48 oral cavity and 4 oropharyngeal carcinomas 
from Srinagarind hospital found 40.8% of OSCC and 50% of OPSCC cases to possess HPV 
E6/E7 mRNA using in situ hybridization (ISH). While we did not find any evidence of HPV in 
our oral cavity samples, 17 of the 96 OPSCC were shown to exhibit HPV DNA as well as p16 
positivity.  
 
In accordance with decreasing smoking rates36,37 and changes in cultural norms around sexual 
behaviors18,38, numerous studies have proposed that the steadily rising incidence rates of OPSCC 
may be tied to increased HPV prevalence39. A study from the Netherlands showed increases in 
HPV+ OPSCC from 5% in 1990 to 29% in 201040, while Australia saw a rise from 19% in 1987-
1990 to 47% for 2001-200541. In the United States, Chaturvedi et al. demonstrated a significant 
increase from 16.3% in 1984-1989 to 72.7% by 2000-20046.  While this etiological shift has 
formerly been proposed to effect predominantly Western, more developed countries42, the results 
of this study provide evidence that Southeast Asia is beginning to similarly experience an 
upsurge in HPV related OPSCC. Among those patients seen at Srinagarind Hospital, whose 
catchment area can be found in Figure 6.1, HPV prevalence increased at a rate of 2% from 16% 
in 2012 to 26% in 2017. If this trend continues at the current rate, Thailand is expected to have 
an OPSCC HPV prevalence over 50% by 2030 (Figure 6.2).  
 
The presentation and behavior of these tumors appears to be similar to those reported in Western 
countries, with younger males bearing the greatest cancer burden42. In regard to HPV strain, 88% 
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of HPV+ OPSCC cases testing positive for HPV16, while the remainder possessed HPV18 
DNA. It is generally accepted that HPV positivity predicts improved survival among OPSCC 
patients23. In accordance with the literature, we found HPV status to confer a strong protective 
effect in our cohort, even after adjustment for sex, age and stage.  
 
While PCR and ISH methods are typically used to diagnose HPV, they are not widely available 
in diagnostic laboratories and do not distinguish between integrated and non-integrated 
genomes21; consequently, p16 staining is commonly used as a surrogate marker for the presence 
of viral oncoproteins associated with HPV infection. The p16 immunohistochemical stain is 
nearly universally available and technically less laborious, allowing costs to be an estimated 2-16 
times lower than HPV-specific tests43. In this study we verified the utility of p16 staining as a 
viable proxy measure for high risk HPV in Thailand, with 100% agreement between the PCR 
and p16 staining results.  
 
Due largely to the retrospective nature of the study, the results should be interpreted in light of 
several limitations. FFPE blocks were obtained based upon availability within the biobank, 
limiting the sample size, particularly in earlier years; nevertheless, registry data was used to 
create inverse probability weights to allow for improved representation and generalizability for 
statistical analyses. Additionally, depletion of FFPE blocks through repeated use may have 
limited the ability to detect tumor tissue characteristics. If applicable, this would likely result in 
an underestimation of HPV prevalence as available tumor tissue is often reduced through 
subsequent cuts. While the role of HPV within the oral cavity is still largely debated44, and not a 
primary aim of this manuscript, the limited sample size of oral cavity tumors available in this 
study preclude us from making any conclusions regarding HPV prevalence within this HNC 
subtype. Because the majority of the available patient data was obtained through hospital registry 
records and not abstracted from patient files, adjustment for potential confounders such as 
smoking, alcohol and betel quid use were not possible. Additional survival analyses based on 
treatment modality were also unachievable and comorbidities could not be accounted for in the 
model. 
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In light of the increasing prevalence of high risk HPV in OPSCC, in addition to the similarities in 
presentation of these cases to those observed in Western countries, we believe it is reasonable to 
suggest the adaptation of p16 staining, corresponding restaging and treatment modalities as 
suggested by the American Joint Committee on Cancer24 in Southeast Asia. While further studies 
need to be conducted in order to validate these results, implementing p16 staining as the standard 
of care for this increasingly common cancer type26 would allow for improved monitoring and 
more informed treatment decisions. In conclusion, screening and subsequent de-escalation of 
treatment would likely allow for decreased mortality and improved quality of life among 
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Mean age (SD), [range] 54.94 (7.67), [42-73] 56.63 (11.97), [36-81] 0.05 
Male, N (%) 13 (76.47) 71 (78.89) 0.82 





Base of tongue 3 (17.65) 38 (42.22) 
Tongue* 0 (0.00) 9 (10.00) 
Hard palate* 0 (0.00) 1 (1.11) 
Soft palate 1 (5.88) 17 (18.89) 
Mandible* 0 (0.00) 1 (1.11) 
Pharynx 0 (0.00) 5 (5.56) 
Tonsil 13 (76.47) 19 (21.11) 




1 0 (0.00) 6 (6.67) 
2 1 (5.88) 10 (11.11) 
3 3 (17.65) 22 (24.44) 
4 13 (76.47) 47 (52.22) 
Missing 0 (0.00) 5 (5.56) 




2012 2 (11.76) 3 (3.33) 
2013 1 (5.88) 11 (12.22) 
2014 2 (11.76) 29 (32.22) 
2015 4 (23.53) 26 (28.89) 
2016 4 (23.53) 12 (13.33) 
2017 4 (23.53) 9 (10.00) 
Source of Sample    
0.13 Biopsy 11 (64.71) 73 (81.11) 
Excision 6 (35.29) 17 (18.89) 




1 4 (23.53) 8 (8.89) 
2 6 (35.29) 35 (38.89) 
3 3 (17.65) 22 (24.44) 
4 3 (17.65) 18 (20.00) 
5 0 (0.00) 4 (4.44) 
Indeterminate 1 (5.88) 3 (3.33) 
Median Survival Time in Days 521.00 376.50 0.59 
* Denotes oral cavity disease sites 
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Mean age (SD), 
[range] 
56.41 (11.44), [36-81] 55.98 (12.81), [25-91] 0.20 
Male, N (%) 79 (82.29) 179 (73.66) 0.09 
Cancer Site, N (%)    
<.0001 Base of Tongue 41 (42.71) 74 (30.45) 
Oropharynx* 23 (23.96) 25 (10.29) 
Tonsil  32 (33.33) 144 (59.26) 
Stage, N (%)    
 
<0.0001 
1 5 (5.21) 9 (3.70) 
2 9 (9.38) 25 (10.29) 
3 23 (23.96) 42 (17.28) 
4 54 (56.25) 79 (32.51) 
Missing 5 (5.21) 88 (36.21) 




2012 4 (4.17) 38 (15.64) 
2013 12 (12.50) 62 (25.51) 
2014 24 (25.00) 53 (21.81) 
2015 27 (28.13) 31 (12.76) 
2016 16 (16.67) 32 (13.17) 
2017 13 (13.54) 27 (11.11) 
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Figure 6.3: Survival Analyses for HPV-positive and -negative OPSCC Patients  
 
 




HPV Negative  (Ref) (Ref) 
HPV Positive 0.79 (0.62,1.02) 0.34 (0.22, 0.52) 
* Adjusted for sex, age and stage 






Pretreatment Diet, Serum Carotenoids and Tocopherols Influence Tumor 




Background: Tumor infiltrating lymphocytes (TILs) have recently emerged as an important 
factor in informing treatment decisions for head and neck squamous cell carcinoma (HNSCC). 
Nevertheless, little is known about the role of modifiable risk factors, such as diet, on TILs.  
 
Methods: Immunohistologic expression of CD4, CD8, CD68, CD103, CD104 and FOXP3 were 
assessed in tissue microarrays from 233 previously untreated HNSCC patients. Associations 
between these markers and pre-treatment dietary patterns were then evaluated using linear 
regression models. Logistic regression models assessing the associations between baseline serum 
carotenoids, tocopherols and TILs were conducted on a smaller subset of 70 patients. Cox 
proportional hazard models were used to evaluate the joint association between diet and TILs on 
overall and recurrence free survival.  
 
Results:  High intake of a Western dietary pattern decreased CD8+ and FOXP3+ infiltrates after 
adjustment for age, sex and batch (p-value: 0.03 and 0.02, respectively). Multivariate logistic 
regression models demonstrated significant increases in CD8+ (OR: 2.21; p-value: 0.001) and 
FOXP3+ (OR: 4.26; p-value: <0.0001) among patients with high gamma tocopherol. Conversely, 
high levels of xanthophylls (OR: 0.12; p-value:<0.0001), lycopene (OR: 0.36; p-value: 0.0001) 
and total carotenoids (OR: 0.31; p-value: <0.0001) significantly decreased CD68+. Among those 
with high CD4+ (HR: 1.77; p-value: 0.03), CD68+ (HR: 2.42; p-value: 0.004), CD103+ (HR: 
3.64; p-value: 0.03) and FOXP3+ (HR: 3.09; p-value: 0.05) infiltrates, having a high Western 
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dietary pattern significantly increased the risk of overall mortality when compared to those with 
a low Western dietary pattern, even after adjusting for age, sex, stage, disease site, HPV status 
and TMA; a similar effect was found between the high Western dietary pattern and FOXP3+ 
(HR: 2.93; p-value: 0.0002) on recurrence free survival in fully adjusted models.  
 
Conclusion: Dietary patterns and serum carotenoids may play an important role in modifying 
TILs, and ultimately, outcome after diagnosis with HNSCC. The results of this study could 





Head and neck cancer (HNC) encompasses malignant lesions found within the epithelial tissue 
of the oral cavity, pharynx, larynx and nasopharynx, together comprising the sixth most common 
cancer worldwide 1.  More than 90% of neoplasms within the head and neck are reported to be 
squamous cell carcinoma (HNSCC), commonly associated with extensive exposure to alcohol 
and tobacco use 2; however, decreases in tobacco consumption in the United States (US)3,4 has 
led to the implication of high-risk human papillomavirus (HPV) as the primary etiologic factor 
associated with oropharyngeal carcinoma 5.  Irrespective of advances in treatment, HNC has 
experienced a relatively stagnant five-year relative survival rate of 40-50% 6, compelling the 
need for further research and understanding of this heterogenous disease.  
 
Recent studies on the role of tumor-infiltrating lymphocytes (TILs) and cancer suggest 
tumorigenesis to be an immunologic disease as well as genetic one. HNC tumors are unique in 
that they lie within close proximity to lymphoid tissue in the Waldeyer’s ring, therefore allowing 
for dense infiltration of immune cells to be easily integrated into the lesion 7. Several studies 
assessing the role of TILs in HNC have suggested these immune markers to be strong prognostic 
tools to guide treatment decisions 7.  HPV+ HNSCC patients commonly display nodal 
metastasis, yet the overall and progression-free survival rates are typically better than those 
among their HPV- counterparts. Due largely to reports of dense lymphocytic infiltrates in HPV+ 
oropharyngeal carcinoma, one proposed rationale for the observed survival benefit is that the 
body’s immune response against the viral antigen, particularly in the form of CD8+ and 
FOXP3+, may aid in driving the elimination of the tumor cells 8-13. In accordance with this 
research, the American Joint Committee on Cancer has recently suggested restaging HPV+ 
HNSCC in an attempt to curb treatment-related morbidity and mortality rates among afflicted 
patients 14.  TILs have also been repeatedly noted as an important indicator in maximizing 
treatment efficacy, with increased CD3+, CD4+, CD8+ and FOXP3+ T-cell infiltrates correlated 
with improved survival among HNSCC chemoradiation therapy patients15-17.   
 
Numerous epidemiologic studies have demonstrated a bi-directional effect of diet on HNSCC 
risk, progression and prognosis18-27.  While poor nutrition is believed to account for an estimated 
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third of all cancer related deaths in the US28,29, the molecular mechanisms underlying the 
protective effects of bioactive dietary agents remains to be fully elucidated. Immune system 
modulation through dietary components that can mediate inflammation within the tumor 
microenvironment is an important mechanism that has been understudied in HNSCC. Although 
pro-inflammatory factors are essential in the biological response to trauma or infection, 
excessive production of cytokines, chemokines, growth factors, prostaglandins, and reactive 
oxygen and nitrogen species have been shown to impact tumor initiation and progression by 
increasing mutation and cellular proliferation rates, decreasing apoptosis and facilitating 
angiogenesis 30,31.  Increased consumption of fruits and vegetables have consistently been shown 
to improve HNSCC prognosis, possibly by counteracting many of the aforementioned 
inflammatory products through their antioxidant, antimutagenic and antiproliferative properties 
32,33. Nevertheless, no studies to date have assessed the role of diet on anti-tumor immune 
response in HNC.  
 
With increasing interest in the role of tumor immune response in personalized medicine and 
immunotherapy, it is important to assess the potential role of diet on tumor immune response 
and, ultimately, outcome. The results of this study will not only impact our knowledge regarding 
disease pathogenesis, but also aid in facilitating a conversation about dietary recommendations 






Incident cases diagnosed with HNSCC were recruited to participate in this prospective cohort 
study as part of the University of Michigan Head and Neck Specialized Program of Research 
Excellence (HN-SPORE). Upon approval from the Institutional Review Board at the University 
of Michigan, study participants provided signed, informed consent to participate. Exclusion 
criteria included being <18 years of age, pregnant, non-English speaking, diagnosed with another 
non-upper aerodigestive tract cancer, diagnosed with mental instability, or diagnosed with 
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another head and neck primary within five years preceding the signed consent. In total, 1,042 
subjects were enrolled into the study between November 2008 and October 2014. 
 
At baseline, subjects were asked to complete a self-administered health questionnaire that 
ascertained data on demographic characteristics, tobacco and alcohol use, physical activity, 
comorbidities, sleep, depression and quality of life. Thirty mL peripheral blood samples were 
taken prior to treatment using routine venipuncture techniques and formalin-fixed paraffin-
embedded (FFPE) tissue blocks were collected from diagnostic biopsies. In order to track patient 
status, participants were routinely followed every three to six months in clinic. Vital status was 
reviewed annually following diagnosis. Mortality and recurrence status were obtained by 
research assistants through medical record review, annual health surveys, the Social Security 
Death Index and LexisNexis through April 2016.  Time to first recurrence was calculated as the 
number of days between the initial diagnosis at Michigan Medicine and the date of first 
recurrence.  Patients who completed treatment but exhibited persistent disease (were never 
determined by a medical doctor to be disease-free) were given a recurrence time of 1 day.  
 
For the purpose of this analysis, patients who had not completed their baseline food 
frequency questionnaire (FFQ) or were not included on a tumor microarray (TMA) were 
excluded. Additional exclusion criteria included patients who had withdrawn consent, had 
uncommon tumor sites or unknown primaries, resulting in a final sample size of 233. Finally, for 
the purposes of the serum carotenoid/tocopherol analysis, those who did not have available 
baseline serum carotenoid data were excluded, resulting in a sample size of 70. 
 
Specimen and Data Collection 
 
Dietary intake  
 
Dietary intake was collected using the self-administered, semi-quantitative Harvard food 
frequency questionnaire (FFQ) and analyzed as pretreatment dietary patterns as described 
previously25. In brief, the FFQ was designed to evaluate respondents’ typical dietary intake from 
food and supplements prior to diagnosis. The questionnaire consists of 131 items, and the 
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reproducibility and validity have both been previously reported 34,35. The FFQ included standard 
portion sizes for each item (eg: 1 banana, 3-5 oz chicken), which allowed 
participants to select their average frequency of consumption over the past year from a list of up 
to 9 choices ranging from “almost never” to “≥6 times per day.” Total energy and nutrient intake 
were ascertained by summing intakes from each food item based on the selected portion size, 
reported frequency of consumption, and nutrient content of each food item34. Estimations for 
daily food group servings were calculated by summing the frequency weights of each food item 
based on reported daily frequency of consumption. Upon exclusion based on missing values and 
energy intake outliers, 39 foods and food groups were isolated using previously defined 
methods25,36,37. Dietary patterns were deduced by principal component analysis and pattern factor 
scores were calculated for each patient by summing the reported consumption of the factor food 




The extraction of serum carotenoids and tocopherols was completed using high-performance 
liquid chromatography as previously described 38,39. In summary, equal volumes of serum and 
ethanol containing butylated hydroxytoluene were mixed and extracted with hexane, utilizing 
Tocol as the internal standard. To separate carotenoids from tocopherols, a YMC C30 reverse-
phase column was used (YMC Company, LTD, Kyoto, Japan) to conduct a gradual elution at 0.2 
mL/min total flow on the Shimadzu LC-20AT HPLC system (Shimadzu Corperation, Kyoto, 
Japan).  While detection for carotenoids was at 450 and 472 nm, electrochemical detection using 
the Coularray electrochemical detector set (Thermo Scientific, Waltham, Mass) was used for 
Tocol and tocopherols at 310, 390 and 470 mV.  
 
Tumor infiltrating lymphocytes  
 
Hematoxylin-eosin stained slides were created from the aforementioned FFPE tissue specimens 
and reviewed by an expert pathologist (JM). Upon verification of histology, those slides that 
expressed >70% cellularity and minimal necrosis were set aside for tissue sampling. Triplicate 
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0.7mm diameter cores were selected, punched and extracted for each patient to comprise six 
tissue microarray (TMA) blocks representative of 621 patients.  
 
Slides cut from TMAs were stained for CD4, CD8, CD68, CD103, CD104 and FOXP3 TILs 
utilizing techniques previously described 15,40. Briefly, after overnight incubation in a 65°C oven, 
the sections were deparaffinized, and rehydrated using xylene, graded alcohols, as well as buffer 
immersion steps. Heat-induced epitope retrieval was then followed by incubation of the slides in 
a preheated pressure cooker with either Citrate buffer pH6 or Tris-EDTA buffer pH9 and 
blocked using horse serum. A DAKO autostainer, with chromogens liquid streptavidin biotin 
horseradish peroxidase and DBA, was then used for immunohistochemical staining. The 
deparaffinated sections, along with positive and negative controls, were then stained with 
monoclonal antibodies at the following titrations: CD4-1:250 (Abcam Ab846); CD8-1:40 (Nova 
Castra VP-C320); CD68 -1:100 (Dako M0814); CD103-1:500 (Abcam Ab129202); CD104 -1:50 
(Beta-4 integrin, eBioscience 439-9b); and FoxP3 -1:200 (Abcam Ab20034). The stained slides 
were digitally imaged to be used in Aperio ImageScope v.12 software (Leica Biosystems).  
 
A technician naive to clinical status scored the stained TMA slides. Grid software (Measure, C 
Thing Software 2.01) was employed to overlay each tissue core before counting TILs. CD104+  
(beta-4 integrin) staining was used before counting TILs to identify the location and extent of 
carcinoma in each core. Cores were scored as 25%, 50%, 75%, or 100% tumor. Cores deemed to 
have <25% tumor parenchyma were not scored and therefore excluded from the analysis. Using 
200 X magnification, TILs stained with CD4, CD8, CD68, CD103 and FoxP3 antibodies were 
manually counted. Only those TILs that infiltrated the tumor parenchyma were counted. The TIL 
count for each core was normalized by dividing each raw value by the fraction of each 0.7 mm 
core that was indicated as malignant through CD104 staining. Normalizing TIL counts ensured 
that variation in counted cells was representative of increased TIL density within the tumor 
parenchyma and not tumor proportion within cores. Normalized mean counts of triplicate 
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Descriptive statistics reflective of demographic, clinical and serum carotenoid/tocopherol 
variables were compared between binary determinants of dietary pattern score using χ² (for 
categorical variables) and t-test (for continuous variables). Due to the fact that participants with 
dietary data were generally healthier than those missing dietary data, we utilized inverse 
probability weighting (IPW) in order to allow our subcohort patients to better represent the larger 
HN-SPORE cohort, thereby improving generalizability41. Propensity scores (PS) were generated 
using baseline demographic variables, including: age at diagnosis, sex, stage, disease site, 
comorbidity score, drinking and smoking status. The reciprocal of the PS was then used as the 
IPW in statistical analyses. To construct parsimonious statistical models, covariates believed to 
be relevant to the analyses were chosen by a priori knowledge and input by treating physicians 
and determined using backward selection. To assess the association between binary dietary 
pattern score (around the median) and each continuous TIL marker, both crude and age, sex and 
TMA adjusted linear regression models were utilized. Logistic regression models were used to 
evaluate associations between binary serum carotenoids and tocopherols (both individually, and 
as total groupings); univariate and multivariate models (adjusted for age, sex, disease site and 
TMA) were compared using Bonferroni correction to account for multiple testing. Finally, Cox 
proportional hazard (HR) models, adjusted for age, sex, stage, disease site, HPV status and 
TMA, was used to assess the joint role of dietary pattern and TILs on overall and recurrence-free 
survival, consequently assessing the potential modification of the relationship between TILs and 
survival by dietary pattern.  All statistical tests were conducted using SAS software 9.4 (SAS 




Five year survival among the 233 participants was 73.4%; during the course of the study, 65 
(27.9%) of patients died and 56 (24.0%) recurred.  The average age at diagnosis was 60.5 (SD: 
11.3) years.  Most of the study subjects were male (73.4%), white (95.7%), and had some post-
secondary education (62.5%). The oral cavity was the most common tumor location (44.2%) and 
just over half of all patients were diagnosed with stage IV tumors (55.8%).  Demographic and 
clinical characteristics stratified by binary dietary pattern score are shown in Table 7.1a.  
Individuals who consumed higher quantities of the whole foods diet, characterized by high intake 
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of fruits, vegetables, legumes, whole grains and low-fat dairy, were more likely to be older, more 
highly educated and former smokers, compared to their counterparts, who were more likely to be 
current smokers. Males were more likely to consume diets high in red and processed meats, 
refined grains, potatoes, French fries, high-fat dairy, condiments, desserts, snacks and sugar-
sweetened beverages characterized by the Western dietary pattern.  
 
Differences in serum carotenoid/tocopherol concentrations by levels of dietary pattern can be 
found in Table 7.1b. While beta carotene and total carotenoids were the only biomarkers found 
to be significantly elevated among high vs. low whole foods diet consumers, high Western 
dietary pattern patients were significantly more likely to have decreased levels of beta carotene, 
xanthophylls, total carotenoids, as well as alpha-, gamma- and total tocopherol when compared 
to low Western dietary pattern participants.  
 
Linear regression model results, assessing the association between individual TIL counts and 
binary dietary pattern (high/low), can be found in Table 7.2. While no significant associations 
were found between any of the TILs and the whole foods dietary pattern, high intake of the 
Western dietary pattern was consistently associated with decreased CD4+, CD8+, CD103+ and 
FOXP3+ infiltrates. Significant decreases were noted for CD8+ and FOXP3+ markers, even after 
adjustment for age, sex and TMA (β: -19.99 and -12.54, respectively).  
 
Serum carotenoids and tocopherols were evaluated for their association with tumor immune 
response using logistic regression models and significance was determined based on Bonferroni 
correction (Table 7.3). Crude models demonstrated an increased odds of having high CD4+ 
infiltrates among those possessing high serum alpha tocopherol concentrations (OR: 2.34 
[95%CI: 1.59, 3.46]); similar findings were found between alpha tocopherol and CD8+ markers 
(OR: 2.09 [95%CI: 1.43, 3.06]), as well as CD8+ and alpha carotene (OR: 2.25 [95%CI: 1.53, 
3.30]). CD68+ myeloid derived suppressor cells, a TIL marker previously associated with poor 
HNSCC prognosis when infiltration is high15, was found to be inversely associated with high 
serum xanthophylls (OR: 0.21 [95%CI: 0.14, 0.32]), lycopene (OR: 0.53 [95%CI: 0.36, 0.78]) 
and total carotenoids (OR: 0.46 [95%CI: 0.31, 0.67]); these finding remained significant after 
adjustment by age, sex, disease site and TMA. Higher levels of serum gamma tocopherol were 
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found to increase the likelihood of having high CD8+ and FOXP3+ infiltrates in multivariate 
models (OR: 2.21 [95%CI: 1.37, 3.56]; OR: 4.26 [95%CI: 2.40, 7.58], respectively).  
 
Cox proportional hazard model results for the joint association between binary TILs and binary 
dietary pattern on overall and recurrence free survival, adjusted for age, sex, stage, disease site, 
HPV status and TMA, can be found in Table 7.4 and 7.5. Surprisingly, among those with high 
CD4+ TIL counts, having a high whole foods dietary pattern (in reference to a low whole foods 
dietary pattern) was associated with increased risk of overall mortality (p for interaction: 0.02). 
Among those with high CD4+ (p for interaction: 0.03), CD68+ (p for interaction: 0.004), 
CD103+ (p for interaction: 0.03)  and FOXP3+ (p for interaction: 0.05) infiltrates, having a high 
Western dietary pattern significantly increased the risk of overall mortality when compared to 
those with a low Western dietary pattern. Similar results were found for recurrence-free survival; 
among those with high CD4+ (p for interaction: <0.0001) and FOXP3+ (p for interaction 0.0002) 
TILs, having a high Western dietary pattern appeared to increase the risk of recurrence when 




This study is the first of its kind to report that both pretreatment dietary patterns, as well as 
serum carotenoids, can not only influence tumor immune response, but may also mediate the 
association between TILs and survival. Consuming a high Western dietary pattern was 
consistently associated with decreased number of infiltrates found within the tumor, with 
significant reductions noted for CD8+ and FOXP3+ in multivariate models. Additionally, we 
found that high serum concentrations of xanthophylls, lycopene and total carotenoids decreased 
the number of detrimental CD68+ cells in HNSCC tumors, while gamma tocopherol appeared to 
significantly increase both CD8+ and FOXP3+ lymphocytes. Finally, we demonstrated that the 
effect the Western dietary pattern exhibits on the tumor microenvironment may have significant 
negative implications on overall and recurrence-free survival among HNSCC patients.  
  
While numerous studies have analyzed the association between dietary factors and HNSCC 25,42-
45, there have been no studies, to our knowledge, that have assessed the role of dietary patterns or 
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serum carotenoids on tumor immune response at a molecular level. Overall, dietary studies have 
largely provided evidence that poor nutritional status, often characterized by low consumption of 
fruits and vegetables, increases the risk of HNSCC46, while high consumption of nutrient rich 
foods have the opposite effect44,45,47. Smoking and alcohol consumption, two primary risk factors 
in HNC development, are believed to play an integral role in counteracting the protective effects 
conferred by dietary nutrients. Tobacco products, combustible and smokeless, have been shown 
to produce free radicals and reactive oxygen molecules, which have the ability to react with the 
lipid bilayer, denature proteins, induce DNA damage, and trigger chronic inflammation 30,48; 
high alcohol consumption can lead to decreased folate absorption and increased oxidative stress 
through ethanol metabolism 49,50.  Nutrient compounds found abundantly in produce have been 
shown to reduce inflammation and oxidative stress, maintain proper function of cellular 
processes, and inhibit angiogenesis, theoretically defending high-risk individuals against the 
carcinogenic effects of tobacco and alcohol use51,52.  Preclinical and clinical studies have 
previously elucidated several bioactive agents believed to affect cell-mediated immune response 
53,54. While the whole foods diet did not appear to significantly affect TILs in our cohort, we did 
find several significant associations between serum carotenoids and tocopherols on tumor 
immune response.  
 
Serum carotenoids and tocopherols have been established by our group and others as valid 
biomarkers of fruit and vegetable intake 38,55. Carotenoids, found abundantly in fruits and 
vegetables, represent a diverse group of natural polyene pigments and can be classified into 
xanthophylls (b-cryptoxanthin, lutein, and zeaxanthin) and carotenes (a-carotene, b-carotene, and 
lycopene) 56,57. Both classes of carotenoids act as antioxidants, efficiently quenching singlet 
oxygen, reducing damage associated with reactive oxygen species and inhibiting lipid 
peroxidation 58-60. In this study, we found significant decreases in the negative prognostic marker 
CD68+ associated with higher consumption of xanthophylls, lycopene and total carotenoids. 
These findings coincide with previous reports that higher pretreatment serum carotenoids are 
associated with progression-free survival in HNSCC patients61, as well as the overall survival 
benefit associated with high serum xanthophyll62 and lycopene concentrations 63. Tocopherols, 
commonly known as vitamin E, have long been used clinically for a variety of oxidative stress-
induced conditions64 due to their functionality in trapping free radicals and protecting lipids in 
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the cell membranes from oxidation65,66.  In our HNC cohort, we found increased levels of serum 
gamma-tocopherol to significantly increase CD8+ and FOXP3+ infiltrates in adjusted models. 
Gamma-tocopherol has previously been shown to be a stronger regulator of inflammation than 
alpha-tocopherol, namely through inhibition of cyclooxygenase (COX) and modulation of 
reactive oxygen species67,68. Several studies have also reported vitamin E supplementation to 
enhance CD4+ lymphocyte proliferation, we well as improve CD4+/CD8+ ratios69,70. Moreover, 
gamma-tocopherol, but not alpha-tocopherol, has recently been reported to exhibit anti-
proliferative and pro-apoptotic effects selectively on cancer, but not normal epithelial cells 71.  
 
Although limited, several studies have suggested an increased risk of HNSCC incidence and 
mortality associated with intake of red and processed meat, eggs and dairy 42,72-74. In this study, 
the Western dietary pattern, characterized by a high consumption of red and processed meats, 
refined grains, potatoes, French fries, high-fat dairy, condiments, desserts, snacks and sugar-
sweetened beverages, was found to decrease all TILs except CD68+, with significant decreases 
noted for CD8+ and FOXP3+. Furthermore, we found that among those individuals who had 
both dietary and carotenoid data, participants who consumed a high Western dietary pattern had 
significantly lower levels of beta carotene, xanthophylls, total carotenoids, as well as alpha-, 
gamma- and total tocopherols. These results suggest that study participants who consumed a high 
Western dietary pattern were not only consuming unhealthier food but were also eating many 
fewer fruits and vegetables than those in the low Western dietary pattern group, thereby 
foregoing the potential protective effects of these nutrients. High intake of red and preserved 
meats have previously been implicated in other cancers due to the production of genotoxic 
heterocyclic amines (HCA) and aromatic hydrocarbons (AH) during cooking, as well as nitrates 
and nitrites for preservation75-77.  The International Agency for Research on Cancer (IARC) has 
classified the consumption of processed meat as “carcinogenic to humans” (Group 1), and red 
meat as “probably carcinogenic to humans” (Group 2A) through mechanisms linked to DNA 
damage and promotion of inflammation 78,79. Based on the current evidence, it is reasonable to 
believe that there may be synergistic effects associated with tobacco, alcohol and meat 
consumption on HNSCC that warrant further investigation.
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TILs are of particular importance in HNSCC due to the close proximity of these tumors to 
lymphoid tissue in the Waldeyer’s ring, as well as the infectious etiology associated with 
oropharyngeal and nasopharyngeal carcinoma. Albeit being more aggressive, HPV and EBV 
related malignancies are associated with improved response to treatment, believed to be 
attributable to the presence of an increased immune response against the viral antigens. 
Nevertheless, irrespective of infection, TILs have consistently been shown to be an important 
prognostic tool in guiding HNSCC treatment. In a large retrospective study, increased CD4+ 
helper T and CD8+ cytotoxic/suppressor T cell levels significantly improved both overall and 
recurrence free survival in HNC patients; similar findings were reported between these infiltrates 
and oral cavity80, laryngeal81,82, oro- and hypopharyngeal12,13,17 carcinoma, particularly among 
patients receiving chemotherapy. FOXP3+ regulatory T cells15,83,84 , and more recently CD103+ 
infiltrates40, or αEβ7 integrin, have also been shown to be positive prognostic markers in 
HNSCC, while CD68+  myeloid‐derived suppressor cells have been associated with poor 
prognosis 15. Accounting for the effect of diet on tumor immune response, we found that among 
those with high CD4+, CD68+, CD103+ and FOXP3+ markers, consumption of a high Western 
dietary pattern was associated with significantly worse overall survival when compared to those 
with a low Western dietary pattern; similar findings were noted between high CD4+ and 
FOXP3+ infiltrates and high Western dietary pattern on recurrence-free survival. These results 
are particularly interesting because previous studies conducted by our group did not find 
differential survival among those consuming various levels of the Western diet25. Given the 
reduction of all but CD68+ TILs found to be associated with increased Western dietary pattern, 
and the significant interaction terms between the aforementioned TILs and Western diet, it is 
reasonable to believe that the protective effect conferred by TILs may be modified by diet. In 
order to validate these results, future research should be conducted among HNSCC patients.   
 
The results of this study should be interpreted in light of several limitations. Due to the fact that 
the FFQ was designed to assess dietary intake over the course of the year preceding HNC 
diagnosis, the effect of lifetime dietary exposure could not be assessed with respect to immune 
response and recall bias could have occurred. In addition, our sample size precluded us from 
being able to assess the associations of interest in stratified models, particularly evaluating 
differences in associations by disease site, smoking status or treatment modality. Nevertheless, 
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smoking and alcohol status were not found to be significant confounders when using backward 
selection, and sensitivity analyses integrating smoking and alcohol consumption into multivariate 
models did not alter the overall results of the study; treatment modality was found to be highly 
colinear with disease site, therefore only site was selected as a covariate in adjusted models. 
While TMAs are significantly more cost and time effective than staining and assessing entire 
slides, they do not fully capture the heterogeneity present within tumors, thereby limiting our 
ability to draw conclusions on the overall tumor microenvironment. In an attempt to minimize 
any potential confounding introduced by using TMAs, we adjusted the TIL counts by the 
percentage of tumor parenchyma present in each core, ran the samples in triplicate to best assess 
the overall sample, had a technician blinded to clinical status count the TILs and adjusted for 
batch effects in statistical models.  
 
In conclusion, dietary patterns and serum carotenoids may play an important role in modifying 
TILs, and ultimately, outcome after diagnosis with HNSCC. As tumor immune response 
continues to emerge as an important prognostic tool in risk and treatment stratification, 
particularly with the advent of immunotherapy and personalized medicine, it is important to 
account for and educate patients on the role of modifiable lifestyle factors in these contexts. 
While further research is needed in order to confirm these results and elucidate some of the 
underlying biological mechanisms between Western dietary patterns, inflammation and immune 
response, the results of this study could inform dietary interventions among high risk individuals 
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Age: Mean±SD [range], y 59±11 [25-95] 62±11 [39-92] 0.04 62±12 [30-95] 59±10 [25-92] 0.12 
Sex, N (%)    
0.25 
   
0.02 Male 89  (79.72) 82 (70.09) 77 (66.38) 94 (80.34) 
Female 27 (23.28) 35 (29.91) 39 (33.62) 23 (19.66) 
Race    
 
0.55 
   
 
0.26 
White 109 (93.97) 114 (97.44) 112 (96.55) 111 (94.87) 
Black 3 (2.59) 1 (0.85) 1 (0.86) 3 (2.56) 
American Indian 3 (2.59) 1 (0.85) 1 (0.86) 3 (2.56) 
Other 1 (0.86) 1 (0.85) 2 (1.72) 0 (0.00) 
Education    
 
0.001 
   
 
0.75 
Less than High School 10 (8.70) 6 (5.13) 9 (7.83) 7 (5.98) 
High School/GED 46 (40.00) 25 (21.37) 36 (31.30) 35 (29.91) 
Some College 42 (36.52) 45 (38.46) 40 (34.78) 47 (40.17) 
4-yr Degree 10 (8.70) 15 (12.82) 11 (9.57) 14 (11.97) 
More than 4-yr Degree 7 (6.09) 26 (22.22) 19 (16.52) 14 (40.17) 











Stage, N (%)    
 
0.92 
   
 
0.96 
1 16 (13.79) 19 (16.24) 18 (15.52) 17 (14.53) 
2 15 (12.93) 17 (14.53) 17 (14.66) 15 (12.82) 
3 18 (15.52) 18 (15.38) 17 (14.66) 19 (16.24) 
4 67 (57.76) 63 (53.85) 64 (55.17) 66 (56.41) 
Site, N (%)    
 
0.95 
   
 
0.08 
Larynx 21 (18.10) 22 (18.80) 14 (12.07) 29 (24.79) 
Oral Cavity 50 (43.10) 53 (45.30) 55 (47.41) 48 (41.03) 
Oropharynx  42 (36.21) 40 (34.19) 45 (38.79) 37 (31.62) 
Hypopharynx 3 (2.59) 2 (1.71) 2 (1.72) 3 (2.56) 
HPV Status, N (%)*     
0.56 
   
0.53 Positive 40 (34.48) 33 (28.21) 49 (42.24) 58 (49.57) 
Negative 50 (43.10) 57 (48.72) 39 (33.62) 34 (29.06) 
Invalid/Missing 26 (22.41) 27 (23.08) 28 (24.14) 25 (21.37) 
ACE-27 Score, N (%)    
 
0.70 
   
 
0.50 
None 33 (28.70) 32 (27.35) 27 (23.48) 38 (32.48) 
Mild 59 (51.30) 56 (47.86) 60 (52.17) 55 (47.01) 
Moderate 16 (13.91) 17 (14.53) 18 (15.65) 15 (12.82) 
Severe 7 (6.09) 12 (10.26) 10 (8.70) 9 (7.69) 
Drinking Status, N (%)    
0.87 
   
0.16 Never 9 (7.76) 9 (7.69) 11 (9.48) 7 (5.98) 
Current 80 (68.97) 84 (71.79) 75 (64.66) 89 (76.07) 
Former (quit >12 
months) 
27 (23.28) 24 (20.51) 30 (25.86) 21 (17.95) 
Smoking, N (%)    
0.01 
   
0.06 Never 30 (25.86) 27 (23.08) 36 (31.03) 21 (17.95) 
Current 55 (47.41) 38 (32.48) 41 (35.34) 52 (44.44) 
Former (quit >12 
months) 
31 (26.72) 52 (44.44) 39 (33.62) 44 (37.61) 
Treatment Modality, N 
(%) 











Surgery Alone 28 (24.14) 30 (25.64) 29 (25.00) 29 (24.79) 
Surgery + Adj rad 17 (14.66) 19 (16.24) 16 (13.79) 20 (17.09) 
Surgery + Adj chemorad 14 (12.07) 14 (11.97) 16 (13.79) 12 (10.26) 
Radiation Alone 10 (8.62) 6 (5.13) 7 (6.03) 9 (7.69) 
Chemorad Alone 38 (32.76) 38 (32.48) 40 (34.48) 36 (30.77) 
Chemo Alone 1 (0.86) 3 (2.56) 1 (0.86) 3 (2.56) 
Palliative, Unknown 8 (6.90) 7 (5.98) 7 (6.03) 8 (6.84) 
Deceased, N (%) 33 (28.45) 32 (27.35) 0.85 30 (25.86) 35 (29.91) 0.49 
* one patient missing ACE-27 score  
Abbreviations: ACE-27, Adult Comorbidity Evaluation-27; BMI, body mass index; HPV, human papillomavirus; SD, standard deviation. 




         Table 7.1b. Serum micronutrient concentrations by dietary pattern 
 
  










Serum Micronutrients μg/d, Mean (SD)       
Alpha Carotene 0.01 (0.02) 0.02 (0.01) 0.15 0.02 (0.01) 0.01 (0.02) 0.49 
Beta Carotene 0.05 (0.07) 0.07 (0.10) 0.03 0.08 (0.11) 0.04 (0.05) 0.0002 
Xanthophylls 0.14 (0.10) 0.17 (0.13) 0.13 0.18 (0.14) 0.14 (0.09) 0.02 
Lycopene 0.05 (0.04) 0.05 (0.04) 0.55 0.05 (0.03) 0.05 (0.04) 0.25 
Total Carotenoids 0.26 (0.14) 0.30 (0.24) 0.01 0.34 (0.27) 0.25 (0.14) 0.001 
Alpha tocopherol 7.98 (5.02) 10.33 (6.07) 0.29 10.59 (7.49) 8.34 (4.13) 0.001 
Gamma tocopherol 1.14 (0.57) 1.18 (0.72) 0.22 1.18 (0.55) 1.13 (0.79) 0.04 
Total tocopherol 9.12 (5.32) 11.50 (6.12) 0.44 11.72 (7.76) 9.52 (4.22) 0.001 
 
 Tumor Infiltrating Lymphocytes (TILs) 
 Unadjusted Adjusted* 
 CD4 CD8 CD68 CD103 FOXP3 CD4 CD8 CD68 CD103 FOXP3 
Sample Size  228 228 130 93 232 228 228 130 93 232 
Whole Foods Pattern 
β(SE) 
  
≤ -0.20 ref ref ref ref ref ref ref ref ref ref 
> -0.20 -1.47 
(6.65) 




3.39 (5.37) -1.89 
(6.71) 
3.48 (9.26) 1.54 (4.92) 20.82 
(22.00) 
4.54 (5.42) 
p-value for trend 0.82 0.66 0.86 0.37 0.53 0.78 0.71 0.76 0.35 0.40 
Western Pattern β(SE)   
≤ -0.16 ref ref ref ref ref ref ref ref ref ref 




















p-value for trend 0.18 0.03 0.95 0.11 0.04 0.21 0.03 0.98 0.08 0.02 
* Adjusted for  age, sex and TMA 
Table 7.2: Linear Regression Model Assessing the Association between Tumor Infiltrating Lymphocytes and Binary Dietary Pattern   
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 Tumor Infiltrating Lymphocytes (TILs) 
 Unadjusted Adjustedǂ 
 CD4 CD8 CD68 FOXP3 CD4 CD8 CD68 FOXP3 
Sample Size 69 69 68 70 69 69 68 70 
Alpha Carotene OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) OR (CI) 
Low (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) 
High 1.48 (1.01, 2.18) 2.25 (1.53, 3.30) 0.86 (0.59, 1.25) 1.54 (1.05, 2.25) 1.05 (0.64, 1.70) 1.05 (0.65, 1.71) 0.53 (0.33, 0.85) 0.44 (0.25, 0.79) 
p-value for trend 0.05 <.0001 0.42 0.03 0.85 0.84 0.01 0.01 
Beta Carotene         
Low (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) 
High 0.91 (0.62, 1.34) 1.51 (1.03, 2.20) 1.08 (0.74, 1.57) 1.13 (0.78, 1.65) 0.74 (0.47, 1.17) 0.95 (0.59, 1.53) 0.91 (0.58, 1.40) 0.48 (0.29, 0.82) 
p-value for trend 0.64 0.03 0.70 0.52 0.19 0.83 0.66 0.01 
Xanthophylls          
Low (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) 
High 1.17 (0.80, 1.71) 0.98 (0.67, 1.43)  0.21 (0.14, 0.32) 0.93 (0.64, 1.36) 0.73 (0.45, 1.18) 0.58 (0.35, 0.96) 0.12 (0.07, 0.21) 0.91 (0.55, 1.51) 
p-value for trend 0.43 0.92 <.0001 0.72 0.20 0.03 <.0001 0.71 
Lycopene         
Low (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) 
High 0.83 (0.56, 1.21) 1.51 (1.03, 2.20) 0.53 (0.36, 0.78) 1.18 (0.81, 1.73) 0.70 (0.43, 1.14) 0.47 (0.27, 0.81) 0.36 (0.22, 0.61) 1.02 (0.59, 1.75) 
p-value for trend 0.33 0.03 0.001 0.38 0.15 0.01 0.0001 0.95 
Total*         
Low (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) 
High 0.90 (0.61, 1.32) 1.23 (0.85, 1.80) 0.46 (0.31, 0.67) 0.80 (0.55, 1.17) 0.61 (0.37, 1.02) 0.44 (0.26, 0.75) 0.31 (0.19, 0.51) 0.56 (0.32, 0.97) 
p-value for trend 0.57 0.27 <.0001 0.25 0.06 0.003 <.0001 0.04 
Alpha tocopherol         
Low (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) 
High 2.34 (1.59, 3.46) 2.09 (1.43, 3.06) 1.30 (0.89, 1.89) 1.68 (1.15, 2.44) 1.61 (1.00, 2.60) 1.68 (1.04, 2.71) 0.94 (0.60, 1.47) 1.08 (0.65, 1.80) 
p-value for trend <.0001 0.0001 0.17 0.01 0.05 0.03 0.78 0.77 
Gamma tocopherol         
Low (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) 
High 0.69 (0.47, 1.02) 1.49 (1.02, 2.17) 1.54 (1.05, 2.24) 1.45 (1.00, 2.11) 0.73 (0.46, 1.15) 2.21 (1.37, 3.56) 1.89 (1.22, 2.93) 4.26 (2.40, 7.58) 
p-value for trend 0.06 0.04 0.03 0.05 0.18 0.001 0.004 <.0001 
Total tocopherol¥         
Low (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) (Ref) 
High 1.79 (1.22, 2.64) 1.60 (1.10, 2.33) 1.12 (0.77, 1.62) 1.29 (0.89, 1.88) 1.25 (0.78, 1.99) 1.44 (0.90, 2.30) 0.96 (0.62, 1.49) 0.93 (0.56, 1.54) 
p-value for trend 0.003 0.01 0.56 0.18 0.35 0.13 0.86 0.78 
* calculates as: alpha carotene+beta carotene+xanthophylls+lycopene 
¥ calculated as: alpha tocopherol+gamma tocopherol 
ǂ Age, sex, disease site and TMA adjusted 
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Table 7.5: Cox Proportional Hazard Models Assessing the Role of Tumor Infiltrating Lymphocytes and Diet on Overall Survival 
 CD4 CD8 CD68 CD103 FOXP3 
 Low High  Low High  Low High  Low High  Low High  
 HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Whole Foods Pattern           
Low Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) 




















0.02 0.21 0.37 0.97 0.91 
Western Pattern           
Low Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) 






















0.03 0.92 0.004 0.03 0.05 
*Models adjusted for age, sex, stage, disease  site, HPV status and TMA 
 CD4 CD8 CD68 CD103 FOXP3 
 Low High  Low High  Low High  Low High  Low High  
 HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Whole Foods 
Pattern 
          
Low Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) 






















0.37 0.73 0.45 0.17 0.06 
Western Pattern           
Low Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) Ref (1.00) 






















<.0001 0.30 0.16 0.06 0.0002 
*Models adjusted for age, sex, stage, disease site, HPV status and TMA 
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Cancer is one of the most common causes of both morbidity and mortality in the world today; 
more than 10 million new cases and 6 million deaths are attributed to cancer each year 1.  An 
estimated 20 million people worldwide are thought to be living with a cancer diagnosis, of which 
more than half reside in developing countries. If trends continue as they are, projections for 2020   
show annual increases in both incidence and mortality rates of 15 million and 10 million 
respectively 2.  While a portion of these trends can be attributed to the aging global population, 
increasing prevalence of exposure to cancer risk factors in both high-income, and particularly in 
low- and middle- income countries, has unquestionably had an impact in driving chronic disease, 
and especially cancer rates 3.    
 
This dissertation has built upon the body of literature that recognizes the importance of 
understanding head and neck cancer etiology from both preventative and treatment standpoints. 
We still lack knowledge and comprehensive understanding of the wide variety of environmental 
exposures that lead to HNSCC carcinogenesis, the role they play in cancer biology and the 
impact they have on global prevalence and survival trends. Head and neck cancer is chronically 
underfunded and understudied, receiving the second-fewest incidence-normalized research 
dollars of any common cancer 4. In order for the scientific community to be better informed and 
adequately prepared to manage the increasing burden of disease, head and neck cancer 
epidemiology, and corresponding risk factors, must be better understood in order to improve 
cancer prevention, screening and treatment strategies. 
 
Aim one, comprised of four manuscripts, leverages cancer registry data in order to assess trends 
in head and neck cancer incidence and mortality. The creation of registries is a crucial first step 
in developing and accessing strategies for both cancer prevention and patient care, consequently 
informing public health and clinical decisions on a local, and potentially global, scale. While 
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these studies are descriptive in nature, understanding temporal patterns in cancer trends is 
important in generating hypotheses regarding etiological changes that propel mechanistic studies 
that inform prevention and treatment modalities.   
 
The first two papers focused specifically on nasopharyngeal carcinoma, which is analyzed 
separately from the other head and neck cancer subsites due to its unique etiology and 
geographical distribution. Thailand is considered an endemic country for NPC, whereas the 
United States has historically reported very few cases, resulting in limited studies with small 
sample sizes. Nasopharyngeal carcinoma is by far not the only cancer type to exhibit varying 
incidence across countries. While some of these variabilities may be due to genetic factors, the 
vast majority of cancers, NPC included, do not display hallmarks of simple inheritance5. 
Migration studies, examining the role of population-based relocation on cancer rates, have long 
been used to illustrate the effects of environmental and lifestyle changes conferred by the host 
country on the incidence of cancer. A seminal study on the topic tracked Japanese immigrants to 
Hawaii and California, discovering that cancer incidence shifts with successive generations to 
more closely mimic trends apparent among their white peers 6. Manuscript one of this aim 
investigated incidence and mortality trends in NPC between 1990 and 2014 across four Thai 
registries and compared them to those found among Asian/Pacific Islanders (A/PI) in the US. To 
our surprise, US Asian/Pacific Islanders had higher age-standardized rates of NPC than the 
endemic Thai population. Furthermore, the A/PI displayed a higher incidence of the non-
keratinizing subtype, which has been reported to account for ~95% of cases in endemic regions7 
and predominated among cases diagnosed in Chiang Mai, Khon Kaen and Lampang. Due to data 
limitations within SEER to ascertain Thai ethnicity and generational shift, a true migration study 
could not be performed, but the findings still emphasized an interesting phenomenon that 
highlights the importance of further etiological studies into NPC to determine the genetic and 
environmental drivers of this cancer. Additional results from this paper found the keratinizing 
NPC subtype, typically associated with combustible tobacco use, to be decreasing among Chiang 
Mai males, as well as both sexes in Songkhla and the US; these reductions in incidence 
correspond to reports of decreased tobacco use. Finally, survival analyses underscored the 
successes of chemoradiation treatment for non-keratinizing NPC, as well as demonstrated the 
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continuing challenges faced by rural populations to gain access to care, irrespective of the 
introduction of universal health care in Thailand.  
 
The second paper in this aim more closely investigated NPC incidence and mortality trends by 
histologic subtype, race, sex and age in the US. While overall NPC appeared to be decreasing 
across all strata, much of this effect was due to reductions in keratinizing NPC, again 
corresponding to decreased smoking rates across the US. Trends in the non-keratinizing subtype, 
on the other hand, raised some interesting questions regarding the etiological differences 
between differentiated and undifferentiated tumors. The current state of literature suggests that 
all non-keratinizing nasopharyngeal carcinomas are associated with EBV infection, but this study 
found stark differences in trends between these two subtypes. Undifferentiated lesions were 
shown to be consistently decreasing, while the differentiated tumors increased across all strata, 
reaching rates are high as 4% annually among white males and females, as well as black males. 
While unable to confirm etiology using these data, exploratory analyses into NK/T-cell 
lymphoma, another EBV related cancer, showed similar increasing incidence rates as NPC, 
further strengthening the hypothesis that EBV may be a relevant factor in explaining the 
observed rates. As expected based on the previously mentioned paper, Asian/Pacific Islanders 
had rates that were more than five times higher among females and seven times higher among 
males when compared with their white counterparts. This race group also appeared to experience 
the highest 5-year relative survival estimates, while black males displayed the worst survival 
regardless of histology. African Americans also appeared to exhibit a bimodal distribution in 
cases, with 25% of patients being diagnosed before age 40 years compared with 12% of their 
white counterparts. This disparity was particularly pronounced in the nonkeratinizing subtype, 
where 32% of cases among blacks occurred before the age of 40. Previous studies using 
NHANES have reported significantly higher EBV seroprevalence among black children as 
opposed to their white peers8 9, raising interest in whether earlier life exposure to EBV may 
increase the risk of NPC development at younger ages. Overall, this paper stressed the need for 
further research into NPC etiology across race and histological subtype. Due to the fact that US-
based prospective cohort studies with comprehensive exposure assessment would require 
decades to recruit a sufficient sample size to assess gene‐environment interactions, multicenter 
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studies or retrospective collection of tumor tissues would be needed to better understand the 
nuances of this cancer in the United States.  
 
The remaining two papers of aim one both assessed overall and subsite specific head and neck 
cancer trends. The first used data from IARC’s CI5plus database from three Thai registries 
(Songkhla, Chiang Mai, Lampang), Singapore, Manila, Shanghai and compared them to rates 
seen in the US. Overall rates of head and neck cancer appeared to decrease among all the 
groupings except Shanghai males. Further subsite analyses revealed that laryngeal cancer, the 
anatomical site most strongly associated with combustible tobacco use, has been increasing at an 
annual percent change of 9.1 from 1988 to 2002 in Shanghai. As the world’s largest tobacco 
manufacturer, China accounts for about 30% of the world’s cigarette consumption, and other 
studies have previously reported minimal interest in smoking cessation within this population10. 
Although the overall rates in Shanghai still appeared to be much lower than expected, given the 
high uptake in tobacco use, smoking-related illnesses should be closely monitored within this 
population and stronger regulations should be considered.  
 
Khon Kaen, Thailand is one of the only places worldwide with higher reported incidence of head 
and neck cancer among women than men 11. This phenomenon is particularly striking for oral 
cavity cancer, where ~74% of cases are diagnosed among women. The custom of chewing betel 
quid is highly prevalent among the older generation of women living in Northeastern Thailand, 
and this etiological factor accounts for disproportionately high cancer rates in the region. Years 
of educational and political campaigns have reduced this high-risk behavior, especially among 
the younger generation, leading to observed decreases in oral cavity cancer at an annual percent 
change of 4.6; nevertheless, tongue and pharyngeal carcinomas appear to be increasing in 
Thailand.  In the Western world, changes in cultural norms and improved control over 
combustible tobacco use has elucidated the role of high-risk HPV as an important etiological 
factor in oral, and especially oropharyngeal, carcinoma. This subset of the disease 
disproportionately effects younger individuals who may not otherwise display high risk 
behaviors for HNSCC development. However, to date, there have been no studies published on 
HPV prevalence in HNSCC in Southeast Asia. Given the findings of increased HPV prevalence 
in the North America and Europe, it is reasonable to believe that the observed increases in 
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tongue and pharyngeal carcinoma noted in Thailand may similarly be due to HPV integration.  
Although believed to be more aggressive, HPV positive tumors have been shown to be more 
responsive to treatment, leading the American Joint Committee on Cancer to suggest restaging 
these lesions12; this suggestion had led to a de-escalation of treatment, consequently improving 
morbidity and mortality among afflicted patients.  If the etiological shift is confirmed in 
Thailand, similar alteration to screening and treatment can be adopted, which would improve 
quality of life, and hopefully survival statistics for this cancer subtype.  
 
The objective of aim two was to validate the finding from the previous manuscript using 
molecular epidemiology. 107 formalin-fixed, paraffin-embedded (FFPE) tissue blocks from 
patients seen at Srinagarind Hospital in Khon Kaen, Thailand between 2012 and 2017 were 
obtained, alongside corresponding patient data, and sent to the University of Michigan for 
analysis. The samples were tested for the presence of HPV using polymerase chain reaction and 
p16 staining. After exclusion of 11 patients due to oral cavity, rather than oropharyngeal, 
carcinoma diagnosis 14 patients were determined to be infected with HPV16, 2 with HPV18 and 
1 was co-infected with both HPV16 and HPV18. On average, HPV+ patients were younger and 
more likely to have tonsil cancer. Taken together, these characteristics, in addition to the clear 
survival benefit shown to be conferred by the presence of HPV in our study, not only 
corroborated the suggested findings of the aforementioned descriptive epidemiology study, but 
also supported the adaptation of p16 staining and consequent restaging of oropharyngeal 
carcinomas as suggested by the American Joint Committee on Cancer. While these results should 
be validated across other parts of Southeast Asia, implementation of these protocols would allow 
for improved monitoring and more informed treatment decisions. Being the first study to show 
the existence, and prognostic significance, of HPV in the region, our hopes are that these results 
will inform medical practice and improve quality of life as well as survival outcomes among 
afflicted patients.   
 
The final aim utilized data from the University of Michigan Head and Neck Cancer SPORE to 
evaluate the potential role of diet on tumor immune response and, ultimately, outcome. On a 
molecular level, the literature into the effects of diet on head and neck cancer is surprisingly 
limited. Individually, TILs have been shown to be important indicators in determining treatment 
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efficacy among HNSCC patients, while diet has been demonstrated to have a bi-directional effect 
on head and neck risk, progression and prognosis. The use of diet to modulate immune system 
function by mediating inflammation within the tumor microenvironment has been proposed for 
HNSCC, nevertheless, no studies to date have tested this hypothesis. In this study, we found the 
Western dietary pattern, characterized by high consumption of red and processed meats, refined 
grains, potatoes, French fries, high-fat dairy, condiments, desserts, snacks and sugar-sweetened 
beverages, to significantly decrease the favorable CD8+ and FOXP3+ markers. While high 
levels of serum gamma tocopherol were shown to increase these markers, elevated levels of 
xanthophylls, lycopene and total carotenoids appeared to decrease the deleterious CD68+ TIL 
count. Survival analyses assessing the joint association between TILs and dietary pattern 
demonstrated that among those with high CD4+, CD68+, CD103+ and FOXP3+ markers, having 
a high Western dietary pattern significantly increased the risk of overall mortality when 
compared to those with a low Western dietary pattern. Similar results were found for recurrence-
free survival, CD4+, FOXP3+ and Western dietary pattern. While the results of this study need 
to be validated, and further studies into the underlying mechanisms of this association need to be 
elucidated, the findings reported here can be used as a support to inform dietary interventions 
among high risk patients. As the medical world continues to gain interest in the utility of 
immunotherapy and personalized medicine, and screening for molecular markers such as TILs 
becomes more routine, it is important to be able to inform patients on modifiable behaviors that 
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